

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (51) International Patent Classification ⁶ : C12Q 1/68, C12N 15/12 | | A1 | (11) International Publication Number: WO 99/10535 (43) International Publication Date: 4 March 1999 (04.03.99) |
| (21) International Application Number: PCT/US98/17283 (22) International Filing Date: 21 August 1998 (21.08.98) | | | (81) Designated States: AU, CA, IL, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). |
| (30) Priority Data: 60/056,861 22 August 1997 (22.08.97) US | | | Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (71) Applicant (for all designated States except US): YALE UNIVERSITY [US/US]; 451 College Street, New Haven, CT 06520 (US). | | | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): LIU, Meng [CN/US]; Apartment 7C, 564 Prospect Street, New Haven, CT 06511 (US). BASKARAN, Namadev [IN/US]; 750 Whitney Avenue, New Haven, CT 06511 (US). WEISSMAN, Sherman, M. [US/US]; 459 Saint Ronan Street, New Haven, CT 06511 (US). | | | |
| (74) Agent: ADLER, Reid, G.; Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20036 (US). | | | |

(54) Title: **A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN STEM CELLS**

(57) Abstract

The present invention includes a method to identify stem cell genes that are differentially expressed in stem cells at various stages of differentiation when compared to undifferentiated stem cells by preparing a gene expression profile of a stem cell population and comparing the profile to a profile prepared from stem cells at different stages of differentiation, thereby identifying cDNA species, and therefore genes, which are expressed. The present invention also includes methods to identify a therapeutic agent that modulates the expression of at least one stem cell gene associated with the differentiation, proliferation and/or survival of stem cells.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|-------------------------------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

-1-

A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN STEM CELLS

Technical Field

This invention relates to compositions and methods useful to identify agents that modulate the expression of at least one gene associated with the differentiation, proliferation, dedication and/or survival of stem cells.

5 Background of the Invention

The identification of genes associated with development and differentiation of cells is an important step for advancing our understanding of hematopoiesis, the differentiation of hematopoietic stem cells into erythrocytes, monocytes, platelets and polymorphonuclear white blood cells or granulocytes. The identification of genes associated with hematopoiesis is also an important step for advancing the development of therapeutic agents which modulate, promote or interfere with the differentiation of stem cells.

Hematopoietic stem cells derive from bone marrow stem cells. The bone marrow stem cells ultimately differentiate into the hematopoietic stem cells, which are responsible for the lymphoid, myeloid and erythroid lineages, and stromal stem cells, which differentiate into fibroblasts, osteoblasts, smooth muscle cells, stromal cells and adipocytes (STEWART SELL, IMMUNOLOGY, IMMUNOPATHOLOGY & IMMUNITY, 5th ed. 39-42 Stamford, CT, 1996). The lymphoid lineage, comprising B-cells and T-cells, provides for the production of antibodies, regulation of the cellular immune system, detection of foreign agents in the blood, detection of cells foreign to the host, and the like. The myeloid lineage, which includes monocytes, granulocytes, megakaryocytes as well as others cells, monitors for the presence of foreign bodies in the blood stream, provides protection against neoplastic cells, scavenges foreign materials in the blood stream,

-2-

produces platelets and the like. The erythroid lineage provides the red blood cells which act as oxygen carriers.

Hematopoietic stem cells differentiate as a result from their interaction with growth factors such as interleukins (ILs), lymphokines, colony-stimulating factors (CSFs), erythropoietin (epo), and stem cell factor (SCF). Each of these growth factors have multiple actions that are not necessarily limited to the hematopoietic system (ROBERT A. MEYERS, ED., MOLECULAR BIOLOGY AND BIOTECHNOLOGY: A COMPREHENSIVE DESK REFERENCE, 392-6, New York, 1995). Proliferation, differentiation and survival of immature hematopoietic progenitor cells are sustained by hematopoietic growth factors (hemopoietins). These growth factors also influence the survival and function of mature blood cells. The kinetics of hematopoiesis vary depending on cell type, and their life span may be as little as 6-12 hours to as much as months or years. As a result, the daily renewal of certain lymphocyte progenitors may be substantially lower than that of leukocytic progenitors. The most primitive cells, pluripotent stem cells (PSCs), have high self-renewal capacity (Nathan, 818-821; Saito, *Recent trends in research on differentiation of hematopoietic cells and lymphokines*, Hum. Cell. 5(1): 54 (1992)).

Growth factors are responsible for differentiating the hematopoietic stem cell into either the hemocytoblast, which is the progenitor cell of erythrocytes, neutrophils, eosinophils, basophils, monocytes and platelets, and lymphoid stem cells, which are progenitors to T cells and B cells. SELL, 41. These circulating blood cells are products of terminal differentiation of recognizable precursors (e.g., erythroblasts, monomyeloblasts and megakaryoblasts, to name but a few). The terminal differentiation of these recognizable precursors may occur exclusively in the marrow cavities of the axial skeleton, with some extension into the proximal femora and humeri (David G. Nathan, *Hematologic Diseases*, IN CECIL TEXTBOOK OF MEDICINE 20th ed., 817, Philadelphia, 1996). White blood cell (WBC) nomenclature may be divided into two major populations on the basis of the form of their nuclei: single nuclei (mononuclear or "round cells") or segmented nuclei (polymorphonuclear).

-3-

In human medicine, the ability to initiate and regulate hematopoiesis is of great importance (McCune *et al.*, *The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function*, *Science* 241: 1632(1988)). A variety of diseases and immune disorders, including malignancies, appear to be related to

- 5 disruptions within the lympho-hematopoietic system. Many of these disorders could be alleviated and/or cured by repopulating the hematopoietic system with progenitor cells, which when triggered to differentiate would overcome the patient's deficiency. In humans, a current replacement therapy is bone marrow transplantation. This type of therapy, however, is both painful (for donor and recipient) because of involvement of
- 10 invasive procedures and can offer severe complications to the recipient, particularly when the graft is allogeneic and Graft Versus Host Disease (GVHD) results. Therefore, the risk of GVHD restricts the use of bone marrow transplantation to patients with otherwise fatal diseases. A potentially more exciting alternative therapy for hematopoietic disorders is the treatment of patients with reagents that regulate the proliferation and
- 15 differentiation of stem cells (Lawman *et al.*, U.S. Patent No. 5,650,299 (1997)).

There is also a strong interest in the development of procedures to produce large numbers of the human hematopoietic stem cell. This will allow for identification of growth factors associated with its self regeneration. Additionally, there may be as yet undiscovered growth factors associated (1) with the early steps of dedication of the stem cell to a particular lineage; (2) the prevention of such dedication; and (3) the negative control of stem cell proliferation. Availability of large numbers of stem cells would be extremely useful in bone marrow transplantation, as well as transplantation of other organs in association with the transplantation of bone marrow.

An *in vitro* system that permits determination of what agents induce differentiation or proliferation of progenitor cells within a hematopoietic cell population would have many applications. For example, controlled production of red blood cells would permit the *in vitro* production of red blood cell units for clinical replacement (transfusion) therapy. As is well known, transfused red cells are used in the treatment of anemia following elective surgery, in cases of traumatic blood loss, and in the supportive care of, *e.g.*, cancer patients. Similarly, controlled production of platelets would permit

-4-

the *in vitro* production of platelets for platelet transfusion therapy, which may be used in cancer patients with thrombocytopenia caused by chemotherapy. For both red cells and platelets, current volunteer donor pools are accompanied by the risk of infectious contamination, and availability of an adequate supply can be limited. Determination of 5 such compounds would lend itself to developing methods of controlled *in vitro* production of specified lineage of mature blood cells to circumvent these problems (Palsson *et al.*, U.S. Patent No. 5,635,386 (1997)).

Alternatively, agents could be isolated that selectively deplete a particular lineage of cells from within a hematopoietic cell population and can similarly confer important 10 advantages. For example, production of stem cells and myeloid cells while selectively depleting T-cells from a bone marrow cell population could be very important for the management of patients with human immunodeficiency virus (HIV) infection. Since the major reservoir of HIV is the pool of mature T-cells, selective eradication of the mature 15 T-cells from a hematopoietic cell mass collected from a patient has considerable potential therapeutic benefit. If one could selectively remove all the mature T-cells from within an HIV infected bone marrow cell population while maintaining viable stem cells, the T-cell depleted bone marrow sample could then be used to "rescue" the patient following hematolymphoid ablation and autologous bone marrow transplantation. Although there 20 are reports of the isolation of progenitor cells (see, *e.g.*, Tsukamoto *et al.*, (1991) as representative) such techniques are distinct from the selective removal of T-cells from a hematopoietic tissue culture (Palsson *et al.*, U.S. Patent No. 5,635,386 (1997)).

Summary of the Invention

While the differentiation of stem cells has been the subject of intense study, little is known about the global transcriptional response of stem cells during cell 25 hematopoiesis. The present inventors have devised an approach to systematically assess the transcriptional regulation of stem cells during hematopoiesis as well as methods for the identification of agents that modulate the expression of at least one gene associated with hematopoiesis.

-5-

The present invention includes a method to identify stem cell genes that are differentially expressed in stem cells at various stages of differentiation when compared to undifferentiated stem cells by preparing a gene expression profile of a stem cell population and comparing the profile to a profile prepared from stem cells at different 5 stages of differentiation, thereby identifying cDNA species, and therefore genes, which are expressed.

The present invention further includes a method to identify an agent that modulates the expression of at least one stem cell gene associated with the differentiation process of a stem cell population, comprising the steps of preparing a first gene 10 expression profile of an undifferentiated stem cell population, preparing a second gene expression profile of a stem cell population at a defined stage of differentiation, treating said undifferentiated stem cell population with the agent, preparing a third gene expression profile of the treated stem cell population, and comparing the first, second and third gene expression profiles. Comparison of the three gene expression profiles for 15 RNA species as represented by cDNA fragments that are differentially expressed upon addition of the agent to the undifferentiated stem cell population identifies agents that modulate the expression of at least one gene in undifferentiated stem cells that is associated with stem cell differentiation.

Another aspect of the invention is a composition comprising a grouping of nucleic 20 acids or nucleic acid fragments affixed to a solid support. The nucleic acids affixed to the solid support correspond to one or more genes whose expression levels are modulated during stem cell differentiation.

Brief Description of the Drawings

Fig. 1 Figure 1 is an autoradiogram of the gene expression profiles generated 25 from cDNAs made with RNA isolated from Lin⁺, LRH, LRH48 and LRBRH cells. All possible 12 anchoring oligo d(T)n1, n2 were used to generate a complete expression profile for the enzyme *Clal*.

Modes of Carrying Out the Invention

General Description

The differentiation of stem cells during the process of hematopoiesis is a subject of primary importance in view of the need to find ways to modulate the stem cell differentiation process. One means of characterizing the process of hematopoiesis is to measure the ability of stem cells to synthesize specific RNA during stem cell differentiation.

The following discussion presents a general description of the invention as well as definitions for certain terms used herein.

10 *Definitions*

The term "stem cells" as used herein, refers to both hematopoietic stem cells and bone marrow stem cells, and includes totipotent cells which serve as progenitors of neoplastic transformation. The term "hematopoietic stem cells" refers to stem cells which differentiate into erythrocytes, monocytes, granulocytes, and platelets. The putative human hematopoietic stem cell may express the cell surface antigen CD34.

The term "hematopoiesis" as used herein, refers to the process by which stem cells differentiate into blood cells, including erythrocytes, monocytes, granulocytes, and platelets.

The term "blood cell", as used herein, refers to all blood cell types derived from the process of hematopoiesis (see STEWART SELL, *IMMUNOLOGY, IMMUNOPATHOLOGY & IMMUNITY*, 5th ed. 39-42, Stamford, CT, 1996)

The term "solid support", as used herein, refers to any support to which nucleic acids can be bound or immobilized, including nitrocellulose, nylon, glass, other solid supports which are positively charged and nanochannel glass arrays disclosed by Beattie (WO 25 95/1175).

The term "gene expression profile", also referred to as a "differential expression profile" or "expression profile" refers to any representation of the expression level of at

least one mRNA species in a cell sample or population. For instance, a gene expression profile can refer to an autoradiograph of labeled cDNA fragments produced from total cellular mRNA separated on the basis of size by known procedures. Such procedures include slab gel electrophoresis, capillary gene electrophoresis, high performance liquid chromatography, and the like. Digitized representations of scanned electrophoresis gels are also included as are two and three dimensional representations of the digitized data.

While a gene expression profile encompasses a representation of the expression level of at least one mRNA species, in practice, the typical gene expression profile represents the expression level of multiple mRNA species. For instance, a gene expression profile useful in the methods and compositions disclosed herein represents the expression levels of at least about 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000 or more preferably, substantially all of the detectable mRNA species in a cell sample or population.

Particularly preferred are gene expression profiles or arrays affixed to a solid support that contain a sufficient representative number of mRNA species whose expression levels are modulated under the relevant infection, disease, screening, treatment or other experimental conditions. In some instances a sufficient representative number of such mRNA species will be about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100.

Gene expression profiles can be produced by any means known in the art, including, but not limited to the methods disclosed by: Prashar et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:659-663; Liang et al. (1992) *Science* 257:967-971; Ivanova et al. (1995) *Nucleic Acids Res.* 23:2954-2958; Guilfoyl et al. (1997) *Nucleic Acids Res.* 25(9):1854-1858; Chee et al. (1996) *Science* 274:610-614; Velculescu et al. (1995) *Science* 270:484-487; Fischer et al. (1995) *Proc. Natl. Acad. Sci. USA* 92(12):5331-5335; and Kato (1995) *Nucleic Acids Res.* 23(18):3685-3690.

As an example, gene expression profiles are made to identify one or more genes whose expression levels are modulated during the process of stem cell differentiation. The assaying of the modulation of gene expression via the production of a gene expression profile generally involves the production of cDNA from polyA⁺ RNA (mRNA) isolated from stem cells as described below.

-8-

Stem cells are harvested or isolated by any technique known in the art. One of the most versatile ways to separate hematopoietic cells is by use of flow cytometry, where the particles, *i.e.*, cells, can be detected by fluorescence or light scattering. The source of the cells may be any source which is convenient. Thus, various tissues, organs, fluids, or 5 the like may be the source of the cellular mixtures. Of particular interest are bone marrow and peripheral blood, although other lymphoid tissues are also of interest, such as spleen, thymus, and lymph node (see Sasaki *et al.*, U.S. Patent No. 5,466,572 and Fei *et al.*, U.S. Patent No. 5,635,387).

Cells of interest will usually be detected and separated by virtue of surface membrane 10 proteins which are characteristic of the cells. For example, CD34 is a marker for immature hematopoietic cells. Markers for dedicated cells may include CD 10, CD19, CD20, and sIg for B cells, CD 15 for granulocytes, CD 16 and CD33 for myeloid cells, CD 14 for monocytes, CD41 for megakaryocytes, CD38 for lineage dedicated cells, CD3, CD4, CD7, CD8 and T cell receptor (TCR) for T cells, Thy-1 for progenitor cells, 15 glycophorin for erythroid progenitors and CD71 for activated T cells. In isolating early progenitors, one may divide a CD34 positive enriched fraction into lineage (Lin) negative, e.g. CD2 -, CD 14 -, CD15 -, CD16 -, CD10 -, CD19 -, CD33 - and glycophorin A -, fractions by negatively selecting for markers expressed on lineage 20 committed cells, Thy-1 positive fractions, or into CD38 negative fractions to provide a composition substantially enriched for early progenitor cells. Other markers of interest include V alpha and V beta chains of the T-cell receptor (Sasaki *et al.*, U. S. Patent No. 5,466,572 (1995)).

After isolation of the appropriate stem cells, total cellular mRNA is isolated from the cell sample. mRNAs are isolated from cells by any one of a variety of techniques. 25 Numerous techniques are well known (*see e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Approach*, Cold Spring harbor Press, NY, 1987; Ausbel *et al.*, *Current Protocols in Molecular Biology*, Greene Publishing Co. NY, 1995). In general, these techniques first lyse the cells and then enrich for or purify RNA. In one such protocol, cells are lysed in a Tris-buffered solution containing SDS. The lysate is extracted with 30 phenol/chloroform, and nucleic acids precipitated. The mRNAs may be purified from

crude preparations of nucleic acids or from total RNA by chromatography, such as binding and elution from oligo(dT)-cellulose or poly(U)-Sepharose®. However, purification of poly(A)-containing RNA is not a requirement. As stated above, other protocols and methods for isolation of RNAs may be substituted.

5 The mRNAs are reverse transcribed using an RNA-directed DNA polymerase, such as reverse transcriptase isolated from AMV, MoMuLV or recombinantly produced. Many commercial sources of enzyme are available (e.g. Pharmacia, New England Biolabs, Stratagene Cloning Systems). Suitable buffers, cofactors, and conditions are well known and supplied by manufacturers (see also, Sambrook *et al.* (1989) *Molecular Cloning: a 10 laboratory manual*, 2nd Ed., Cold Spring Harbor Laboratory; and Ausbel *et al.*, (1987) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, N.Y.).

Various oligonucleotides are used in the production of cDNA. In particular, the methods utilize oligonucleotide primers for cDNA synthesis, adapters, and primers for 15 amplification. Oligonucleotides are generally synthesized so single strands by standard chemistry techniques, including automated synthesis. Oligonucleotides are subsequently de-protected and may be purified by precipitation with ethanol, chromatographed using a sized or reversed-phase column, denaturing polyacrylamide gel electrophoresis, high-pressure liquid chromatography (HPLC), or other suitable method. In addition, within 20 certain preferred embodiments, a functional group, such as biotin, is incorporated preferably at the 5' or 3' terminal nucleotide. A biotinylated oligonucleotide may be synthesized using pre-coupled nucleotides, or alternatively, biotin may be conjugated to the oligonucleotide using standard chemical reactions. Other functional groups, such as fluorescent dyes, radioactive molecules, digoxigenin, and the like, may also be 25 incorporated.

Partially-double stranded adaptors are formed from single stranded oligonucleotides by annealing complementary single-stranded oligonucleotides that are chemically synthesized or by enzymatic synthesis. Following synthesis of each strand, the two oligonucleotide strands are mixed together in a buffered salt solution (e.g., 1 M NaCl, 30 100 mM Tris-HCl pH 8.0, 10 mM EDTA) or in a buffered solution containing Mg⁺² (e.g.,

-10-

10 mM MgCl₂) and annealed by heating to high temperature and slow cooling to room temperature.

The oligonucleotide primer that primes first strand DNA synthesis may comprise a 5' sequence incapable of hybridizing to a polyA tail of the mRNAs, and a 3' sequence that 5 hybridizes to a portion of the polyA tail of the mRNAs and at least one non-polyA nucleotide immediately upstream of the polyA tail. The 5' sequence is preferably a sufficient length that can serve as a primer for amplification. The 5' sequence also preferably has an average G+C content and does not contain large palindromic sequence; some palindromes, such as a recognition sequence for a restriction enzyme, may be 10 acceptable. Examples of suitable 5' sequences are CTCTCAAGGATCTACCGCT (SEQ ID No. _____), CAGGGTAGACGACGCTACGC (SEQ ID No. _____), and TAATACCGCGCCACATAGCA (SEQ ID No. _____)

The 5' sequence is joined to a 3' sequence comprising sequence that hybridizes to a portion of the polyA tail of mRNAs and at least one non-polyA nucleotide immediately 15 upstream. Although the polyA-hybridizing sequence is typically a homopolymer of dT or dU, it need only contain a sufficient number of dT or dU bases to hybridize to polyA under the conditions employed. Both oligo-dT and oligo-dU primers have been used and give comparable results. Thus, other bases may be interspersed or concentrated, as long as hybridization is not impeded. Typically, 12 to 18 bases or 12 to 30 bases of dT or dU 20 will be used. However, as one skilled in the art appreciates, the length need only be sufficient to obtain hybridization. The non-poly A⁺ nucleotide is A, C, or G, or a nucleotide derivative, such as inosinate. If one non-polyA nucleotide is used, then three oligonucleotide primers are needed to hybridize to all mRNAs. If two non-polyA nucleotides are used, then 12 primers are needed to hybridize to all mRNAs (AA, AC, 25 AG, AT, CA, CC, CG, CT, GA, GC, GG, GT). If three non-poly A nucleotides are used then 48 primers are needed (3 X 4 X 4). Although there is no theoretical upper limit on the number of non-polyA nucleotides, practical considerations make the use of one or two non-polyA nucleotides preferable.

For cDNA synthesis, the mRNAs are either subdivided into three (if one non-polyA 30 nucleotide is used) or 12 (if two non-polyA nucleotides are used) fractions, each

-11-

containing a single oligonucleotide primer, or the primers may be pooled and contacted with a mRNA preparation. Other subdivisions may alternatively be used. Briefly, first strand cDNA is initiated from the oligonucleotide primer by reverse transcriptase (RTasc). As noted above, RASE may be obtained from numerous sources and protocols 5 are well known. Second strand synthesis may be performed by RASE (Gubler and Hoffman, *Gene* 25: 263, 1983), which also has a DNA-directed DNA polymerase activity, with or without a specific primer, by DNA polymerase 1 in conjunction with RNaseH and DNA ligase, or other equivalent methods. The double-stranded cDNA is generally treated by phenol:chloroform extraction and ethanol precipitation to remove 10 protein and free nucleotides.

Double-stranded cDNA is subsequently digested with an agent that cleaves in a sequence-specific manner. Such cleaving agents include restriction enzymes, chemical cleaving agents, triple helix, and any other cleaving agent available. Restriction enzyme digestion is preferred; enzymes that are relatively infrequent cutters (*e.g.*, ≥ 5 bp 15 recognition site) are preferred and those that leave overhanging ends are especially preferred. A restriction enzyme with a six base pair recognition site cuts approximately 8% of cDNAs, so that approximately 12 such restriction enzymes should be needed to digest every cDNA at least once. By using 30 restriction enzymes, digestion of every cDNA is assured.

20 The adapters for use in the present invention are designed such that the two strands are only partially complementary and only one of the nucleic acid strands that the adapter is ligated to can be amplified. Thus, the adapter is partially double-stranded (*i.e.*, comprising two partially hybridized nucleic acid strands), wherein portions of the two strands are non-complementary to each other and portions of the two strands are 25 complementary to each other. Conceptually, the adapter may be "Y-shaped" or "bubble-shaped." When the 5' region is non-paired, the 3' end of other strand cannot be extended by a polymerase to make a complementary copy. The ligated adapter can also be blocked at the 3' end to eliminate extension during subsequent amplifications. Blocking groups include dideoxynucleotides and other available blocking agents. In this type of adapter 30 ("Y-shaped"), the non-complementary portion of the upper strand of the adapters is

-12-

preferably a length that can serve as a primer for amplification. As noted above, the non-complementary portion of the lower strand need only be one base, however, a longer sequence is preferable (e.g., 3 to 20 bases; 3 to 15 bases; 5 to 15 bases, or 14 to 24 bases. The complementary portion of the adapter should be long enough to form a duplex under 5 conditions of ligation.

For "bubble-shaped" adapters, the non-complementary portion of the upper strands is preferably a length that can serve as a primer for amplification. Thus, this portion is preferably 15 to 30 bases. Alternatively, the adapter can have a structure similar to the Y-shaped adapter, but has a 3' end that contains a moiety that a DNA polymerase cannot 10 extend from.

Amplification primers are also used in the present invention. Two different amplification steps are performed in the preferred aspect. In the first, the 3' end (referenced to mRNA) of double stranded cDNA that has been cleaved and ligated with an adapter is amplified. For this amplification, either a single primer or a primer pair is 15 used. The sequence of the single primer comprises at least a portion of the 5' sequence of the oligonucleotide primer used for first strand cDNA synthesis. The portion need only be long enough to serve as an amplification primer. The primer pair consists of a first primer whose sequence comprises at least a portion of the 5' sequence of the oligonucleotide primer as described above; and a second primer whose sequence 20 comprises at least a portion of the sequence of one strand of the adapter in the non-complementary portion. The primer will generally contain all the sequence of the non-complementary portion, but may contain less of the sequence, especially when the non-complementary portion is very long, or more of the sequence, especially when the non-complementary portion is very short. In some embodiments, the primer will contain 25 sequence of the complementary portion, as long as that sequence does not appreciably hybridize to the other strand of the adapter under the amplification conditions employed. For example, in one embodiment, the primer sequence comprises four bases of the complementary region to yield a 19 base primer, and amplification cycles are performed at 56°C (annealing temperature), 72°C (extension temperature), and 94°C (denaturation 30 temperature). In another embodiment, the primer is 25 bases long and has 10 bases of

-13-

sequence in the complementary portion. Amplification cycles for this primer are performed at 68 °C (annealing and extension temperature) and 94 °C (denaturation temperature). By using these longer primers, the specificity of priming is increased.

The design of the amplification primers will generally follow well-known guidelines, such as average G-C content, absence of hairpin structures, inability to form primer-dimers and the like. At times, however, it will be recognized that deviations from such guidelines may be appropriate or desirable.

In instances where small numbers of cells are available for the initial RNA extraction, such as small numbers of stem cells, the preferred method of producing a gene expression profile comprises the following general steps. Total RNA is extracted from as few as 10 5000 stem cells. Using an oligo-dT primer, double stranded cDNA is synthesized and ligated to an adapter in accordance with the present invention. Using adapter primers, the cDNA is PCR amplified using the protocol of Baskaran and Weissman (1996) *Genome Research* 6(7): 633 and/or Liv *et al.* (1992) *Methods of Enzymology*. The original cDNA 15 is therefore amplified several fold so that a large quantity of this cDNA is available for use in the display protocol according to the present invention. For the display, an aliquot of this cDNA is incubated with an anchored oligo-dT primer. In one method, this mixture is first heat denatured and then allowed to remain at 50 °C for 5 minutes to allow the anchor nucleotides of the oligo-dT primers to anneal. This provides for the synthesis 20 of cDNA utilizing Klenow DNA polymerase. The 3'-end region of the parent cDNA (mainly the polyA region) that remains single stranded due to pairing and subsequent synthesis of cDNA by the anchored oligo-dT primer at the beginning of the polyA region, is removed by the 5'-3' exonuclease activity of the T4 DNA polymerase. Following 25 incubation of the cDNA with T4 DNA polymerase for this purpose, dNTPs are added in the reaction mixture so that the T4 DNA polymerase initiates synthesis of the DNA over the anchored oligo-dT primer carrying the heel. The net result of this protocol is that the cDNA with the 3' heel is synthesized for display from the double stranded cDNA as the starting material, rather than RNA as the starting material as occurs in conventional 3'-end cDNA display protocol. The cDNA carrying the 3'-end heel is then subjected to 30 restriction enzyme digestion, ligation, and PCR amplification followed by running the

-14-

PCR amplified 3'-end restriction fragments with the Y-shaped adapter on a display gel. An alternate method is presented in Example 1.

After amplification, the lengths of the amplified fragments are determined. Any procedure that separates nucleic acids on the basis of size and allows detection or 5 identification of the nucleic acids is acceptable. Such procedures include slab gel electrophoresis, capillary gel electrophoresis, 2-dimensional electrophoresis, high performance liquid chromatography, and the like.

Electrophoresis is technique based on the mobility of DNA in an electric field. Negatively charged DNA migrates towards a positive electrode at a rate dependent on 10 their total charge, size, and shape. Most often, DNA is electrophoresed in agarose or polyacrylamide gels. For maximal resolution, polyacrylamide is preferred and for maximal linearity, a denaturant, such as urea is present. A typical gel setup uses a 19:1 mixture of acrylamide:bisacrylamide and a Tris-borate buffer. DNA samples are denatured and applied to the gel, which is usually sandwiched between glass plates. A 15 typical procedure can be found in Sambrook *et al.* (*Molecular Cloning: A Laboratory Approach*, Cold Spring Harbor Press, NY, 1989) or Ausbel *et al.* (*Current Protocols in Molecular Biology*, Greene Publishing Co., NY, 1995). Variations may be substituted as long as sufficient resolution is obtained.

Capillary electrophoresis (CE) in its various manifestations (free solution, 20 isotachophoresis, isoelectric focusing, polyacrylamide gel. micellar electrokinetic "chromatography") allows high resolution separation of very small sample volumes. Briefly, in capillary electrophoresis, a neutral coated capillary, such as a 50 μ m X 37 cm column (eCAP neutral, Beckman Instruments, CA), is filled with a linear polyacrylamide (e.g., 0.2% polyacrylamide), a sample is introduced by high-pressure injection followed 25 by an injection of running buffer (e.g., 1X TBE). The sample is electrophoresed and fragments are detected. An order of magnitude increase can be achieved with the use of capillary electrophoresis. Capillaries may be used in parallel for increased throughput (Smith *et al.* (1990) *Nuc. Acids. Res.* 18:4417; Mathies and Huang (1992) *Nature* 359:167). Because of the small sample volume that can be loaded onto a capillary, 30 sample may be concentrated to increase level of detection. One means of concentration

-15-

is sample stacking (Chien and Burgi (1992) *Anal. Chem.* 64:489A). In sample stacking, a large volume of sample in a low concentration buffer is introduced to the capillary column. The capillary is then filled with a buffer of the same composition, but at higher concentration, such that when the sample ions reach the capillary buffer with a lower electric field, they stack into a concentrated zone. Sample stacking can increase detection by one to three orders of magnitude. Other methods of concentration, such as isotachophoresis, may also be used.

High-performance liquid chromatography (HPLC) is a chromatographic separation technique that separates compounds in solution. HPLC instruments consist of a reservoir of mobile phase, a pump, an injector, a separation column, and a detector. Compounds are separated by injecting an aliquot of the sample mixture onto the column. The different components in the mixture pass through the column at different rates due to differences in their partitioning behavior between the mobile liquid phase and the stationary phase. IP-RO-HPLC on non-porous PS/DVB particles with chemically bonded alkyl chains can also be used to analyze nucleic acid molecules on the basis of size (Huber et al. (1993) *Anal. Biochem.* 121:351; Huber et al. (1993) *Nuc. Acids Res.* 21:1061; Huber et al. (1993) *Biotechniques* 16:898).

In each of these analysis techniques, the amplified fragments are detected. A variety of labels can be used to assist in detection. Such labels include, but are not limited to, radioactive molecules (e.g., ^{35}S , ^{32}P , ^{33}P), fluorescent molecules, and mass spectrometric tags. The labels may be attached to the oligonucleotide primers or to nucleotides that are incorporated during DNA synthesis, including amplification.

Radioactive nucleotides may be obtained from commercial sources; radioactive primers may be readily generated by transfer of label from γ - ^{32}P -ATP to a 5'-OH group by a kinase (e.g., T4 polynucleotide kinase). Detection systems include autoradiograph, phosphor image analysis and the like.

Fluorescent nucleotides may be obtained from commercial sources (e.g., ABI, Foster city, CA) or generated by chemical reaction using appropriately derivatized dyes. Oligonucleotide primers can be labeled, for example, using succinimidyl esters to conjugate to amine-modified oligonucleotides. A variety of fluorescent dyes may be used,

-16-

including 6 carboxyfluorescein, other carboxyfluorescein derivatives, carboxyrhodamine derivatives, Texas red derivatives, and the like. Detection systems include photomultiplier tubes with appropriate wave-length filters for the dyes used. DNA sequence analysis systems, such as produced by ABI (Foster City, CA), may be used.

5 After separation of the amplified cDNA fragments, cDNA fragments which correspond to differentially expressed mRNA species are isolated, reamplified and sequenced according to standard procedures. For instance, bands corresponding the cDNA fragments can be cut from the electrophoresis gel, reamplified and subcloned into any available vector, including pCRscript using the PCR script cloning kit (Stratagene).

10 The insert is then sequenced using standard procedures, such as cycle sequencing on an ABI sequencer (Foster City, CA).

An additional means of analysis comprises hybridization of the amplified fragments to one or more sets of oligonucleotides immobilized on a solid substrate. Historically, the solid substrate is a membrane, such as nitrocellulose or nylon. More recently, the 15 substrate is a silicon wafer or a borosilicate slide. The substrate may be porous (Beattie et al. WO 95/11755) or solid. Oligonucleotides are synthesized *in situ* or synthesized prior to deposition on the substrate using standard procedures. Various chemistries are known for attaching oligonucleotides. Many of these attachment chemistries rely upon functionalizing oligonucleotides to contain a primary amine group. The oligonucleotides 20 are arranged in an array form, such that the position of each oligonucleotide sequence can be determined.

The amplified fragments, which are generally labeled according to one of the methods described herein, are denatured and applied to the oligonucleotides on the substrate under appropriate salt and temperature conditions. In certain embodiments, the conditions are 25 chosen to favor hybridization of exact complementary matches and disfavor hybridization of mismatches. Unhybridized nucleic acids are washed off and the hybridized molecules detected, generally both for position and quantity. The detection method will depend upon the label used. Radioactive labels, fluorescent labels and mass spectrometry label are among the suitable labels.

-17-

The present invention as set forth in the specific embodiments, includes methods to identify a therapeutic agent that modulates the expression of at least one stem cell gene associated with the differentiation, proliferation and/or survival of stem cells.

As an example, the method to identify an agent that modulates the expression of at

5 least one stem cell gene associated with the differentiation of a stem cell population, comprises the steps of preparing a first gene expression profile of an undifferentiated stem cell population, preparing a second gene expression profile of a stem cell population at a defined stage of differentiation, treating said undifferentiated stem cell population with the agent, preparing a third gene expression profile of the treated stem cell

10 population, and comparing the first, second and third gene expression profiles.

Comparison of the three gene expression profiles for RNA species as represented by cDNA fragments that are differentially expressed upon addition of the agent to the undifferentiated stem cell population identifies agents that modulate the expression of at least one gene in undifferentiated stem cells that is associated with stem cell

15 differentiation.

While the above methods for identifying a therapeutic agent comprise the comparison of gene expression profiles from treated and not-treated stem cells, many other variations are immediately envisioned by one of ordinary skill in the art. As an example, as a variation of a method to identify a therapeutic agent that modulates the expression of at

20 least one stem cell gene associated with the differentiation, the second gene expression profile of a stem cell population at a defined stage of differentiation and the third gene expression profile of the treated stem cell population can each be independently normalized using the first gene expression profile prepared from the undifferentiated stem cell population. Normalization of the profiles can easily be achieved by scanning

25 autoradiographs corresponding to each profile, and subtracting the digitized values corresponding to each band on the autoradiograph from undifferentiated stem cells from the digitized value for each corresponding band on autoradiographs corresponding to the second and third gene expression profiles. After normalization, the second and third gene expression profiles can be compared directly to detect cDNA fragments which

-18-

correspond to mRNA species which are specifically expressed during differentiation of a stem cell population.

Specific Embodiments

Example 1

5 *Production of gene expression profiles generated from cDNAs made with RNA isolated from undifferentiated and partially differentiated stem cells.*

Crude Marrow Preparation

Expression profiles of RNA expression levels from undifferentiated stem cells and 10 stem cells at various levels of differentiation, including partially differentiated and terminally differentiated stem cells, offer a powerful means of identifying genes whose expression levels are associated with stem cell differentiation or proliferation. As an example, the production of expression profiles from murine lineage negative, rhodamine low, Hoechst low and rhodamine bright, Hoechst low hematopoietic precursor cells allows for the identification of mRNA species and their encoding genes whose 15 expression levels are associated with stem cell differentiation

Hoechst^{low}/Rhodamine^{low} hematopoietic stem cells were isolated by sacrificing 30 Balb/c female mice (6-12 weeks) and surgically removing the iliac crests, femurs and tibiae. The bones were cleaned and placed in 10 ml PBS/5% HI-FBS on ice. One tube 20 was used for the bones from 10 mice. The bones were ground thoroughly with a pestle until completely broken. Following grinding, the supernatant was removed into a 50 ml conical tube through a 40 µM filer(Falcon #2340). 10 ml PBS/FBS was added to the mix and the supernatant removed. The supernatant was then centrifuged (1250 rpm) for 5-10 minutes. The supernatant which contains a high concentration of lipid was then decanted and discarded.

25 The cells were then pooled into 25 or 50 ml fresh PBS/FBS, and tiny bone fragments removed by settling. The cells were then counted in crystal violet. Cells were diluted and underlaid with LSM, centrifuged at 2000rpm(1000xg) for 20 minutes. To harvest the buffy coat, the supernatant was removed to within 1 cm of the cells. The next 8-

-19-

10ml of medium and cells were harvested by swirling the media around in the tube to draw cells from all sides of the gradient. The cell volume was then brought up to 50 ml with PBS/FBS and spun at 1400rpm 5-10 minutes.

Lineage Depletion

5 Cells were counted in Crystal Violet and resuspended in fresh PBS/FBS. Lineage-specific antibodies were added as follows:

| | | |
|----|-----------|------------------------------------|
| | TER 119 | 0.1 μ g/ml final concentration |
| | B220 | 15 μ l/10 ⁸ cells |
| | Mac-1 | 15 μ l/10 ⁸ cells |
| 10 | Gr-1 | 15 μ l/10 ⁸ cells |
| | Lyt-2 | 1/20 final dilution |
| | L3T4 | 1/20 final dilution |
| | Yw25.12.7 | 1/100 final dilution |

15 The cells were incubated on ice for 15 minutes, brought to a volume of 50ml with PBS/FBS and collected at 1400rpm for 5-10 minutes, and washed to remove unbound antibodies.

During the antibody binding step, Magnetic Beads(Dynabeads M-450) were prepared at a ratio of 5 beads/cell. The beads were coated with Sheep anti-Rat antibodies that bind to the lineage-specific antibodies, which are all of rat origin. When the beads are placed in 20 a magnetic field, the Lin⁺ cells are removed. The resulting supernatant contains the Lin⁻ population (granulocytes and lymphocyte populations will be substantially depleted or absent after this step.)

Hoechst/Rhodamine Staining

25 Rhodamine 123 was added to a final concentration of 0.1 μ g/ml, then incubated at 32°C for 20 minutes in the dark. Without further manipulation or washing, HOECHST 33342 was added to a final concentration of 10 μ M then incubated at 37°C for an additional hour. The aliquot of crude marrow was brought to 0.5 ml with PBS/FBS and Hoechst to this cell preparation as well. The volume was brought to 50 ml with PBS/FBS, centrifuged at 1400rpm for 5-10 minutes, supernatant discarded and cells 30 resuspended to 2x10⁷ cells/ml. The rhodamine only and Hoechst Only/Crude Marrow

-20-

were washed in parallel. These two populations were then resuspended in 0.5ml PBS/FBS for flow cytometry analysis

Total RNA was extracted from approximately 5000 stem cells. Using an oligo-dT primer, double stranded cDNA is synthesized and ligated to an adapter in accordance

5 with the present invention. Using adapter primers, the cDNA is PCR amplified using the protocol of Baskaran and Weissman (1996) *Genome Research* 6(7): 633 and Lie *et al.*, *Methods of Enzymology*, _____. The original cDNA is therefore amplified several fold so that a large quantity of this cDNA is available for use in the display protocol according to the present invention.

10 10 Synthesis of cDNA for the gene expression profiles was performed as below:

Materials and Reagents

A microPoly(A)Pure mRNA Isolation kit (Ambion Inc.) was used for mRNA isolation. All the reagents for cDNA synthesis were obtained from Life Technologies Inc. Klentaq1 DNA polymerase (25U/ μ l) was from Ab peptides Inc. Native *Pfu* DNA polymerase 15 (2.5U/ μ l) was purchased from Stratagene Inc. Betaine monohydrate was from Fluka BioChemica and dimethylsulfoxide (DMSO) was from Sigma Chemical Company. Deoxynucleoside triphophates (dNTPs, 100mM) and bovine serum albumin (BSA, 10 mg/ml) were purchased from New England Biolabs, Inc. Qiaquick PCR purification kit (Qiagen) was used to purify the amplified PCR products. The oligonucleotides used in the 20 Examples were synthesized and gel purified in the DNA synthesis laboratory (Department of Pathology, Yale University School of Medicine, New Haven, CT).

Table 1. Sequences of oligonucleotides.

| | |
|----------------------------------|------------------------------------------------------------------------------------------------------|
| T ₇ -SalI-oligo-d(T)V | 5'-ACG TAA TAC GAC TCA CTA TAG GGC GAA TTG GGT CGA C- d (T) ₁₈ V-3', where V = A, C, G |
| anti-NotI Long | 5'-CTT ACA GCG GCC GCT TGG ACG-3' |

-21-

| | |
|----------------|-----------------------------------------------|
| NotI Short | 5'-AGC GGC CGC TGT AAG-3' |
| NotI/RI primer | 5'-GCG GAA TTC CGT CCA AGC GGC CGC TGT AAG-3' |

Methods

I. Preparation of mRNA

5 MicroPoly(A)Pure mRNA isolation kit was used for the isolation of Poly(A)⁺ RNA following the kit instructions. mRNA from a small number of mouse hematopoietic cells (5,000-10,000 cells) was extracted, eluted from the column, and precipitated by adding 0.1 volume of 5M ammonium acetate and 2.5 volumes of chilled ethanol with 2 μ g glycogen as carrier. The tubes were left at -20°C overnight. The pellets were collected by centrifugation
10 at top speed for 30 minutes, washed with 70% ethanol and air-dried at room temperature. The pellets were resuspended in 10 μ l H₂O/0.1mM EDTA solution. We observed that the dissolved mRNA solution was cloudy due to the leaching of column materials, therefore the samples were centrifuged at 4°C for 5 minutes. The supernatant was collected for further use.

15 II. cDNA synthesis

First strand cDNA synthesis

The cDNA synthesis reaction (final reaction volume is 20 μ l) was carried out as described in the instruction manual (Superscript Choice System) provided by Life Technologies Inc. For the first strand cDNA synthesis, mRNA (10 μ l) isolated from a small
20 number of cells was annealed with 200ng (1 μ l) of T₇-SalI-oligo-d(T)V-primer (see Table-1) in a 0.5-ml micro centrifuge tube (no stick, USA Scientific Plastics) by heating the tubes at 65°C for 5 minutes, followed by quick chilling on ice for 5 minutes. This step was repeated

-22-

once and the contents were collected at the bottom of the tube by a brief centrifugation. The following components were added to the primer annealed mRNA on ice prior to initiating the reaction, 1 μ l of 10mM dNTPs, 4 μ l of 5 x first strand buffer [250mM Tris-HCl (pH 8.3), 375mM KCl, 15mM MgCl₂], 2 μ l of 100mM DTT and 1 μ l of RNase Inhibitor (40U/ μ l). All 5 the contents were mixed gently and the tubes were pre-warmed at 45°C for 2 minutes. The cDNA synthesis was initiated by adding 200 units (1 μ l) of Superscript II Reverse Transcriptase and the incubation continued at 45 °C for 1 hour.

Second strand cDNA synthesis

At the end of first strand cDNA synthesis, the tubes were kept on ice. Second 10 strand cDNA synthesis reaction (final volume is 150 μ l) was set up in the same tube on ice by adding 91 μ l of nuclease free water, 30 μ l of 5x second strand buffer [100mM Tris-HCl (pH 6.9), 23mM MgCl₂, 450mM KCl, 0.75mM (β -NAD⁺ and 50mM ammonium sulfate], 3 μ l of 10mM dNTPs, 1 μ l of *E.coli* DNA ligase (10U/ μ l), 4 μ l of *E.coli* DNA polymerase I (10U/ μ l) and 1 μ l of *E.coli* RNase H (2U/ μ l). The contents were 15 mixed gently and the tubes were incubated at 16 °C for 2 hours. Following the incubation, the tubes were kept on ice, 2 μ l of T₄ DNA polymerase (3U/ μ l) was added and the incubation was continued for another 5 minutes at 16 °C. The reaction was stopped by the addition of 10 μ l of 0.5M EDTA (pH 8.0) and extracted once with equal volume of phenol: chloroform 1:1 (v/v) and once with chloroform. The aqueous phase was then 20 transferred to a new tube and precipitated by adding 0.5 volumes of 7.5M ammonium acetate (pH 7.6), 2 μ g of glycogen (as carrier) and 2.5 volumes of chilled ethanol. The samples were left at -20°C for overnight and the cDNA pellets were collected by centrifugation at top speed for 20 minutes. The pellets were washed once with 70% ethanol, air-dried and dissolved in 14 μ l of nuclease free water.

25 As the amount of cDNA derived from a small number of cells may be low, it may be necessary to amplify the cDNA for further analysis. To uniformly amplify the cDNA, an adaptor (NotI adaptor) was first ligated to both ends of the cDNA. Following adaptor

-23-

ligation, the cDNAs were amplified with NotI/RI primer (see *table 1*), by a modified PCR method using betaine and DMSO.

Ligation of cDNA with NotI adaptor

Preparation of NotI adaptor: The NotI adaptor was prepared by annealing

5 NotI-short and anti-NotI-long oligonucleotides (see Table 1). The anti-NotI-long oligonucleotide was phosphorylated to ensure that both the adaptor oligonucleotides are ligated to the cDNA. 1 μ g of anti-NotI-long was mixed with 1 μ l of 10x T₄ polynucleotide kinase buffer [700mM Tris-HCl (pH 7.6), 100mM MgCl₂ and 50mM DTT], 1 μ l of 10mM adenosine triphosphate (ATP), adjusted the volume to 9 μ l with water and the 10 reaction was initiated by adding 1 μ l of T₄ polynucleotide kinase (10U/ μ l). The tubes were incubated at 37°C for 30 minutes and then the enzyme was inactivated at 65°C for 20 minutes. The annealing was carried out by adding the following components to the above phosphorylated anti-NotI-long: 1 μ g of NotI-short, 2 μ l of 10x oligo annealing buffer [100mM Tris-HCl (pH 8.0), 10mM EDTA (pH 8.0) and 1M NaCl] and water to adjust 15 the final volume to 20 μ l. The sample was heated at 65°C for 10 minutes and allowed to cool down to room temperature. The annealed adaptor was stored at -20°C.

Ligation of cDNA with annealed NotI adaptor: To set up this reaction,

14 μ l of cDNA was mixed with 100ng of annealed NotI adaptor in a 0.5-ml micro centrifuge tube. To this mixture 2 μ l of 10x T₄ DNA ligase buffer [500mM Tris-HCl (pH 20 7.8), 100mM MgCl₂, 100mM DDT, 10mM ATP and 250mg/ml BSA] was added and adjusted the volume with water to 18 μ l and mixed gently. The reaction was initiated by adding 2 μ l of T₄ DNA ligase (400U/ μ l) and incubated at 16°C overnight.

III. cDNA amplification

A modified betaine-DMSO PCR method (Baskaran *et al.* (1996)) Genome

25 Research 6:633) was used to uniformly amplify the cDNA with different GC content. This method uses the LA system, which combines a highly thermostable form of *Taq* DNA polymerase (Klentaq1, which is devoid of 5'-exonuclease activity) and a proofreading enzyme (*Pfu* DNA polymerase, which has 3'-exonuclease activity). The

-24-

LA16 enzyme consists of 1 part of *Pfu* DNA polymerase and 15 parts of KlenTaq1 DNA Polymerase (v/v). The NotI adaptor-ligated cDNA was diluted 10 fold with water. 2 μ l of this diluted cDNA was used as the template for PCR. The PCR reaction (50 μ l final volume) was set up with the following components: 5 μ l of 10x PCR buffer [200mM Tris-HCl (pH 9.0), 160mM ammonium sulfate and 25mM MgCl₂], 16 μ l of water, 0.8 μ l of BSA (10mg/ml), 1 μ l of NotI/RI PCR primer (100ng/ μ l), 5 μ l of 50% DMSO (v/v), 15 μ l of 5M Betaine and 0.2 μ l of LA16 enzyme. These components were mixed gently on ice and then heated to 95°C for 15 seconds on a PCR machine, and held at 80°C while 5 μ l of 2mM dNTPs were added to start the reaction. The PCR conditions were as follows: *Stage 1*: 95°C for 15 seconds, 55°C for 1 minute, 68°C for 5 minutes, 5 cycles. *Stage 2*: 95°C for 15 seconds, 60°C for 1 minute, 68°C for 5 minutes, 15 cycles.

After amplification, cDNA was purified with the Qiaquick PCR purification kit (following the instructions provided by the supplier). The purified cDNA was eluted in the desired volume of water.

Gene expression profiles were prepared from the purified cDNA as previously described by Prashar *et al.* in WO 97/05286 and in Prashar *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:659-663. Briefly, the adapter oligonucleotide sequences were CTTACAGCGGCCGCTTGGACG, GAATGTCGCCGGCGA or alternatively, A1 (TAGCGTCCGGCGCAGCGACGGCCAG) and A2 (GATCCTGGCCGTCGGCTGTCTGTCGGCGC). When A1/A2 were used, one microgram of oligonucleotide A2 was first phosphorylated at the 5' end using T4 polynucleotide kinase (PNK). After phosphorylation, PNK was heated denatured, and 1 μ g of the oligonucleotide A1 was added along with 10 \times annealing buffer (1 M NaCl/100 mM Tris-HCl, pH8.0/10 mM EDTA, pH8.0) in a final vol of 20 μ l. This mixture was then heated at 65°C for 10 min followed by slow cooling to room temperature for 30 min, resulting in formation of the Y adapter at a final concentration of 100 ng/ μ l. About 20 ng of the cDNA was digested with 4 units of a restriction enzyme such as *Clal*, *Bgl* II, etc. in a final vol of 10 μ l for 30 min at 37°C. Two microliters (\approx 4 ng of digested cDNA) of this reaction mixture was then used for ligation to 100 ng (\approx 50-fold) of the Y-shaped adapter in a final vol of 5 μ l for 16 hr at 15°C. After ligation, the

-25-

reaction mixture was diluted with water to a final vol of 80 μ l (adapter ligated cDNA concentration, \approx 50 pg/ μ l) and heated at 65°C for 10 min to denature T4 DNA ligase, and 2- μ l aliquots (with \approx 100 pg of cDNA) were used for PCR.

The following sets of primers were used for PCR amplification of the adapter 5 ligated 3' -end cDNAs: GCGGAATTCCGTCCAAGCGGCCGCTGTAAG or alternatively, RP 5.0 (CTCTCAAGGATCTTACCGCTT₁₈AT), RP 6.0 (TAATACCGCGCCACATAGCAT₁₈CG), or RP 9.2 (CAGGGTAGACGACGCTACGCT₁₈GA) were used as 3' primer while A1.1 (TAGCGTCCGGCGCAGCGAC) served as the 5' primer. To detect the PCR products 10 on the display gel, 24 pmol of oligonucleotide A1.1 was 5' -end-labeled using 15 μ l of [γ -³²P]ATP (Amersham; 3000 Ci/mmol) and PNK in a final volume of 20 μ l for 30 min at 37°C. After heat denaturing PNK at 65°C for 20 min, the labeled oligonucleotide was diluted to a final concentration of 2 μ M in 80 μ l with unlabeled oligonucleotide A1.1. The PCR mixture (20 μ l) consisted of 2 μ l (\approx 100 pg) of the template, 2 μ l of 10 \times PCR 15 buffer (100 mM Tris-HCl, pH 8.3/500 mM KCl), 2 μ l of 15 mM MgCl₂ to yield 1.5 mM final Mg²⁺ concentration optimum in the reaction mixture, 200 μ M dNTPs, 200 nM each 5' and 3' PCR primers, and 1 unit of AmpliTaq. Primers and dNTPs were added after preheating the reaction mixture containing the rest of the components at 85°C. This "hot 20 start" PCR was done to avoid artefactual amplification arising out of arbitrary annealing of PCR primers at lower temperature during transition from room temperature to 94°C in the first PCR cycle. PCR consisted of 28-30 cycles of 94°C for 30 sec, 50°C for 2 min, and 72°C for 30 sec. A higher number of cycles resulted in smearable gel patterns. PCR products (2.5 μ l) were analyzed on 6% polyacrylamide sequencing gel. For double or multiple digestion following adapter ligation, 13.2 μ l of the ligated cDNA sample was 25 digested with a secondary restriction enzyme(s) in a final vol of 20 μ l. From this solution, 3 μ l was used as template for PCR. This template vol of 3 μ l carried \approx 100 pg of the cDNA and 10 mM MgCl₂ (from the 10 \times enzyme buffer), which diluted to the optimum of 1.5 mM in the final PCR vol of 20 μ l. Since Mg²⁺ comes from the restriction enzyme buffer, it was not included in the reaction mixture when amplifying 30 secondarily cut cDNA. Bands may then be extracted from the display gels as described

-26-

by Liang *et al.* (1995 *Curr. Opin. Immunol.* 7:274-280), reamplified using the 5' and 3' primers, and subcloned into pCR-Script with high efficiency using the PCR-Script cloning kit from Stratagene. Plasmids were sequenced by cycle sequencing on an ABI automated sequencer.

5 Figure 1 presents an autoradiogram of the gene expression profiles generated from cDNAs made with RNA isolated from Lin⁺, LRH, LRH48 and LRBRH cells. All possible 12 anchoring oligo d(T)n1, n2 were used to generate a complete expression profile for the enzyme *Clal*.

10 Table 2 presents the sequences of numerous differentially expressed bands from expression profiles made from LIN⁺, LRH, LRH48 and LRBRH.

TABLE 2

| | |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-006 | TTAATTAGCGCTCTATATACATTGCG GAACCTCCCCGACTGCAGCAGTTGA CTTGGCACACATCAAGTCCATTTC TTTGGACATTGGATTCTGTTGANA GTATGTATGCCCAAAGCATTTCAGT GTCATCAGGATTAGTTGGGCCATTCA CAGTAATTCANANATC |
| HSC-DD-285 | TAGAATACCTGGATGGCTTCTCTTGTC CACCCGATCTCCCGTGTACCAATGTG TATGGTCTCCTCTCCGAAAGTGTAC TTAATCTTGCTTCTTGACAAATGTC TTTGGTTGCAAGTCATAAGCCTGAGGC AAATAAAATTCC |

-27-

| | |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-007B | GATCTGGCTAGACAGTTATTCTGAAC ATGGCTTCAAGATGAACAAGACAAGC CTAAAAGGATGGAGAGAGGCAATGGA GATAATGTTTGGAGGAAGTATGTCAC TCAAGCATGAACCTCTGTTATTAGAA ATGAGATTCCATATATGTGGTACATGT GGAAAGAATCTAAAAAGTCCTTAAA TTTTTCATTCCAAAAG |
| HSC-DD-238 | CTNNANNAGCACTCTTCTTGGCCAGAC CTCTGTCCAAGGCTCATTAGAAAGCTG GGGTTNTGTCACGTNACNNACTTNAT CNAAACTNTGCTGTNTGGCATAAGT TGTGTNTCTGGACTGTNNTGTATCCC CTCTAGACAAAGGANCAACNNAAAAG TNNTTGCNNNTTNCCAGAACATNCT CAAAGCCTNTGATGGAGGGAGCACAAG GACCCTGTCTGCTGAGGGCCCATGGNT CCTCTCAGGGTTCTNCCACCNAGG CAGTGCCTTCATTNGCTAGTNGTNCAG TTACTTGTAGNTTATCTTNAATAAAAT TTNAATAAAANCTA |
| HSC-DD-206 | CTAGATTGTGTGGTTGCCTCATTGTG CTATTGCGCACTTCCTTCCCTGAAG AAATANCTGTGAANCTTCTTCTGTT AGTCCTAANATTCAAATANAGTGAG ACTATG |

-28-

| | |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-214 | CTCAAGNACGGGCCAGGTAAAGGGCCT TTAACACAACATAATCAAGGTGTGCTT NCCTCCGGGTTCTATGCAAGCAAGGCA TACACACTGCACTCTCNCNCTNCTAA ACTGGAAANGTACAGTNGCAGGGCTG GTTTCAGACNACGTGATGCNTGTTAC AAAC |
| HSC-DD-035 | TTTTTATTCAATATATTAAATATATTAA TCAGAAAAGTCACATCCTATAAAATCCA GGAAAATACACAAATATAAATCAGAA TCTGTCAATCACCTTCTTGAGTGACAG TTATGTACACATGGAAGGAGAGCGGA AGAGATC |
| HSC-DD-129 | CGATATAACCCATCGGTCTGGGCCAA CGCTAATACTACTTGGTGCTGCCAATT GAATTCTGGTTGCTGTGAATCTCTAT CAACAAGAGTATCATTGTGAATGCTT TAATTATTGAGAAAGAACAAAGAAGA TGATGGATACATTGATACATTGCGCA GCCTTGCAGCCTGACTCAATTCTGCTG TTCATCAGTTTAATGTCCCTTCTGTGT CATACGTG |

-29-

| | |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-040 | GATCTTTTCCTCACTTATTGCTGAA ACCAAGNGCACAATTCCCATTAGNG AAGGATCTCTGTGCTGTAAACTAAACA AATTGTGCATTTCTGGGCCATTG TTTTGGTTATTTGTTATTTGTTTG TTTTGTTTTGGTTTCATTTGTTT GGGTTGGTCCAATTAAAAGGAAATA CTACAATAAAATGTTA |
| HSC-DD-011 | GATCTGATTGCTAGTTCTCCTGGTA GAGTTATAAAATGGAAAGATTACACTAT CTGATTAATAGTTCTTCATACTCTGC ATATAATTGTGGCTGCAGAATATTGT AATTGTGCACACTATGTAACAAAAC TGAAGATATGTTAATAAAATTGTAC T |
| HSC-DD-121 | GCGATGTTCTTCTACTCACAACTCACG TTGGTGGCCTGGGCCTGAACTTGACTG GAGCTGACACTGTGGTGGTGTGGAGC ATGACTGGAACCCATGCGAGATCTGC AGGCCATGGACCAGGGCCATCGTATTG GGCAGAAACGTGTGGTTAATGTCTACC GGTTGATAACCAGA |
| HSC-DD-015B | GATCTGGAAGGGAAATGTCCAAAGAGA AGAAGGAGGAGTGGGACCGCAAGGCT GAGGATGCTAGGAGGGAGTATGAGAA AGCCATGAAAGAGTATGAAGGGAGGAA GAGGGGACTCATCTAAAAG |

-30-

| | |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-039 | GATCTTCGACACAGAGAAGGAGAAAT ACGAGATTACAGAGCAGCGAAAGGCT GACCAGAAAGCTGTGGATTGCAGATT TTGCCAAAGATTAAAGCTGTTCTCAG CTCCAGGGCTACCTGCGCTCTCAGTTT TCCCTGACAAACGGGATGTATCCTCAC AAACTGGTCTTCTAAATTGTTAACCTA ATTAAACAG |
| HSC-DD-042 | ACTCAATCTCTTCAAACCTTTATACT GGNCTATNATNAGNGGGATGTGNCA ANATNGACNCTGGTGGTGTATGAAAG AAAAGNTCNATGGACNTNGGCATNCC AAGATTGAATTCACCTGCTTCTACGA TGTGTGAAACTGCTAATAGCAAAATAT CTCTANGTTATGANGAGTACTGTCGT TCTGCAAATATTCACTTCANAACCTANN CACCACTTNAAA |
| HSC-DD-256A | CTAGATAATCCCTTACTGAGTCTTCTT CNCAGGTGATTCAATTGAGTTGACAAT TANNNCTAAGAATTCAATGGACTANT GAGGTGCCTCAGCAGNTAATAGCANT TGCTGTTCTCCAGAGGACCAGAGTTC AGTTTCTCATCCCAAGTTGGGCTGCTC GTNAGTGTGGTAANTCCAGCTTCAGG GGCTTGAATTATACTGACCATGGCA CCTGTACCCCAACACANACACATACA CAT |

-31-

| | |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-256B | CTAGAAGTTAACCTGTNAAGCATGGT AAGAATANCATTCTCAANATCTTGAGT TAANAAAGATCTTGGAGGNGGCTGGN GAGATGGCTCANTGGTTAACAGANCNCT GAUTGCTCTTCCAGAGGTCTGANTTC AATTCCCANCAACCACATGGTGGNTCA CAACCANCTGTAATGATACTGATGCC ATCNTCCGTGGTGTATCTGAANACANC TACAGTGACAGCTACANCG |
| HSC-DD-045 | GGATTATTCTAGGCTTGGCCAGATA CAGGTTGGCATCCTAGGGAGGAAGA TAACAATGTCATAGGTGAATTGTTAG GAGAGGCAAGACATGGGAAATCATTG ATTTCTTCAGATTCTTAAAGCAAAT TAGAAGATAAATGTCTAAAGAGATA CACTTAAAAAATGGTGAAACTATAAC CCCTTAAGGAGAGGCCAGATGTGGCAG GAGCCAGGTCTGAAAATGGTAGCTGA AGTAAGCAGACCAGCGTAAGATC |
| HSC-DD-068 | CGATGAGTCAGAGAGGAAGTGGACAG TGCCTTATTCTTACAGCAAAGGATT CGTTGGCATAAAACTAAGTTGTT TACAAAGATTGTTTTAGTACTAAGCT GCCTTGGCAGTTGCATTGAGCCA AACAAAAATATATTATTTC |

-32-

| | |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-143 | CGATTCAATTGTATAAATGATTATAAT TTCTTTCATGGAAGCATGATCCTCTG ATTAAGAACTGTACCCATATTTATG CTGGTTGTCTGCAAGCTTGTGCGATGA TGTTATGTTCATGTTAACCTATTGTA AAATGAAGTGTCCCTGACCTTATGTTA AAAAGAGAGAAGTAAATAACAGACAT TATTCAAGTTATTTGTCCCTTATCGAAA AACCAAGATTCATTTCCCTTTGT GTGATCTCATTGGAAATAATTGGCAA GTTGAGGTACTTCTTCCATGCTTGT ACAATATAAACTGTTATGCCTTCAGT GCGTTACTGTGGG |
| | |
| | |
| HSC-DD-263A | CTAGAGGTGGAACTGGCTCCACTCCA CACAGCAGCCAGTTAGTTAGTGACGGT CAGCTGCATGCAGGGAAATGAAGGAC TCGGAGAGAACGTTCTGTGCTATGTGT GTTCCATAGAGATTAAAAAGGAGGCC TGGAGCCGAGCATGGTGGTGCACGCC TTAATCCCAGCACTGGGAGGCAGAG TCAGGTGGATTCTGAGTTCAATTGCCA GCCTGGTCTACAGAGTGAATTCCAGGA CAGGCAGGGCTACACAGAGAAACCCCT GTCTAAAAAA |
| HSC-DD-263B | CTAGAATTGCAGTAGCATTAAATTCAA GCCTACGTATTCAACCTCCTAGTAAGC CTATATCTACAT |

-33-

| | |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-239A1 | CTAGACATAAGATATTGTACATAAAG ANAATTTTTTGCCTTAAATAGATA AAAGTATCTATCAGATAAAAATCANG TTGTAAGTTATATTGAAGACAATTGA TACATAATAAAAGAT |
| HSC-DD-239A1' | GGGGAGNNNCNAGNAANNAGANTC GTACGTAAANAGAANNNTGGTGCNTT TANATAGAAAANGTACTATCANATAA NAATCAGGTTGTAAGTTATATTGAAGA CGNTTGATACATAATAAAAGAT |
| HSC-DD-261 | CTAGACTGACAAAGACTTTGTCAAC TTGTACAATCTGAAGCAATGTCTGGCC CACAGACAGCTGAGCTGAAACAAAT GTCACATGGAAATAAAACTTTATC |
| HSC-DD-028A | CTCTCTGCCACCCAGATGGTTAGGAT GATTCTGAAGATGATGACATCCGTAAG CCTGGAGAATCTGAAGAATAAACTGT ACCAT |
| 5 HSC-DD-021 | ATCTCTGGCAGGTCAAGTCTGGGACAA TCTTGACAATTCCTCATCACCACTG ATGAGGCCTATGCAGCCAGTTCTAGCG CAGCTCACACTGAGAGTGTAAAGAACT ACGAACAAAATNTCTATTAAATTAAG |

-34-

| | |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-025 | GATCTCGGAATGGACCCAATGCTCCT GCTCCACCGGCGGCTCCTGCACTGCA CCAGCTCCTGCGCCTGCAAGAACTGCA AGTGCACCTCCTGCAAGAAGAGCTGCT GCTCCTGCTGTCCCCTGGGCTGCTCCA AATGTGCCAGGGCTGTGTCTGCAAAG GCGCCGCGGACAAGTGCACGTGCTGT GCCTGATGTGACGAACAGCGCTGCCA CCACGTGTAAATAGTATCGGACCAACC CAGCGTCTCCTATACAGTTCCACCCCT GTTTACTAAACCCCCGTTTCTACCGA GTACGTGAATAATAAAAGCCT |
| HSC-DD-077 | ATTCAGACGAATGAGACTCCTCCACAT TGGAGACAAGAGAGATGCAGAGAGCTCA GAGAATGAGGGTGTCAAGTGGTGAAA GATGGATCAAAGGGATAAGAGTGAG TTAAATGAAATAAAAGAAAATCAAAG GAGCC |
| HSC-DD-245 | NGCNNNNNNCCAGNAGGAGGAGAA GATGACTGGCCAGTATCANAATGGGA TAAGATGAGGCAGCGCCCTGGAGTACA CCATCTACAACCAGGAGCTAACGAG ACCGCGCTAACGCTCGACGAGCTTCT GCTAACGAGAACNAGTGGAGAGAA ATCCNGACAACTAAGGGATGCCAGC AGGATGCANGAGACAAAATGGAGGAT ATTGAGCGCCAGGTTAGAGAACTGAA AACAAATNAT |

-35-

| | |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-226 | CTCAAGGAAAAGACAGCACCNCGTGC CTGGCATCTGNTGNNTAGNTNATNTN NAANTNTCNNNTNGNCCTGGCAACGG TTCCTGAACNAATTACCACTCCTCTT GCCAGTCNAANAGGGTGGGAAAGTCC GAGCCTTANGACCCAGTTCAAGTCTG GTTTCTTCCCTCCTGANACACCATCGGT TGTTAGTTGCCTTGAGTTGGAACGTT TGCATCGACACCTGTAAATGTATTCAT TCTTTAATTATGTAAGGTTNTGTNC TCAATTCTTAAGAAATGACAAATTTT GGTTTCTACTGTTCAATGAGAACATT AGGCCCCAGCAACACGTCATTGTGTAA ANAAATAAAA |
| HSC-DD-182 | CGATGGCTCCATCCTGGCCTCACTGTC CACCTTCCAGCAGATCGGCTCAGCAAG CAGGAGTAGGATGAGTCTGGCCCCCTCC ATCGTGCACCGCAAATGCTTCTAGGCG GACTGTTTACACCCTTCTTGACAA AACC |

-36-

| | |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-089 | CNNATGCTACATGCTGNAGGATGCCTA AGGCTGCCCCCCCACCATCCCCTGGCTC TGCTGNCCGGANCAAATTGCTTCAGA TGTGACTTTGGAACCTTCNCACCCCTN ACCCNACCNNTCTCNAGAANNTCTTT ATTTAAAGGAGGAAANANNACATCCA AGAAAANGGGGGAGGGGGATGGA AANNCGCATCCCCTTCTAGCCAGCTG TTCCCAAAAGGTACCCTTCCTCTGC TGCTCCCCAACNCAAANCCACTTCN GANCCTCCACCTAAANCATCANGCAA GTCACNTACACCCTGTTANCCCCNA CTCTCTGCTTATACCCNGGAACAATTN NTGCTCG |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

-37-

| | |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-151 | CGATGGTGGGGATCTTACTGGGAAG AGGAAGGACCATTAGCACACCATCAT GATGTCAGATGACAAAATGGAAGCCA AGACACCTTGAAGGTGACTTTCTAGGA AGGTCTTAAGCATGTAATGTCCCTTA TCAGAGGGAAGGGACAAACTCAGGG CAGCCCTGTCCAGGTAGAAATATTTT GCCCCCTGTCTGATGTTGATGAGGGG TCATACCANCCAGGGAGACCCTCTGG GAGGAAGCTGCCACACACAANGACTC TGGAAAGTATCCAGATGTGAGCCCAGC CAGGGTCCTATGGTCCAAATCTGAAN AAAAGGTTTTCACACACTCCTTGCTT TCTGCTAAGATAANAAAGGCGTCACTC TGCCAGAGTGTGACTTTACAGATTA AATAAAGCTGTTAT |
| HSC-DD-013 | GATCTACTCCATTCCCCTGGAAATCAT GCAGGGCACCGGGGGTGAGCTGTTG ATCACATTGTCTCCTGCATCTCCGACT TCCTGGACTACATGGGATCAAAGGC CCCGGATGCCTCTGGCTTCACCTTCT CGTTTCCCTGCAAGCAGACGAGCCTAT ATTGCGGAATCTGATCACGTGGACAA AGGGATTCAAAGCCACCGACTGTGTG GGTCACNATGTANCCACTTACTGAG |
| HSC-DD-029 | GATCTGAGTCGAGGCCAGCCTGGTCT ACAGAGTGAGTTCCAGGNCAGCCAGG NCTACACAGAGAAACCCTGTCTCGAA AAAACAGAAAGAGA |

-38-

| | |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-034 | CTTTCATTAAAAAGAAACCAGGGCT GGANAGATGGCTCAGTGGTTAAGAGC ACCAACTGCTCTTCCCAGGGTCTAA GTTCAAATCCCAGCAACCACATGGTGG CTAACAAACCACTCGTAATGAGATC |
| HSC-DD-082B | ATCGCNGCTCTCCTGNGGCCTGGCN TACGACNNNGAAAAGGAGTGTCCACGG CTGCTGTCGNGGCCACGATTAATTAAA ACTGAAGTACCGAGGNTNCCCCAGNG NCNGANTGTGGGTCNNGCCNTTCNT GNTCCACAANCCAACCTGGCAGACGC TTACTGTNCTGTCAACTNTCNNNNGAA TACCNCCACCCNCATGCTAAAATGATG ACTGACGTTAANCCATGCTGGT |
| HSC-DD-084 | CGATGACAAAGGAGTCCTGAGGCAGA TTACTCTGAATGACCTTCCCTGTCGGAA GATCAGTGGACGAGACACTGCGTTG GTTCAAGCCTCCAGTACACTGACAAG CATGGAGAAGTCTGCCCTGCTGGCTGG AAACCTGGTAGTGAAACAATAATCCC AGATCCAGCTGGAAAAGTGAAGTATT CGACAAGCTAAACTGAAAAGTACTTC AGTTATGATGTTGGACCTTCTCAATA AAGGTCAATTGTG |

-39-

| | |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-128 | CGATGCTGAATAAGCTCCTCAAAAAGT GGTAAATTAACCTTTNAAAAAACAA GCTTCTCTGTACAGCTCTGGCTGTTT GTTCTGGAATACATTCTGTAGAATTGT CTGGCCTCTAACCTGGAGATCCAACTC CCTCTGCCTCTTGAGTGCTGGGATTAA TGGCATGTGACACTGT |
| HSC-DD-140 | CGATGACCTCATGCCGGCCCAGAAGT GAAGCCTGGCCCTGCCACCATCAGG CTGCCGCTTCTAACTTATTAAACCGGG CAGTGCCGCCATGCATCCTTGANGTT TGCCGCCTGGCGGCTGAGCCCTAGCC TCGCTGTAGAGACTTCTGTCGCCCTGG GTAGAGTTATTTTTGATGGNTAAN CTGTTGCTGACACTGAAAATAANCTAG GGTTT |
| HSC-DD-148 | CGATCAATGAAAAGATGACGAGTTCT TTCAAATGGGCAGTTACTCCCTGATAA CTTCATAGCTGCCCTGCACAGAGAAGA AAATCCCTGTTGTGTTAGACTACAAG AGGGTTATGATCATAGCTACTACTCA TTGCAACTTTCATCGCTGACCACATCA GACACCATGCTAAGTACCTGAATGCAT GANAAGCCTCAGCCAAGAGAATCTCA TCAGGAGGCCGGAAGGGAATCAACAG GAGTGCTGACTTCCTCGCAGAAGATCA TGCTCCTGCAGCTGAATCGCTTTCTG AATAAAATAT |

-40-

| | |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-176 | CGATGTNTACTCATTGCCACCCGT ANTCCTCTGGAAGGTGTCCGTATCAC CTTGGTCAGCTGTCTCCCCCTATGT CCTCAAGTACCTGCGGAGACGGTTCTC CCCACCCAGCTACTCGAACGCTCACTTC CTAAGCTGCAGGGCTGCCCTGGCAG GGCCTCCGGCCTCCGGCGCTCTCCAG GAGGAGGTCAAGTCCACACGCACGA GCCGCCTCTGCTGGACGGTGCAGTCAT GGCTGGCACATGAGGCTTCGCTGAGG CGACACTGGGCACCTAATGGGGATGG AACATTGGTGGAACCGGAGGGAGGGA CCTGAGAGCTGTACCTATCAGAACCTT GGGTGCTAAGCTGTGCTGAGGGGGAA GACGTGGGACCGGATGGCCGTCTGA GGTTTGTGGGTCACTGTGCAAGCTTC CTTATGGTTGAACCTCTGTATGTG ATAAAAGT |
| HSC-DD-178 | CGATTACGTATTGACTGAAATGAAA GTTCCACTAAACGGTATTGCTCTGT GATATGTGGCACATTGTGATATTTCT TAGTCTGTTCTGTTCATTTAAAAAAAT AAAACTGCTGAT |
| HSC-DD-180 | CCGATGTNCGATAATAGTAAATACCTT AATTANTAAATAATTGATTGNATTGT TTCAGAGACGTTGGAAATTACTGTAT ACATTACAACCTAATGACTTTGTAT TTTATTTCAAAANAAAAGCTTA |

-41-

| | |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-186 | CNTTNGNNNTCCNTNCATCNCNGCN GTNTGAGTCCCNCCTAANNAGTCCATC CAANANCCANNGCATNNCAGCTTAT CATGACAACAAANTGGAGNAAGAAGA AGATGAGTTCGGCCACTGTTGAGGCA AATCANTGNNANTCNTAATANACAC CTGGTCCGCTCATCCTCAACGTTGTT NTNTANAANTTACCTCCCAGTAGAAA NGCTAGCAANTTNACCTGCCACNGGT TNTA |
| HSC-DD-191 | CGATCAGATGTCACGCCGGACACANC NCCGCCNCAGTNAATGGNAATATATT GCATGTTACCCCAAATTANCTTCTNTG CATNGAACATANGTANGTGTCTTG GACACGTGTGTTCTACTAC |

-42-

| | |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-158 | CGATTACAAATGAACAAANCAAGATT ACATATANTGAAAATCCACGCAGGAC CTATTACANAGCATGGTGAAATAGATT ATGAAGCAATTGTAAAGCTTCAGATG GCTTAATGGAGCATGACCTGACAAAT GTTGTACTGAAGCAGGTATGTTGCA ATTCGTGCCGATCATGATTTGTANTT CAGGAAGACTTCATGAAAGCAGTCAN GAANGTGGCTGACTCCAAGAAGCTGG AGTCCAAGCTGGACTACAAACCTGTGT GATTCACTANNAGGGTTGGTGGCTGC ATGACAGACATTGGTTAATGTANACT TAACNGTTANNGAAACTAATGTANNT ATTGGCAATGANCTTATTANAAGTGAA TANACATGTG |
| HSC-DD-099 | CGATGTTTTAATTAAGAAGAAATTCA CTTCTCATTACCTATGAATCTGTGCC AGGGCAGGTGATTTGAGTATGAGA ACTTGTCCCTCCACAGTTGTACAA AAATGGTCCCTCTCATTGAACTATTG TGGCATGCTAATTAAGAAGTGAGTGA CCACTTGGGAGGCAGAGGCAGGTGGA TTCTGAGTTGAGGCCAGCCTGGTCT ACAAAGTGAGTTCTAAGACAGCCAGG GCTATACAGAGAAACC |

-43-

| | |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-222 | CCAAGNAATATGGTCTAATCAAAGGT CGTCTGTCTGCTTGATTGTCTACATC ACAGCAATCCCTGGAAATTCTATCCA TTTAAATGCNGCCGCTTCATCTGTTT AGCCAGCACACCCAATGGTTCACTAA CTAGCCCAGTTGACCTTGGAAAGTTT GAGCCTTGAGCACCTCAACAAAATTG AGCACTCTGATTAGGATATCCACTTG CAAATAAAACCAAATGTTTGTCAAC |
| HSC-DD-104 | CGATGAGGGGAAGATGACCTGGGCCG GGGAGGCCATCCCTTATCCAAGATCAC AGGGATTCTGGGAAGAGGTTGGCCT GTGGCATCATTGCACGCTCTGCCGGCC TTTCCAGAACCCCAAGCAGATCTGCT CCTGTGATGGCCTCACTATCTGGGAGG AGCGAGGCCGGCCCATTGCCGGTCAA GGCCGAAAGGACTCAGCCAACCCCC AGCTCACCTCTAAACAGAGCCTCATGT CAGGTTATTGGTCCTCGTAGCTGAAC ATCTTCTTGCAGAGGGAGCTGCNGGCC CTTGCTTGTACAGGCCTAAGTACAGGG CAGATAAGTGTGCTAGCCTGAACAAA TTAAATTGTTAC |

-44-

| | |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-172 | CGATTAGCTGNGGTCTCTAGGANATAC TCGTCACTATATGAGCTCAGGANGCCA GCTCTTAGTAGCTCTGAANCAGGTGAA GAATCCTCCTCTGAGGAAACAGACTG GGAGGAAGAACAGCAGCCATTACCAGC CAGCTAATTGGTCAAGAAAAAGCCA AAAGCNGCTGGCGAAAGTCAGCGTAC TGTCAACCTCCCGCAGTCGGTTCA AGGTCCGCCCTATGCAGGAGCCCCCGCC CTGCGTAGTGCAGCAATGCGCAG AGGGGCAATGCGCAGAGAGGTGCGCA GAGGGGCAGTGCAGAGAGAGGTGCGC AGAGAGGCAGTGCAGAGAGAGGCAGT GCGCAGACTCAT |
| HSC-DD-169 | CGATTCTAAATCAGTCTGCCTGTGC TAGGATGACCGGTAATGAGCCTGTTA AAATAAGACTAAAAGTGTGCGTT GGCCGGCGGTAGGGCGCATGCCTT TAATTCTAACTGGAGGTAGAGACA GGCGGATCTTGTGAGTTCAAGGTAG CCTGGTGTACAGAGTGACTTCCAGAAC AGCCAGGGCTGTTAACAGAGAAC |
| HSC-DD-003A | TTGTTTGTNTTCAGATAGGGTCTTAC ATATCCCATGCTGGTCTCAAACACTACA TTATGCATGCAGGGAAAGCCATTACT GACTGATATAACCCCTGGCCCTAAGATA GATC |

-45-

| | |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-092 | CGATCGTCGTTCTGGTAAGAAGCTGGA AGATGGCCCCAAGTCCTGAAGTCTGG CCATTAAAGTTAATAGAAAAGACTG GTTAATGATAACAATGCATCGTAAAAC |
| HSC-DD-114 | CGATCGTCGTTCTGAGTAANAAGCTGG AANANGGCCCAAGTCCTGNNGTCT GGCGATGCTGCCATTAAAGTTNANNAG ANANAAGACTGGCTNATGATAACAAT GCANCNTAAAACCTTCAGGNAGGNAA CGAATGTTGTGGACCATTNTNTGNG TGTGGCAGTTNAAGTTATNAAGNTTT CAAAANCANTACTNTTAANGGAAAC AACTTGACCCATCANCTGTCACAGAAT NTTGANGACCATTAAACAC |
| HSC-DD-213A1 | NCTACGATCATCTAGATCTACTAGACC TACNACNAGACCATGGGCCAAANATG GTCGACCTGCAAACCTGCAAGGTTAT TTTANATACACATTATGGCGTTTATN TTTGTAATTCTAAGTTGTAATTGAGCT TTAACAAATCTTTT |
| HSC-DD-213A1' | CCAAGNANATCNAGACTACTAGACCT ACTACNAGACCATNGGNCAAACATGG TCGACCNCAAACGNATANGTATATT NANATACACANANATAGCGTTNTATG TCTNGTAATTCTAAGTNGTANATCANC TATTANCAAATCTTTNTTT |

-46-

| | |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-155 | CGATGGAAGTTCTGCTGAGCCCTCTG ACGTAACCCTGGCNATGGCTAACACTG TCCTTCCTGCAATGTTCTGGTGGACA CANCTTCTCTGGANATAACCCTGAANGT GGCACGCCCTGTTCCAGCCCACCTGGT GTGCACTTTGCCCTCTTACCTCATT ANTAAATGTTTCNTGCTCCTAATG |
| HSC-DD-212 | CTNAGNAAGGANCTGTACTTCGTATTG CAAGGCAGTCTCTTGTGTCTTCTTAGA GTGTCTTCCCCATGCACAGCCTCAGTT TGGAGCACTAGTTATAATGTTATTAA CAATTAAATAAAATTGANTAGGTAGTA A |
| HSC-DD-090 | TCNTCNTTCTGGTAAGAACTGGAATAT GGCCCCAAGTTCCCTGAAGTCTGGCGAT GCTGCCATTGTTGATATGGTCCCTGGC AANCCCATGTGTGTTGAGAGCTCTCT GAECTACCCTCCACTGGTCGCTTGCT GTTCGTACATGAGGCAGACAGTTGCT GTGGGTGTCATCAAAGCTGTGGACAA AAANGCTGCTGGAGCTGGCNAAGTC CCAAGTCTGCCCANAAAGCTCAGAAG GCTAAATGAATATTACCCCTAACANCT GCCACCNCANTCTTAATCAGTGGTGG AGAACGGTCTCAGAACTGTTNGTCTCA ANTGGCCATTAAAGTTAATANTAAAA GAECTGGTTAATGATAAC |

-47-

| | |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-173 | CGATCNCCTCGTAAGANNCNGG AACATGGCCCCAAGTTCCNGANNTCTG GCGANGCNGCCANTGTTGATATGGTCC CTGGCAAGCCCATGTGTNTTGAGAGCT TCACNNACNACCCCTCCANTGGTCGCT TTGCTGTTCGTGACATGAGGCAGACAG TTGCTGTGGGTGTCANCAAANCTGTGG ACAANANGGCTGCTGGAGCTGGCAAG NTCACCAANTCTGCCAGAAAGCTCA GAATGCTAAATNAATATTACCCCTAAN ACCTGCCACCCCAGTCNTAATCAGTGG TGGAATAACNGTCTCAGAACTGTTGT CNCATTGGCCANTTANGTTAATNAT ACAAGACTG |
| HSC-DD-249 | GNNNNNNNNNNCNANGAAAAAGAG GTGAAAAATGCTTGGCTCTAGCTGATG ACAGAAAGCTGAAATCCATGCCCTTCC CATCCATTGGCAGCGGCAGGAACGGG TTCCCGGAAGCAGACAGCGGCCAGC TCATTCTGAAGTGCCATCTCCAGCTAC NTTGTCTCCACGATGTCCTCCTCCATC AAAATGTGTACTTCATGCTTTGAC AGTGAGAGCATAGGTATCTATGTGCA GGAAATGGCCAAGCTGGACGCCAACT AGGCCAGTGATCCCTAGAGCCAGCAC ATGCGGTGTCCCCCA |

-48-

| | |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-250 | CTNANGAAAGCTGCTGGGCNCCTG ACATCACTCATCACTCACTATGCTACC AATTCTATTATTCGGAATTACAAGA TATCGGGAATCTCTCTGCAGGCTGGAC TGGCAGGCTGTGGGTGGCGGGACA CGGCTCTAACATTNCAGAGGGAAAC GCGCANATGTCCAAAAGTCTAAATAA ATGCATTCAAGAGGTTNTGGGTCCAT GGCCAAGTGGAGTTCCCCNCAGGGG GAGGTGGGTAAAGTGCCTCCAGGAAG GCAGGCAGCCTGCCTANACTTGCANC CCGGNTGTGGGAATGAATCATTGGAG TAATAAACT |
| HSC-DD-108 | CGATGCCAATGGCATCCTCAATGTTTC TGCTGTAGATAAGAGCACAGGAAAGG AGAAAGTCTGCAACCCTATCATTACCA AGCTGTACCAAGAGTGCAGGTGGCATG CCTGGGGGAATGCCTGGTGGCTTCCA GGTGGAGGAGCTCCCCATCTGGTGGT GCTTCTTCAGGCCACCATTGAAGAG GTGGATTAAGTCAGTCCAAGAAGAAG GTGTAGCTTGTCCACAGGGACCCAA AACAAAGTAACATGGAATAATAAAACT ATTAA |

-49-

| | |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-116 | CGATGAAGATGAGGTCACTGCAGAGG AGCCCAGTGCTGCTGTTCTGATGAGA TCCCCCTCTGGAAGGCGATGAGGATG CCTCGCGCATGGAAGAGGGTGGATTAA AGCCTCCTGGAAGAAGCCCTGCCCTCT GTATAGTATCCCCGTGGCTCCCCAGC AGCCCTGACCCACCTGGATCTCTGCTC ATGTCTACAAGAATCTTCTATCCTGTC CTGTGCCTTAAGGCAGGAAGATCCCT CCCACAGAATAGCAGGGTTGGGTGTT ATGTATTGTGGTTTTTTGTTGTTTA TTTGTCTAAAATT |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

-50-

| | |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-166 | CGATGCCAATGGCATCCTCAATGTTTC TGCTGTAGATAAGAGCACAGGAAAGG AGAACAAAGATCACCATCACCAATGAC AAGGGCCGCTTGAGTAAGGAAGATAT TGAGCGCATGGTCCAAGAAGCTGAGA AGTACAAGGCTGAGGATGAGAAGCAG AGAGATAAGGTTCTCCAAGAACTCA CTGGAGTCCTATGCCTCAACATGAAA GCAACTGTGGAAGATGAGAAACTTCA AGGCAAGATCAATGATGAGGACAAAC AGAAGATTCTTGACAAGTGCAATGAA ATCATCAGCTGGCTGGATAAGAACCA GAUTGCAGAGAAGGAAGAATTGAGC ATCAGCAGAAAGAACTGGAGAAAGTC TGCAACCCTATCATTACCAAGCTGTAC CAGAGTGCAGGTGGCATGCCTGGGG AATGCCTGGTGGCTTCCCAGGTGGAGG AGCTCCCCCATCTGGTGGTGCTTCTTC AGGCCACCATTGAANAGGTGGNTT AAGTNATCCANNAAGAAAGGNTNCCT TTTTTCCAAAGGGANCCAAAAAAGTA ANATGGATAATAAAACCTATTTAATT |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

-51-

| | |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-184 | CGATGCCAATAGNANCCAANTNTCT GCNGTNGATAAGACACANGAAAAGAG AACAAAGATCACCACCATCACCAATGACAA GGGCCGCTTGAGTAAGGAAGATATTG AGCGCATGGTCCAAGATCAATGATGA GGACAAACAGAAAGATTCTTGACAAGT GCAATGAAATCATCAGCTGGCTGGAT AAGA |
| HSC-DD-101 | CGATTAGCGGAGGTCTCTAGGAGATA CTCGTCACTAGATGAGCTCAGGAAGCC AGCTCTTAGTAGCTCTGAAGCAAGTGA AGAATCCTCCTCTGAGGAAACAGACT GGGAGGAAGAAGCAGCCCATTACCAAG CCAGCTAATTGGTCAAGAAAAAGCC AAAAGCGGCTGGCGAAAGTCAGCGTA CTGTTCAACCTCCCGCAGTCGGTTTC AAGGTCCGCCCTATGCGGAGCCCCCG CCCTGCGTAGTGCCTCAGCAATGCGCA GAGGGGCAATGCGCAGAGAGGGAGTG CGCAGAGAGGCAGTGCGCAGACTCAT TCATT |
| HSC-DD-017 | TCTCTGTATAACCCTGGATGTCCCTGGA ACTCACTTGTAGACCAGGTTGGCCTC GAACTCAGAAATCCGCCTGCCTCTGCC AAGCGCTGGATTAAAGGTGTGCGCC ACCACACCCGGCAGGTAATTTTTCT TTTAAAGATTATTATGTATAACAGGT TCTGCCTACATGTGTACCTGCCGGCCA GAAGAGGGCATCANATC |

-52-

| | |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-026 | GATCTTGTAGGCACAAAATGAATCCC GCACCTGGTACCCATGATGCTCGTAC TATTGGTACCCCTGATCCCCTCATCAA GGTGAACGACACCATTAGATTGATT GGAGACAGGCAAAATAACTGACTTCA TCAAGTTGACACTGGGAACCTGTGTA TGGTGACTGGAGGTGCTAACTGGGA AGAATTGGTGTAAATCACCAACAGAGA GAGACATCCCGGCTCTTGATGTGGT TCATGTGAAAGATGCCAATGGCAACA GCTTGCCACTCGGCTGTCCAACATT TTGTTATTGGCAAGGGTAACAAACCAT GGATCTCTCTCCCAGAGGAAAAGGA ATCCGCCTCACCATTGCTGAAGAGAGA GACAAGAGGCTTGCAGGCCAACAGAG CAGTGGGTTGAAATGGTCTCCTAGGAG ACATGCCTGGAAAGTTGTTTGTACAA CCTTCTCAGGCAACATACATTGCTAG AATTAAACAGCCATG |
| HSC-DD-064 | CGATCGAGAGGGCAAACCAACCGGAAGG TGGTTGGTTGCAGTTGCGTAGTGGTTA AGGACTATGGCAAAGAATCTCAGGCC AAGGATGTCATCGAGGAAACTTCA AGTGCAAGAAATAAATAAATTGGCT GATT |

-53-

| | |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-066 | ATTCCAGATGAGGACCACAAGCGACT CATTGATTTACATAGTCCTCTGAGAT TGTAAAGCAGATTACTTCATCAGTAT TGAGCCGGAGTTGAGGTTGAAGTCA CCATTGCAGATGCCTAAGACAACTGA ATAAAATCG |
| HSC-DD-041 | GATCTATACAGTCGGAAACGCTTCAA GGAAGCAAATAACTTCCTGTGGCCCTT CAAGTTATCTTCCCCACGAGGTGGGAT GAAGAAAAAGACAACACTCACTTTGTAG AAGGTGGAGATGCTGGCAACAGGGAA GACCAGATAAACAGGCTTATTAGACG GATGAACTAAGGTGTCACCCATTGTAT TTTGTAAATCTGGTCAGTTAATAAACAA GTC |
| HSC-DD-111 | CGATGTGGCCAAAGTCAATACCCTGAT AAGGCCCGACGGAGAGAAGAAGGGCGT ATGTTCGCTTGGCTCCTGATTATGATG CCCTAGATGTTGCCAACAAAGATTGGGA TCATCTAAACTGAGTCCAGATGGCTAA TTCTAAATATATACTTT |
| HSC-DD-028B | GATCTGGAACCATAGATGCGAGCATC AGCAACAGAATACAAGAAATGGAAGN GNGAATCTCAGGTGCAGAAGNTTCCA TAGAGAACATCG |

| | |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HSC-DD-142 | GCGATGCAAAATCCTTAATANAATTCT TGCTAACCGAATCCAAGAACACATTA AAGCAATCATCCATCCTGACCAAGTAG GTTTTATTCCAGGGATGCNGNGATGGT TTAATATATGAAAATCCATCAATGTAA TCCATTNTATAAACAAACANCTCAANGACA NAAACCACATGATCATCTCGTTAGNTG CAGAAAAAGCATTTGACAAGATCCAA CACACATTGATAANAGTTTGGNA AGATCAGGAATTCAAG |
| HSC-DD-095 | CGATNNACCGCTCTACCTCACCATCT CTTGCTAATTCAAGCCTATATAACGCCA TCTTCAGCAAACCCCTAAATNAGGTATT AAAGTAAGCATCNAGAATCANCCATA CTCAACGTNACGTCAAGGTGTACCCAA TGNAATGGGAAGAAATGGGCTACATT TTCTTATANAAGAACATTNCTATACCC TTTNTGAAACTAA |

Table 3 presents the expression patterns of the differentially expressed bands set

5 forth in Table 2. The band fragment length (size) in Table 3 is the length before
unwanted terminal sequences were removed. Table 3 also presents the results of a
GenBank Search and analysis of the sequences of Table 2.

Summary of Known Genes from Mouse HSC Differential Display (I)

| Items No. | Size (bp) | Enzyme | N1 N2 (oligo-dT) | Poly (A) Sign | Expression pattern | | | | Gene Bank Search & Analysis | | | | |
|-------------|-----------|--------|------------------|---------------|--------------------|-------|----------|----------|-----------------------------|-------------------------------|------------------------------|----------------------------------------|--------------------------------------------------|
| | | | | | I m- | I RII | I RII/48 | I RII/II | mouse homeobox protein | human homeobox gene regulator | human zinc finger protein 10 | mouse cell division control protein 19 | human HS1 hematopoietic protein |
| HSC-DD-006 | 213 | Bgl II | Xba I | GG | good | + | + | + | + | + | + | + | mouse homeobox protein |
| HSC-DD-285 | 158 | Bgl II | AC | fair | 0 | 3+ | / | / | + | + | + | + | human homeobox gene regulator |
| HSC-DD-007B | 213 | Bgl II | AC | fair | + | 2+ | / | / | + | + | + | + | human zinc finger protein 10 |
| HSC-DD-238 | 363 | Xba I | AG | good | 3+ | 0 | 3+ | 3+ | 3+ | 3+ | 3+ | 3+ | mouse cell division control protein 19 |
| HSC-DD-206 | 123 | Xba I | AC | good | 3+ | 0 | 2+ | 2+ | + | + | + | + | human HS1 hematopoietic protein |
| HSC-DD-214 | 192 | Xba I | AC | fair | + | 2+ | 0 | 0 | 3+ | 3+ | 3+ | 3+ | mouse pim-1 proto-oncogene |
| HSC-DD-035 | 151 | Bgl II | AC | fair | + | 2+ | / | / | + | + | + | + | mouse thyroid hormone receptor |
| HSC-DD-129 | 234 | Cla I | AC | poor | 0 | 3+ | 0 | 0 | 0 | 0 | 0 | 0 | mouse inositol 1,4,5-trisphosphate receptor |
| HSC-DD-040 | 220 | Bgl II | AC | fair | + | 2+ | / | / | 0 | 0 | 0 | 0 | mouse G protein beta-36 subunit |
| HSC-DD-011 | 173 | Bgl II | AC | good | + | + | / | / | 2+ | 2+ | 2+ | 2+ | mouse ras-related YPT1 protein |
| HSC-DD-121 | 186 | Cla I | CT | poor | 0 | 3+ | + | + | + | + | + | + | human TBP-associated factor 170 |
| HSC-DD-015B | 133 | Bgl II | AG | poor | 0 | 3+ | / | / | + | + | + | + | mouse HMG1-related DNA binding protein |
| HSC-DD-039 | 206 | Bgl II | AC | fair | 2+ | 4+ | / | / | 4+ | 4+ | 4+ | 4+ | mouse TAX responsive element binding protein 107 |
| HSC-DD-042 | 235 | Bgl II | AC | fair | + | 0 | / | / | + | + | + | + | mouse retinoblastoma binding protein isoform III |
| HSC-DD-256 | 272 | Xba I | AA | poor | 0 | 2+ | + | + | 0 | 0 | 0 | 0 | Rat androgen-binding protein |
| HSC-DD-045 | 270 | Bgl II | AC | good | + | 2+ | / | / | + | + | + | + | similar to Rat oca2 |
| HSC-DD-068 | 164 | Cla I | AC | fair | + | 4+ | 4+ | 4+ | 4+ | 4+ | 4+ | 4+ | mouse Jerky mRNA |
| HSC-DD-143 | 350 | Cla I | AG | fair | + | 2+ | + | + | + | + | + | + | similar to human memd |
| HSC-DD-263 | 292 | Xba I | AT | good | 0 | 2+ | + | + | 0 | 0 | 0 | 0 | mouse interleukin 5 |
| HSC-DD-239 | 156 | Xba I | CA | good | + | 3+ | 3+ | 3+ | + | + | + | + | human CD9 |
| HSC-DD-261 | 115 | Xba I | AA | good | 0 | + | 0 | 0 | 0 | 0 | 0 | 0 | mouse gamma chain IgM |
| HSC DD 028A | 95 | Bgl II | AC | good | + | 4+ | / | / | + | + | + | + | mouse chaperon containing ICP-1 e subunit |
| HSC DD 021 | 143 | Bgl II | AG | low | 1 | + | 1 | 1 | 2+ | 2+ | 2+ | 2+ | mouse cathepsin |
| HSC DD 025 | 326 | Bgl II | AG | good | 1 | 2+ | 1 | 1 | 2+ | 2+ | 2+ | 2+ | mouse metallocarboxypeptidase 1 |

-56-

Summary of Known Genes from Mouse HSC Differential Display (II)

| Item No. | Size (hp) | Enzyme (Klenow-dT) | NIN2 | Poly(A) Sign | Expression pattern | | | | | | Gene Bank Search & Analysis |
|-------------|-----------|--------------------|------|--------------|--------------------|------|-------|--------|--------|---------|------------------------------------------------------|
| | | | | | 1 m. | 1 RI | 1 RII | 1 RIIA | 1 RIIA | 1 RIIII | |
| HSC-DD-077 | 203 | Cla I | AC | good | + | 2+ | 2+ | 2+ | 3+ | 3+ | Rat malrin cyclophilin |
| HSC-DD-200 | 450 | Cla I | AA | fair | + | + | 2+ | 2+ | + | + | mouse G-utrophin |
| HSC-DD-245 | 272 | Xba I | CA | fair | 3+ | + | 3+ | 3+ | 2+ | 2+ | rat basement membrane-associated chondroitin |
| HSC-DD-226 | 387 | Xba I | AC | good | + | 3+ | + | + | 0 | 0 | mouse cytoplasmic g-actin |
| HSC-DD-182 | 149 | Cla I | GC | poor | + | 3+ | + | + | + | + | mouse A-X actin |
| HSC-DD-089 | 364 | Cla I | AC | poor | + | 3+ | 2+ | 2+ | + | + | mouse TIE receptor tyrosine kinase |
| HSC-DD-151 | 424 | Cla I | GA | good | 0 | + | 2+ | 2+ | + | + | rat elk, brain-specific receptor tyrosine kinase |
| HSC-DD-013 | 248 | Bgl II | AC | fair | + | 2+ | 1 | 1 | 3+ | 3+ | mouse hexokinase |
| HSC-DD-029 | 103 | Bgl II | AC | fair | 0 | + | 1 | 1 | 0 | 0 | mouse Brunton agammaglobulinemia tyrosine kinase |
| HSC-DD-034 | 140 | Bgl II | AC | fair | 0 | 2+ | 1 | 1 | 2+ | 2+ | mouse spermine synthase |
| HSC-DD-082B | 244 | Cla I | AC | fair | + | 4+ | 2+ | 2+ | 2+ | 2+ | mouse stearoyl-CoA desaturase (SCD2) |
| HSC-DD-084 | 261 | Cla I | AC | good | + | + | + | + | 2+ | 2+ | mouse antioxidant enzyme AOE 372 |
| HSC-DD-128 | 189 | Cla I | AC | fair | 0 | 3+ | 3+ | 3+ | + | + | mouse casein kinase II beta chain |
| HSC-DD-140 | 229 | Cla I | AG | good | + | 0 | 0 | 0 | 0 | + | mouse creatine kinase B |
| HSC-DD-148 | 313 | Cla I | GA | good | + | + | + | 2+ | 2+ | 2+ | human esterase D |
| HSC-DD-176 | 470 | Cla I | CG | fair | + | 3+ | + | + | 0 | 0 | mouse putative E1-E2 ATPase |
| HSC-DD-178 | 130 | Cla I | GC | good | + | 3+ | 0 | 0 | + | + | mouse aspartate aminotransferase |
| HSC-DD-180 | 142 | Cla I | GC | good | + | + | + | 0 | + | + | mouse tyrosylprotein sulfotransferase-1 |
| HSC-DD-186 | 252 | Cla I | GC | poor | + | + | 2+ | 2+ | 2+ | 2+ | mouse ubiquitin-conjugating enzyme E214K |
| HSC-DD-191 | 136 | Cla I | AA | fair | 0 | + | 3+ | 3+ | 2+ | 2+ | mouse b-1,4-galactosyltransferase |
| HSC-DD-158 | 391 | Cla I | GT | fair | + | 3+ | 0 | 0 | + | + | spERMophilin indecemlinealus 26s proteasome |
| HSC-DD-099 | 265 | Cla I | CC | fair | + | 3+ | 0 | 0 | + | + | mouse proteasome epsilon chain precursor |
| HSC-DD-222 | 270 | Xba I | AC | good | 0 | 2+ | 3+ | 3+ | + | + | Rat 3-hydroxyso-butyrate |
| HSC-DD-104 | 368 | Cla I | CC | fair | 0 | + | + | + | + | + | human copper chaperone for superoxide dismutase |
| HSC-DD-172 | 365 | Cla I | CG | fair | + | 3+ | 2+ | 2+ | 0 | 0 | mouse Erc-4 DNA repair gene |
| HSC-DD-169 | 223 | Cla I | CG | fair | 1 | 1 | 2+ | 2+ | 0 | 0 | Cricetulus gausei nucleotide excision repair protein |
| HSC-DD-003A | 148 | Bgl II | AC | poor | 0 | + | 1 | 1 | 1 | 1 | human G-rich sequence factor |

-57-

Summary of Known Genes from Mouse HSC Differential Display (III)

| Items No. | Size (bp) | Enzyme | NIN2 (oligo-dT) | Poly(A) Sign | Expression pattern | | | | | | Gene Rank Search & Analysis |
|-------------|--------------|--------|--------------------|-----------------|--------------------|------|--------|------|--------|------|-----------------------------------------------|
| | | | | | L.in+ | L.RH | L.RH48 | L.RH | L.RH48 | L.RH | |
| HSC-DD-092 | 118 | Cla I | CC | fair | + | 3+ | ± | + | + | + | mouse elongation factor 1-a |
| HSC-DD-288 | 480 | Xba I | GC | fair | ± | + | + | ± | + | ± | human elongation factor 1-delta |
| HSC-DD-114 | 267 | Cla I | CA | poor | ± | + | ± | + | + | + | Rat elongation factor 1-alpha |
| HSC-DD-213 | 178 | Xba I | AC | fair | ± | 3+ | + | + | + | + | human splicing factor (SFRS7) |
| HSC-DD-155 | 198 | Cla I | GT | fair | 0 | 2+ | + | 0 | 0 | 0 | mouse transcription elongation factor S-II-T1 |
| HSC-DD-212 | 162 | Xba I | AC | poor | 0 | 3+ | ± | 0 | 0 | 0 | mouse translation initiation factor 4E |
| HSC-DD-090 | 375 | Cla I | AC | fair | ± | 3+ | 3+ | + | + | + | mouse protein synthesis elongation factor Tu |
| HSC-DD-173 | 367 | Cla I | CG | fair | ± | 3+ | + | 0 | 0 | 0 | mouse protein synthesis elongation factor Tu |
| HSC-DD-249 | 304 | Xba I | CA | poor | 4+ | + | 4+ | 4+ | 4+ | 4+ | rat histone macroH2A1.2 |
| HSC-DD-250 | 356 | Xba I | CA | good | + | 2+ | 3+ | 2+ | 2+ | 2+ | mouse MER9 processed pseudogene |
| HSC-DD-108 | 281 | Cla I | GG | good | + | 2+ | + | + | + | 2+ | mouse heat shock protein 70 |
| HSC-DD-116 | 326 | Cla I | CA | fair | ± | 2+ | 0 | 2+ | 2+ | 2+ | mouse 84 kD heat shock protein |
| HSC-DD-166 | 587 | Cla I | AT | good | ± | 2+ | 3+ | + | + | + | mouse heat shock protein 70 cognate |
| HSC-DD-184 | 196 | Cla I | GC | fair | ± | 2+ | 0 | ± | ± | ± | mouse breast heat shock protein 73 |
| HSC-DD-101 | 331 | Cla I | CC | fair | + | 3+ | 0 | ± | ± | ± | mouse MHC locus II region |
| HSC-DD-017 | 215 | Bgl II | AG | good | 0 | 4+ | 1 | 0 | 0 | 0 | mouse MHC class III region |
| HSC-DD-026 | 505 | Bgl II | AG | fair | 2+ | 4+ | 1 | 4+ | 4+ | 4+ | mouse ribosomal protein S4 |
| HSC-DD-064 | 146 | Cla I | AC | good | 2+ | 2+ | 2+ | 3+ | 3+ | 3+ | mouse ribosomal protein S12 |
| HSC-DD-066 | 150 | Cla I | AC | good | 2+ | 3+ | 2+ | 2+ | 2+ | 2+ | mouse ribosomal protein S20 |
| HSC-DD-041 | 226 | Bgl II | AC | good | + | 3+ | 1 | 3+ | 3+ | 3+ | mouse ribosomal protein L7 |
| HSC DD 111 | 161 | Cla I | CA | low | 1 | + | 1 | + | + | + | rat ribosomal protein L23a |
| HSC DD 0268 | 100 | Bgl II | AC | low | 0 | 4+ | 1 | + | + | + | mouse LINE-11.1 element |
| HSC DD 142 | 267 | Cla I | AG | low | 1 | 2+ | 1 | 1 | 1 | 1 | mouse microsatellite 12S ribosomal RNA |
| HSC DD 095 | 210 | Cla I | CC | low | 1 | 2+ | 1 | 1 | 1 | 1 | mouse microsatellite 12S ribosomal RNA |

As is apparent to one of ordinary skill in the art, this same procedure can be used to identify stem cells genes whose expression levels are associated with stem cell proliferation, dedicated differentiation and survival.

5 Example 2

Method to identify a therapeutic agent that modulates the expression of at least one stem cell gene associated with the differentiation process of a stem cell population.

The methods set forth in Example 1 offer a powerful approach for identifying therapeutic agents that modulate the expression of at least one stem cell gene associated with the differentiation process of a stem cell population. For instance, gene expression profiles of undifferentiated stem cells and partially differentiated or terminally differentiated stem cells are prepared as set forth in Example 1. A profile is also prepared from an undifferentiated stem cell sample that has been exposed to the agent to be tested. By examining for differences in the intensity of individual bands between the three profiles, agents which up or down regulate genes associated with the differentiation process of a stem cell population are identified.

Example 3

Method to identify a therapeutic agent that modulates the expression of at least one stem cell gene associated with the proliferation of a stem cell population.

The methods set forth in Example 1 offer a powerful approach for identifying therapeutic agents that modulate the expression of at least one stem cell gene associated with the proliferation of a stem cell population. For instance, gene expression profiles of undifferentiated stem cells and actively proliferating stem cells are prepared as set forth in Example 1. A profile is also prepared from an undifferentiated stem cell sample that has been exposed to the agent to be tested. By examining for differences in the intensity of individual bands between the three profiles, agents which up or down regulate genes associated with the proliferation of a stem cell population are identified.

-59-

As is apparent to one of ordinary skill in the art, this same procedure can be used to identify stem cells genes whose expression levels are associated with stem cell dedicated differentiation and survival.

Example 4

5 *Production of solid support compositions comprising groupings of nucleic acids or nucleic acid fragments that correspond to genes whose expression levels are associated with the differentiation, proliferation, dedicated differentiation or survival of stem cells.*

As set forth in Example 1, expression profiles prepared from stem cells at different stages of differentiation, from proliferating stem cells, from stem cells that are 10 dedicated to a differentiation pathway and from stem cells resistant to apoptosis (which may be linked to increased survival) provide a means to identify genes whose expression levels are associated with stem cell differentiation, proliferation, dedicated differentiation and survival, respectively.

Solid supports can be prepared that comprise immobilized representative 15 groupings of nucleic acids or nucleic acid fragments corresponding to the genes from stem cells whose expression levels are modulated during stem cell differentiation, proliferation, dedicated differentiation and survival. For instance, representative nucleic acids can be immobilized to any solid support to which nucleic acids can be immobilized, such as positively charged nitrocellulose or nylon membranes (see Sambrook *et al.* 20 (1989) *Molecular Cloning: a Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory) as well as porous glass wafers such as those disclosed by Beattie (WO 95/11755). Nucleic acids are immobilized to the solid support by well established techniques, including charge interactions as well as attachment of derivatized nucleic acids to silicon dioxide surfaces such as glass which bears a terminal epoxide moiety. At 25 least one species of nucleic acid molecule, or fragment of a nucleic acid molecule corresponding to the genes from stem cells whose expression levels are modulated during stem cell differentiation, proliferation, dedicated differentiation and survival may be immobilized to the solid support. A solid support comprising a representative grouping of nucleic acids can then be used in standard hybridization assays to detect the presence

-60-

or quantity of one or more specific nucleic acid species in a sample (such as a total cellular mRNA sample or cDNA prepared from said mRNA) which hybridize to the nucleic acids attached to the solid support. Any hybridization methods, reactions, conditions and/or detection means can be used, such as those disclosed by Sambrook *et al.* (1989) *Molecular Cloning: a Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Ausbel *et al.* (1987) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience. N.Y. or Beattie in WO 95/11755.

One of ordinary skill in the art may determine the optimal number of genes that must be represented by nucleic acid fragments immobilized on the solid support to effectively differentiate between samples that are at the various stages of stem cell differentiation, including terminal differentiation, proliferating stem cells, stem cells dedicated to a given differentiation pathway and/or stem cells with increased survival rates. Preferably, at least about 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000 or more preferably, substantially all of the detectable mRNA species in a cell sample or population will be present in the gene expression profile or array affixed to a solid support. More preferably, such profiles or arrays will contain a sufficient representative number of mRNA species whose expression levels are modulated under the relevant differentiation process, disease, screening, treatment or other experimental conditions. In most instances, a sufficient representative number of such mRNA species will be about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100 in number and will be represented by the nucleic acid molecules or fragments of nucleic acid molecules immobilized on the solid support. For example, nucleic acids encoding all or a fragment of one or more of the known genes or previously reported ESTs that are identified in Tables 2 and 3 may be so immobilized. Additionally, the skilled artisan may select nucleic acids encoding the protein cell surface markers discussed above at page 8 (*i.e.*, CD 34) in order to help identify the particular stage of differentiation of a given stem cell population and to identify agents that are involved in promoting such differentiation. The skilled artisan will be able to optimize the number and particular nucleic acids for a given purpose, *i.e.*, screening for modulating agents, identifying activated stem cells, etc.

In general, nucleic acid fragments comprising at least one of the sequences or part of one of the sequences of Table 2 can be used as probes to screen nucleic acid samples from cell populations in hybridization assays. Alternatively, nucleic acid fragments derived from the identified genes in Table 3 which correspond to the sequences of Table 5 2 may be employed as probes. To ensure specificity of a hybridization assay using probe derived from the sequences presented in Table 2 or the genes of Table 3, it is preferable to design probes which hybridize only with target nucleic acid under conditions of high stringency. Only highly complementary nucleic acid hybrids form under conditions of high stringency. Accordingly, the stringency of the assay conditions determines the 10 amount of complementarity which should exist between two nucleic acid strands in order to form a hybrid. Stringency should be chosen to maximize the difference in stability between the probe:target hybrid and potential probe:non-target hybrids.

Probes may be designed from the sequences of Table 2 or the genes of Table 3 through methods known in the art. For instance, the G+C content of the probe and the 15 probe length can affect probe binding to its target sequence. Methods to optimize probe specificity are commonly available in Sambrook *et al.* (*Molecular Cloning: A Laboratory Approach*, Cold Spring Harbor Press, NY, 1989) or Ausubel *et al.* (*Current Protocols in Molecular Biology*, Greene Publishing Co., NY, 1995). Any available format may be used in designing hybridization assays, including immobilizing the probes to a solid 20 support or immobilizing the cellular test sample nucleic acids to a solid support.

It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It therefore should be apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. All documents, 25 patents and references, including provisional patent application 60/056,861, referred to throughout this application are herein incorporated by reference.

What is Claimed Is:

1. A method to identify an agent that modulates the expression of at least one stem cell gene associated with the differentiation process of a stem cell population, comprising the steps of:
 - 5 preparing a first gene expression profile of an undifferentiated stem cell population;
 - preparing a second gene expression profile of a stem cell population at a defined stage of differentiation;
 - treating said undifferentiated stem cell population with the agent;
 - 10 preparing a third gene expression profile of the treated undifferentiated stem cell population;
 - comparing the first, second and third gene expression profiles; and
 - identifying an agent that modulates the expression of a least one gene in undifferentiated stem cells that is associated with stem cell differentiation.
- 15 2. A method to identify an agent that modulates the expression of at least one stem cell gene associated with the proliferation of a stem cell population, comprising the steps of:
 - preparing a first gene expression profile of a non-proliferating stem cell population;
 - 20 preparing a second gene expression profile of a proliferating stem cell population;
 - treating the non-proliferating stem cell population with the agent;
 - preparing a third gene expression profile of the treated stem cell population;
- 25 comparing the first, second and third gene expression profiles; and
- identifying an agent that modulates the expression of a least one gene that is associated with stem cell proliferation.

-63-

3. A composition comprising a grouping of nucleic acid molecules that correspond to at least part of the sequences of Table 2 or genes of Table 3 affixed to a solid support.




FIG. 1




FIG. 1 (Cont.)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17283

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/68; C12N 15/12

US CL : 435/6; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Medline, WPIDS

search terms: hematopoietic stem cell, differential display

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X | TAGOH et al. Molecular Cloning and Characterization of a Novel Stromal Cell-Derived cDNA Encoding a Protein That Facilitates Gene Activation of Recombination Activating Gene (RAG)-1 in Human Lymphoid Progenitors. Biochem. Biophys Res. Commun. 1996, Vol. 221, pages 744-749, especially page 744. | 1, 2 |
| X | MOREB et al. Human A1, a Bcl-2-related gene, is induced in leukemic cells by cytokines as well as differentiating factors. Leukemia. July 1997, Vol. 11, Number 7, pages 998-1004, especially page 998. | 1, 2 |

Further documents are listed in the continuation of Box C. See patent family annex.

| | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| * Special categories of cited documents: | *T* | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be of particular relevance | *X* | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *B* earlier document published on or after the international filing date | *Y* | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *A* | document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | | |
| *P* document published prior to the international filing date but later than the priority date claimed | | |

Date of the actual completion of the international search

30 NOVEMBER 1998

Date of mailing of the international search report

24 DEC 1998


Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN S. BRUSCA

Telephone No. (703) 308-0196



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17283

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 3 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

No sequence listing or computer readable form of sequence listing has been supplied, and claim 3 is drawn to specific sequences that therefore cannot be searched.

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:


4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| (51) International Patent Classification 6 : C12Q 1/68, C12N 15/12 | | A1 | (11) International Publication Number: WO 99/10535 (43) International Publication Date: 4 March 1999 (04.03.99) |
| <p>(21) International Application Number: PCT/US98/17283</p> <p>(22) International Filing Date: 21 August 1998 (21.08.98)</p> <p>(30) Priority Data: 60/056,861 22 August 1997 (22.08.97) US</p> <p>(71) Applicant (for all designated States except US): YALE UNIVERSITY [US/US]; 451 College Street, New Haven, CT 06520 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): LIU, Meng [CN/US]; Apartment 7C, 564 Prospect Street, New Haven, CT 06511 (US). BASKARAN, Namadev [IN/US]; 750 Whitney Avenue, New Haven, CT 06511 (US). WEISSMAN, Sherman, M. [US/US]; 459 Saint Ronan Street, New Haven, CT 06511 (US).</p> <p>(74) Agent: ADLER, Reid, G.; Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20036 (US).</p> | | <p>(81) Designated States: AU, CA, IL, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> | |

(54) Title: A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN STEM CELLS

(57) Abstract

The present invention includes a method to identify stem cell genes that are differentially expressed in stem cells at various stages of differentiation when compared to undifferentiated stem cells by preparing a gene expression profile of a stem cell population and comparing the profile to a profile prepared from stem cells at different stages of differentiation, thereby identifying cDNA species, and therefore genes, which are expressed. The present invention also includes methods to identify a therapeutic agent that modulates the expression of at least one stem cell gene associated with the differentiation, proliferation and/or survival of stem cells.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|-------------------------------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

-1-

A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN STEM CELLS

Technical Field

This invention relates to compositions and methods useful to identify agents that modulate the expression of at least one gene associated with the differentiation, proliferation, dedication and/or survival of stem cells.

5 Background of the Invention

The identification of genes associated with development and differentiation of cells is an important step for advancing our understanding of hematopoiesis, the differentiation of hematopoietic stem cells into erythrocytes, monocytes, platelets and polymorphonuclear white blood cells or granulocytes. The identification of genes 10 associated with hematopoiesis is also an important step for advancing the development of therapeutic agents which modulate, promote or interfere with the differentiation of stem cells.

Hematopoietic stem cells derive from bone marrow stem cells. The bone marrow stem cells ultimately differentiate into the hematopoietic stem cells, which are 15 responsible for the lymphoid, myeloid and erythroid lineages, and stromal stem cells, which differentiate into fibroblasts, osteoblasts, smooth muscle cells, stromal cells and adipocytes (STEWART SELL, IMMUNOLOGY, IMMUNOPATHOLOGY & IMMUNITY, 5th ed. 39-42 Stamford, CT, 1996). The lymphoid lineage, comprising B-cells and T-cells, provides for the production of antibodies, regulation of the cellular immune system, detection of 20 foreign agents in the blood, detection of cells foreign to the host, and the like. The myeloid lineage, which includes monocytes, granulocytes, megakaryocytes as well as others cells, monitors for the presence of foreign bodies in the blood stream, provides protection against neoplastic cells, scavenges foreign materials in the blood stream,

-2-

produces platelets and the like. The erythroid lineage provides the red blood cells which act as oxygen carriers.

Hematopoietic stem cells differentiate as a result from their interaction with growth factors such as interleukins (ILs), lymphokines, colony-stimulating factors (CSFs), erythropoietin (epo), and stem cell factor (SCF). Each of these growth factors have multiple actions that are not necessarily limited to the hematopoietic system (ROBERT A. MEYERS, ED., MOLECULAR BIOLOGY AND BIOTECHNOLOGY: A COMPREHENSIVE DESK REFERENCE, 392-6, New York, 1995). Proliferation, differentiation and survival of immature hematopoietic progenitor cells are sustained by hematopoietic growth factors (hemopoietins). These growth factors also influence the survival and function of mature blood cells. The kinetics of hematopoiesis vary depending on cell type, and their life span may be as little as 6-12 hours to as much as months or years. As a result, the daily renewal of certain lymphocyte progenitors may be substantially lower than that of leukocytic progenitors. The most primitive cells, pluripotent stem cells (PSCs), have high self-renewal capacity (Nathan, 818-821; Saito, *Recent trends in research on differentiation of hematopoietic cells and lymphokines*, Hum. Cell. 5(1): 54 (1992)).

Growth factors are responsible for differentiating the hematopoietic stem cell into either the hemocytoblast, which is the progenitor cell of erythrocytes, neutrophils, eosinophils, basophils, monocytes and platelets, and lymphoid stem cells, which are progenitors to T cells and B cells. SELL, 41. These circulating blood cells are products of terminal differentiation of recognizable precursors (e.g., erythroblasts, monomyeloblasts and megakaryoblasts, to name but a few). The terminal differentiation of these recognizable precursors may occur exclusively in the marrow cavities of the axial skeleton, with some extension into the proximal femora and humeri (David G. Nathan, *Hematologic Diseases*, IN CECIL TEXTBOOK OF MEDICINE 20th ed., 817, Philadelphia, 1996). White blood cell (WBC) nomenclature may be divided into two major populations on the basis of the form of their nuclei: single nuclei (mononuclear or "round cells") or segmented nuclei (polymorphonuclear).

-3-

In human medicine, the ability to initiate and regulate hematopoiesis is of great importance (McCune *et al.*, *The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function*, *Science* 241: 1632(1988)). A variety of diseases and immune disorders, including malignancies, appear to be related to

5 disruptions within the lympho-hematopoietic system. Many of these disorders could be alleviated and/or cured by repopulating the hematopoietic system with progenitor cells, which when triggered to differentiate would overcome the patient's deficiency. In humans, a current replacement therapy is bone marrow transplantation. This type of therapy, however, is both painful (for donor and recipient) because of involvement of

10 invasive procedures and can offer severe complications to the recipient, particularly when the graft is allogeneic and Graft Versus Host Disease (GVHD) results. Therefore, the risk of GVHD restricts the use of bone marrow transplantation to patients with otherwise fatal diseases. A potentially more exciting alternative therapy for hematopoietic disorders is the treatment of patients with reagents that regulate the proliferation and

15 differentiation of stem cells (Lawman *et al.*, U.S. Patent No. 5,650,299 (1997)).

There is also a strong interest in the development of procedures to produce large numbers of the human hematopoietic stem cell. This will allow for identification of growth factors associated with its self regeneration. Additionally, there may be as yet undiscovered growth factors associated (1) with the early steps of dedication of the stem

20 cell to a particular lineage; (2) the prevention of such dedication; and (3) the negative control of stem cell proliferation. Availability of large numbers of stem cells would be extremely useful in bone marrow transplantation, as well as transplantation of other organs in association with the transplantation of bone marrow.

An *in vitro* system that permits determination of what agents induce

25 differentiation or proliferation of progenitor cells within a hematopoietic cell population would have many applications. For example, controlled production of red blood cells would permit the *in vitro* production of red blood cell units for clinical replacement (transfusion) therapy. As is well known, transfused red cells are used in the treatment of anemia following elective surgery, in cases of traumatic blood loss, and in the supportive

30 care of, *e.g.*, cancer patients. Similarly, controlled production of platelets would permit

-4-

the *in vitro* production of platelets for platelet transfusion therapy, which may be used in cancer patients with thrombocytopenia caused by chemotherapy. For both red cells and platelets, current volunteer donor pools are accompanied by the risk of infectious contamination, and availability of an adequate supply can be limited. Determination of 5 such compounds would lend itself to developing methods of controlled *in vitro* production of specified lineage of mature blood cells to circumvent these problems (Palsson *et al.*, U.S. Patent No. 5,635,386 (1997)).

Alternatively, agents could be isolated that selectively deplete a particular lineage of cells from within a hematopoietic cell population and can similarly confer important 10 advantages. For example, production of stem cells and myeloid cells while selectively depleting T-cells from a bone marrow cell population could be very important for the management of patients with human immunodeficiency virus (HIV) infection. Since the major reservoir of HIV is the pool of mature T-cells, selective eradication of the mature 15 T-cells from a hematopoietic cell mass collected from a patient has considerable potential therapeutic benefit. If one could selectively remove all the mature T-cells from within an HIV infected bone marrow cell population while maintaining viable stem cells, the T-cell depleted bone marrow sample could then be used to "rescue" the patient following hematolymphoid ablation and autologous bone marrow transplantation. Although there 20 are reports of the isolation of progenitor cells (see, e.g., Tsukamoto *et al.*, (1991) as representative) such techniques are distinct from the selective removal of T-cells from a hematopoietic tissue culture (Palsson *et al.*, U.S. Patent No. 5,635,386 (1997)).

Summary of the Invention

While the differentiation of stem cells has been the subject of intense study, little is known about the global transcriptional response of stem cells during cell 25 hematopoiesis. The present inventors have devised an approach to systematically assess the transcriptional regulation of stem cells during hematopoiesis as well as methods for the identification of agents that modulate the expression of at least one gene associated with hematopoiesis.

The present invention includes a method to identify stem cell genes that are differentially expressed in stem cells at various stages of differentiation when compared to undifferentiated stem cells by preparing a gene expression profile of a stem cell population and comparing the profile to a profile prepared from stem cells at different 5 stages of differentiation, thereby identifying cDNA species, and therefore genes, which are expressed.

The present invention further includes a method to identify an agent that modulates the expression of at least one stem cell gene associated with the differentiation process of a stem cell population, comprising the steps of preparing a first gene 10 expression profile of an undifferentiated stem cell population, preparing a second gene expression profile of a stem cell population at a defined stage of differentiation, treating said undifferentiated stem cell population with the agent, preparing a third gene expression profile of the treated stem cell population, and comparing the first, second and third gene expression profiles. Comparison of the three gene expression profiles for 15 RNA species as represented by cDNA fragments that are differentially expressed upon addition of the agent to the undifferentiated stem cell population identifies agents that modulate the expression of at least one gene in undifferentiated stem cells that is associated with stem cell differentiation.

Another aspect of the invention is a composition comprising a grouping of nucleic 20 acids or nucleic acid fragments affixed to a solid support. The nucleic acids affixed to the solid support correspond to one or more genes whose expression levels are modulated during stem cell differentiation.

Brief Description of the Drawings

Fig. 1 Figure 1 is an autoradiogram of the gene expression profiles generated 25 from cDNAs made with RNA isolated from Lin⁺, LRH, LRH48 and LRBRH cells. All possible 12 anchoring oligo d(T)_{n1}, n₂ were used to generate a complete expression profile for the enzyme *Clal*.

Modes of Carrying Out the Invention**General Description**

The differentiation of stem cells during the process of hematopoiesis is a subject of primary importance in view of the need to find ways to modulate the stem cell differentiation process. One means of characterizing the process of hematopoiesis is to measure the ability of stem cells to synthesize specific RNA during stem cell differentiation.

The following discussion presents a general description of the invention as well definitions for certain terms used herein.

10 *Definitions*

The term "stem cells" as used herein, refers to both hematopoietic stem cells and bone marrow stem cells, and includes totipotent cells which serve as progenitors of neoplastic transformation. The term "hematopoietic stem cells" refers to stem cells which differentiate into erythrocytes, monocytes, granulocytes, and platelets. The 15 putative human hematopoietic stem cell may express the cell surface antigen CD34.

The term "hematopoiesis" as used herein, refers to the process by which stem cells differentiate into blood cells, including erythrocytes, monocytes, granulocytes, and platelets.

The term "blood cell", as used herein, refers to all blood cell types derived from the 20 process of hematopoiesis (see STEWART SELL, *IMMUNOLOGY, IMMUNOPATHOLOGY & IMMUNITY*, 5th ed. 39-42, Stamford, CT, 1996)

The term "solid support", as used herein, refers to any support to which nucleic acids can be bound or immobilized, including nitrocellulose, nylon, glass, other solid supports which are positively charged and nanochannel glass arrays disclosed by Beattie (WO 25 95/1175).

The term "gene expression profile", also referred to as a "differential expression profile" or "expression profile" refers to any representation of the expression level of at

least one mRNA species in a cell sample or population. For instance, a gene expression profile can refer to an autoradiograph of labeled cDNA fragments produced from total cellular mRNA separated on the basis of size by known procedures. Such procedures include slab gel electrophoresis, capillary gene electrophoresis, high performance liquid 5 chromatography, and the like. Digitized representations of scanned electrophoresis gels are also included as are two and three dimensional representations of the digitized data.

While a gene expression profile encompasses a representation of the expression level of at least one mRNA species, in practice, the typical gene expression profile represents the expression level of multiple mRNA species. For instance, a gene expression profile 10 useful in the methods and compositions disclosed herein represents the expression levels of at least about 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000 or more preferably, substantially all of the detectable mRNA species in a cell sample or population.

Particularly preferred are gene expression profiles or arrays affixed to a solid support that contain a sufficient representative number of mRNA species whose expression levels are 15 modulated under the relevant infection, disease, screening, treatment or other experimental conditions. In some instances a sufficient representative number of such mRNA species will be about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100.

Gene expression profiles can be produced by any means known in the art, including, but not limited to the methods disclosed by: Prashar et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:659-663; Liang et al. (1992) *Science* 257:967-971; Ivanova et al. (1995) *Nucleic Acids Res.* 23:2954-2958; Guilfoyl et al. (1997) *Nucleic Acids Res.* 25(9):1854-1858; Chee et al. (1996) *Science* 274:610-614; Velculescu et al. (1995) *Science* 270:484-487; Fischer et al. (1995) *Proc. Natl. Acad. Sci. USA* 92(12):5331-5335; and Kato (1995) *Nucleic Acids Res.* 23(18):3685-3690.

25 As an example, gene expression profiles are made to identify one or more genes whose expression levels are modulated during the process of stem cell differentiation. The assaying of the modulation of gene expression via the production of a gene expression profile generally involves the production of cDNA from polyA⁺ RNA (mRNA) isolated from stem cells as described below.

-8-

Stem cells are harvested or isolated by any technique known in the art. One of the most versatile ways to separate hematopoietic cells is by use of flow cytometry, where the particles, *i.e.*, cells, can be detected by fluorescence or light scattering. The source of the cells may be any source which is convenient. Thus, various tissues, organs, fluids, or 5 the like may be the source of the cellular mixtures. Of particular interest are bone marrow and peripheral blood, although other lymphoid tissues are also of interest, such as spleen, thymus, and lymph node (see Sasaki *et al.*, U.S. Patent No. 5,466,572 and Fei *et al.*, U.S. Patent No. 5,635,387).

Cells of interest will usually be detected and separated by virtue of surface membrane 10 proteins which are characteristic of the cells. For example, CD34 is a marker for immature hematopoietic cells. Markers for dedicated cells may include CD 10, CD19, CD20, and sIg for B cells, CD 15 for granulocytes, CD 16 and CD33 for myeloid cells, CD 14 for monocytes, CD41 for megakaryocytes, CD38 for lineage dedicated cells, CD3, CD4, CD7, CD8 and T cell receptor (TCR) for T cells, Thy-1 for progenitor cells, 15 glycophorin for erythroid progenitors and CD71 for activated T cells. In isolating early progenitors, one may divide a CD34 positive enriched fraction into lineage (Lin) negative, e.g. CD2 -, CD 14 -, CD15 -, CD16 -, CD10 -, CD19 -, CD33 - and glycophorin A -, fractions by negatively selecting for markers expressed on lineage 20 committed cells, Thy-1 positive fractions, or into CD38 negative fractions to provide a composition substantially enriched for early progenitor cells. Other markers of interest include V alpha and V beta chains of the T-cell receptor (Sasaki *et al.*, U. S. Patent No. 5,466,572 (1995)).

After isolation of the appropriate stem cells, total cellular mRNA is isolated from the cell sample. mRNAs are isolated from cells by any one of a variety of techniques. 25 Numerous techniques are well known (see *e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Approach*, Cold Spring harbor Press, NY, 1987; Ausbel *et al.*, *Current Protocols in Molecular Biology*, Greene Publishing Co. NY, 1995). In general, these techniques first lyse the cells and then enrich for or purify RNA. In one such protocol, cells are lysed in a Tris-buffered solution containing SDS. The lysate is extracted with 30 phenol/chloroform, and nucleic acids precipitated. The mRNAs may be purified from

-9-

crude preparations of nucleic acids or from total RNA by chromatography, such as binding and elution from oligo(dT)-cellulose or poly(U)-Sepharose®. However, purification of poly(A)-containing RNA is not a requirement. As stated above, other protocols and methods for isolation of RNAs may be substituted.

- 5 The mRNAs are reverse transcribed using an RNA-directed DNA polymerase, such as reverse transcriptase isolated from AMV, MoMuLV or recombinantly produced. Many commercial sources of enzyme are available (e.g. Pharmacia, New England Biolabs, Stratagene Cloning Systems). Suitable buffers, cofactors, and conditions are well known and supplied by manufacturers (see also, Sambrook *et al.* (1989) *Molecular Cloning: a laboratory manual*, 2nd Ed., Cold Spring Harbor Laboratory; and Ausbel *et al.*, (1987) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, N.Y.).
- 10
- 15
- 20
- 25

Various oligonucleotides are used in the production of cDNA. In particular, the methods utilize oligonucleotide primers for cDNA synthesis, adapters, and primers for amplification. Oligonucleotides are generally synthesized as single strands by standard chemistry techniques, including automated synthesis. Oligonucleotides are subsequently de-protected and may be purified by precipitation with ethanol, chromatographed using a sized or reversed-phase column, denaturing polyacrylamide gel electrophoresis, high-pressure liquid chromatography (HPLC), or other suitable method. In addition, within certain preferred embodiments, a functional group, such as biotin, is incorporated preferably at the 5' or 3' terminal nucleotide. A biotinylated oligonucleotide may be synthesized using pre-coupled nucleotides, or alternatively, biotin may be conjugated to the oligonucleotide using standard chemical reactions. Other functional groups, such as fluorescent dyes, radioactive molecules, digoxigenin, and the like, may also be incorporated.

Partially-double stranded adaptors are formed from single stranded oligonucleotides by annealing complementary single-stranded oligonucleotides that are chemically synthesized or by enzymatic synthesis. Following synthesis of each strand, the two oligonucleotide strands are mixed together in a buffered salt solution (e.g., 1 M NaCl, 30 100 mM Tris-HCl pH 8.0, 10 mM EDTA) or in a buffered solution containing Mg²⁺ (e.g.,

-10-

10 mM MgCl₂) and annealed by heating to high temperature and slow cooling to room temperature.

The oligonucleotide primer that primes first strand DNA synthesis may comprise a 5' sequence incapable of hybridizing to a polyA tail of the mRNAs, and a 3' sequence that 5 hybridizes to a portion of the polyA tail of the mRNAs and at least one non-polyA nucleotide immediately upstream of the polyA tail. The 5' sequence is preferably a sufficient length that can serve as a primer for amplification. The 5' sequence also preferably has an average G+C content and does not contain large palindromic sequence; some palindromes, such as a recognition sequence for a restriction enzyme, may be 10 acceptable. Examples of suitable 5' sequences are CTCTCAAGGATCTACCGCT (SEQ ID No. _____), CAGGGTAGACGACGCTACGC (SEQ ID No. _____), and TAATACCGCGGCCACATAGCA (SEQ ID No. _____)

The 5' sequence is joined to a 3' sequence comprising sequence that hybridizes to a portion of the polyA tail of mRNAs and at least one non-polyA nucleotide immediately 15 upstream. Although the polyA-hybridizing sequence is typically a homopolymer of dT or dU, it need only contain a sufficient number of dT or dU bases to hybridize to polyA under the conditions employed. Both oligo-dT and oligo-dU primers have been used and give comparable results. Thus, other bases may be interspersed or concentrated, as long as hybridization is not impeded. Typically, 12 to 18 bases or 12 to 30 bases of dT or dU 20 will be used. However, as one skilled in the art appreciates, the length need only be sufficient to obtain hybridization. The non-poly A⁺ nucleotide is A, C, or G, or a nucleotide derivative, such as inosinate. If one non-polyA nucleotide is used, then three oligonucleotide primers are needed to hybridize to all mRNAs. If two non-polyA nucleotides are used, then 12 primers are needed to hybridize to all mRNAs (AA, AC, 25 AG, AT, CA, CC, CG, CT, GA, GC, GG, GT). If three non-poly A nucleotides are used then 48 primers are needed (3 X 4 X 4). Although there is no theoretical upper limit on the number of non-polyA nucleotides, practical considerations make the use of one or two non-polyA nucleotides preferable.

For cDNA synthesis, the mRNAs are either subdivided into three (if one non-polyA 30 nucleotide is used) or 12 (if two non-polyA nucleotides are used) fractions, each

-11-

containing a single oligonucleotide primer, or the primers may be pooled and contacted with a mRNA preparation. Other subdivisions may alternatively be used. Briefly, first strand cDNA is initiated from the oligonucleotide primer by reverse transcriptase (RTase). As noted above, RASE may be obtained from numerous sources and protocols 5 are well known. Second strand synthesis may be performed by RASE (Gubler and Hoffman, *Gene* 25: 263, 1983), which also has a DNA-directed DNA polymerase activity, with or without a specific primer, by DNA polymerase 1 in conjunction with RNaseH and DNA ligase, or other equivalent methods. The double-stranded cDNA is generally treated by phenol:chloroform extraction and ethanol precipitation to remove 10 protein and free nucleotides.

Double-stranded cDNA is subsequently digested with an agent that cleaves in a sequence-specific manner. Such cleaving agents include restriction enzymes, chemical cleaving agents, triple helix, and any other cleaving agent available. Restriction enzyme digestion is preferred; enzymes that are relatively infrequent cutters (*e.g.*, ≥ 5 bp 15 recognition site) are preferred and those that leave overhanging ends are especially preferred. A restriction enzyme with a six base pair recognition site cuts approximately 8% of cDNAs, so that approximately 12 such restriction enzymes should be needed to digest every cDNA at least once. By using 30 restriction enzymes, digestion of every cDNA is assured.

20 The adapters for use in the present invention are designed such that the two strands are only partially complementary and only one of the nucleic acid strands that the adapter is ligated to can be amplified. Thus, the adapter is partially double-stranded (*i.e.*, comprising two partially hybridized nucleic acid strands), wherein portions of the two strands are non-complementary to each other and portions of the two strands are 25 complementary to each other. Conceptually, the adapter may be "Y-shaped" or "bubble-shaped." When the 5' region is non-paired, the 3' end of other strand cannot be extended by a polymerase to make a complementary copy. The ligated adapter can also be blocked at the 3' end to eliminate extension during subsequent amplifications. Blocking groups include dideoxynucleotides and other available blocking agents. In this type of adapter 30 ("Y-shaped"), the non-complementary portion of the upper strand of the adapters is

-12-

preferably a length that can serve as a primer for amplification. As noted above, the non-complementary portion of the lower strand need only be one base, however, a longer sequence is preferable (e.g., 3 to 20 bases; 3 to 15 bases; 5 to 15 bases, or 14 to 24 bases. The complementary portion of the adapter should be long enough to form a duplex under 5 conditions of ligation.

For "bubble-shaped" adapters, the non-complementary portion of the upper strands is preferably a length that can serve as a primer for amplification. Thus, this portion is preferably 15 to 30 bases. Alternatively, the adapter can have a structure similar to the Y-shaped adapter, but has a 3' end that contains a moiety that a DNA polymerase cannot 10 extend from.

Amplification primers are also used in the present invention. Two different amplification steps are performed in the preferred aspect. In the first, the 3' end (referenced to mRNA) of double stranded cDNA that has been cleaved and ligated with an adapter is amplified. For this amplification, either a single primer or a primer pair is 15 used. The sequence of the single primer comprises at least a portion of the 5' sequence of the oligonucleotide primer used for first strand cDNA synthesis. The portion need only be long enough to serve as an amplification primer. The primer pair consists of a first primer whose sequence comprises at least a portion of the 5' sequence of the oligonucleotide primer as described above; and a second primer whose sequence 20 comprises at least a portion of the sequence of one strand of the adapter in the non-complementary portion. The primer will generally contain all the sequence of the non-complementary portion, but may contain less of the sequence, especially when the non-complementary portion is very long, or more of the sequence, especially when the non-complementary portion is very short. In some embodiments, the primer will contain 25 sequence of the complementary portion, as long as that sequence does not appreciably hybridize to the other strand of the adapter under the amplification conditions employed. For example, in one embodiment, the primer sequence comprises four bases of the complementary region to yield a 19 base primer, and amplification cycles are performed at 56°C (annealing temperature), 72°C (extension temperature), and 94°C (denaturation 30 temperature). In another embodiment, the primer is 25 bases long and has 10 bases of

-13-

sequence in the complementary portion. Amplification cycles for this primer are performed at 68°C (annealing and extension temperature) and 94°C (denaturation temperature). By using these longer primers, the specificity of priming is increased.

The design of the amplification primers will generally follow well-known guidelines,
5 such as average G-C content, absence of hairpin structures, inability to form primer-dimers and the like. At times, however, it will be recognized that deviations from such guidelines may be appropriate or desirable.

In instances where small numbers of cells are available for the initial RNA extraction, such as small numbers of stem cells, the preferred method of producing a gene expression
10 profile comprises the following general steps. Total RNA is extracted from as few as 5000 stem cells. Using an oligo-dT primer, double stranded cDNA is synthesized and ligated to an adapter in accordance with the present invention. Using adapter primers, the cDNA is PCR amplified using the protocol of Baskaran and Weissman (1996) *Genome Research* 6(7): 633 and/or Liv *et al.* (1992) *Methods of Enzymology*. The original cDNA
15 is therefore amplified several fold so that a large quantity of this cDNA is available for use in the display protocol according to the present invention. For the display, an aliquot of this cDNA is incubated with an anchored oligo-dT primer. In one method, this mixture is first heat denatured and then allowed to remain at 50°C for 5 minutes to allow the anchor nucleotides of the oligo-dT primers to anneal. This provides for the synthesis
20 of cDNA utilizing Klenow DNA polymerase. The 3'-end region of the parent cDNA (mainly the polyA region) that remains single stranded due to pairing and subsequent synthesis of cDNA by the anchored oligo-dT primer at the beginning of the polyA region, is removed by the 5'-3' exonuclease activity of the T4 DNA polymerase. Following incubation of the cDNA with T4 DNA polymerase for this purpose, dNTPs are added in
25 the reaction mixture so that the T4 DNA polymerase initiates synthesis of the DNA over the anchored oligo-dT primer carrying the heel. The net result of this protocol is that the cDNA with the 3' heel is synthesized for display from the double stranded cDNA as the starting material, rather than RNA as the starting material as occurs in conventional 3'-end cDNA display protocol. The cDNA carrying the 3'-end heel is then subjected to
30 restriction enzyme digestion, ligation, and PCR amplification followed by running the

-14-

PCR amplified 3'-end restriction fragments with the Y-shaped adapter on a display gel. An alternate method is presented in Example 1.

After amplification, the lengths of the amplified fragments are determined. Any procedure that separates nucleic acids on the basis of size and allows detection or 5 identification of the nucleic acids is acceptable. Such procedures include slab gel electrophoresis, capillary gel electrophoresis, 2-dimensional electrophoresis, high performance liquid chromatography, and the like.

Electrophoresis is technique based on the mobility of DNA in an electric field. Negatively charged DNA migrates towards a positive electrode at a rate dependent on 10 their total charge, size, and shape. Most often, DNA is electrophoresed in agarose or polyacrylamide gels. For maximal resolution, polyacrylamide is preferred and for maximal linearity, a denaturant, such as urea is present. A typical gel setup uses a 19:1 mixture of acrylamide:bisacrylamide and a Tris-borate buffer. DNA samples are denatured and applied to the gel, which is usually sandwiched between glass plates. A 15 typical procedure can be found in Sambrook *et al.* (*Molecular Cloning: A Laboratory Approach*, Cold Spring Harbor Press, NY, 1989) or Ausbel *et al.* (*Current Protocols in Molecular Biology*, Greene Publishing Co., NY, 1995). Variations may be substituted as long as sufficient resolution is obtained.

Capillary electrophoresis (CE) in its various manifestations (free solution, 20 isotachophoresis, isoelectric focusing, polyacrylamide gel, micellar electrokinetic "chromatography") allows high resolution separation of very small sample volumes. Briefly, in capillary electrophoresis, a neutral coated capillary, such as a 50 μm X 37 cm column (eCAP neutral, Beckman Instruments, CA), is filled with a linear polyacrylamide (e.g., 0.2% polyacrylamide), a sample is introduced by high-pressure injection followed 25 by an injection of running buffer (e.g., 1X TBE). The sample is electrophoresed and fragments are detected. An order of magnitude increase can be achieved with the use of capillary electrophoresis. Capillaries may be used in parallel for increased throughput (Smith *et al.* (1990) *Nuc. Acids. Res.* 18:4417; Mathies and Huang (1992) *Nature* 359:167). Because of the small sample volume that can be loaded onto a capillary, 30 sample may be concentrated to increase level of detection. One means of concentration

-15-

is sample stacking (Chien and Burgi (1992) *Anal. Chem.* 64:489A). In sample stacking, a large volume of sample in a low concentration buffer is introduced to the capillary column. The capillary is then filled with a buffer of the same composition, but at higher concentration, such that when the sample ions reach the capillary buffer with a lower 5 electric field, they stack into a concentrated zone. Sample stacking can increase detection by one to three orders of magnitude. Other methods of concentration, such as isotachophoresis, may also be used.

High-performance liquid chromatography (HPLC) is a chromatographic separation technique that separates compounds in solution. HPLC instruments consist of a reservoir 10 of mobile phase, a pump, an injector, a separation column, and a detector. Compounds are separated by injecting an aliquot of the sample mixture onto the column. The different components in the mixture pass through the column at different rates due to differences in their partitioning behavior between the mobile liquid phase and the stationary phase. IP-RO-HPLC on non-porous PS/DVB particles with chemically 15 bonded alkyl chains can also be used to analyze nucleic acid molecules on the basis of size (Huber et al. (1993) *Anal. Biochem.* 121:351; Huber et al. (1993) *Nuc. Acids Res.* 21:1061; Huber et al. (1993) *Biotechniques* 16:898).

In each of these analysis techniques, the amplified fragments are detected. A variety of labels can be used to assist in detection. Such labels include, but are not limited to, 20 radioactive molecules (e.g., ^{35}S , ^{32}P , ^{33}P), fluorescent molecules, and mass spectrometric tags. The labels may be attached to the oligonucleotide primers or to nucleotides that are incorporated during DNA synthesis, including amplification.

Radioactive nucleotides may be obtained from commercial sources; radioactive 25 primers may be readily generated by transfer of label from γ - ^{32}P -ATP to a 5'-OH group by a kinase (e.g., T4 polynucleotide kinase). Detection systems include autoradiograph, phosphor image analysis and the like.

Fluorescent nucleotides may be obtained from commercial sources (e.g., ABI, Foster city, CA) or generated by chemical reaction using appropriately derivatized dyes. 30 Oligonucleotide primers can be labeled, for example, using succinimidyl esters to conjugate to amine-modified oligonucleotides. A variety of fluorescent dyes may be used,

-16-

including 6 carboxyfluorescein, other carboxyfluorescein derivatives, carboxyrhodamine derivatives, Texas red derivatives, and the like. Detection systems include photomultiplier tubes with appropriate wave-length filters for the dyes used. DNA sequence analysis systems, such as produced by ABI (Foster City, CA), may be used.

- 5 After separation of the amplified cDNA fragments, cDNA fragments which correspond to differentially expressed mRNA species are isolated, reamplified and sequenced according to standard procedures. For instance, bands corresponding the cDNA fragments can be cut from the electrophoresis gel, reamplified and subcloned into any available vector, including pCRscript using the PCR script cloning kit (Stratagene).
- 10 The insert is then sequenced using standard procedures, such as cycle sequencing on an ABI sequencer (Foster City, CA).

An additional means of analysis comprises hybridization of the amplified fragments to one or more sets of oligonucleotides immobilized on a solid substrate. Historically, the solid substrate is a membrane, such as nitrocellulose or nylon. More recently, the substrate is a silicon wafer or a borosilicate slide. The substrate may be porous (Beattie et al. WO 95/11755) or solid. Oligonucleotides are synthesized *in situ* or synthesized prior to deposition on the substrate using standard procedures. Various chemistries are known for attaching oligonucleotides. Many of these attachment chemistries rely upon functionalizing oligonucleotides to contain a primary amine group. The oligonucleotides are arranged in an array form, such that the position of each oligonucleotide sequence can be determined.

The amplified fragments, which are generally labeled according to one of the methods described herein, are denatured and applied to the oligonucleotides on the substrate under appropriate salt and temperature conditions. In certain embodiments, the conditions are chosen to favor hybridization of exact complementary matches and disfavor hybridization of mismatches. Unhybridized nucleic acids are washed off and the hybridized molecules detected, generally both for position and quantity. The detection method will depend upon the label used. Radioactive labels, fluorescent labels and mass spectrometry label are among the suitable labels.

-17-

The present invention as set forth in the specific embodiments, includes methods to identify a therapeutic agent that modulates the expression of at least one stem cell gene associated with the differentiation, proliferation and/or survival of stem cells.

As an example, the method to identify an agent that modulates the expression of at

5 least one stem cell gene associated with the differentiation of a stem cell population, comprises the steps of preparing a first gene expression profile of an undifferentiated stem cell population, preparing a second gene expression profile of a stem cell population at a defined stage of differentiation, treating said undifferentiated stem cell population with the agent, preparing a third gene expression profile of the treated stem cell

10 population, and comparing the first, second and third gene expression profiles.

Comparison of the three gene expression profiles for RNA species as represented by cDNA fragments that are differentially expressed upon addition of the agent to the undifferentiated stem cell population identifies agents that modulate the expression of at least one gene in undifferentiated stem cells that is associated with stem cell

15 differentiation.

While the above methods for identifying a therapeutic agent comprise the comparison of gene expression profiles from treated and not-treated stem cells, many other variations are immediately envisioned by one of ordinary skill in the art. As an example, as a variation of a method to identify a therapeutic agent that modulates the expression of at

20 least one stem cell gene associated with the differentiation, the second gene expression profile of a stem cell population at a defined stage of differentiation and the third gene expression profile of the treated stem cell population can each be independently normalized using the first gene expression profile prepared from the undifferentiated stem cell population. Normalization of the profiles can easily be achieved by scanning

25 autoradiographs corresponding to each profile, and subtracting the digitized values corresponding to each band on the autoradiograph from undifferentiated stem cells from the digitized value for each corresponding band on autoradiographs corresponding to the second and third gene expression profiles. After normalization, the second and third gene expression profiles can be compared directly to detect cDNA fragments which

-18-

correspond to mRNA species which are specifically expressed during differentiation of a stem cell population.

Specific Embodiments

Example 1

5 *Production of gene expression profiles generated from cDNAs made with RNA isolated from undifferentiated and partially differentiated stem cells.*

Crude Marrow Preparation

Expression profiles of RNA expression levels from undifferentiated stem cells and 10 stems cells at various levels of differentiation, including partially differentiated and terminally differentiated stem cells, offer a powerful means of identifying genes whose expression levels are associated with stem cell differentiation or proliferation. As an example, the production of expression profiles from murine lineage negative, rhodamine low, Hoechst low and rhodamine bright, Hoechst low hematopoietic precursor cells allows for the identification of mRNA species and their encoding genes whose 15 expression levels are associated with stem cell differentiation

Hoechst^{low}/Rhodamine^{low} hematopoietic stem cells were isolated by sacrificing 30 Balb/c female mice (6-12 weeks) and surgically removing the iliac crests, femurs and tibiae. The bones were cleaned and placed in 10 ml PBS/5% HI-FBS on ice. One tube was used for the bones from 10 mice. The bones were ground throughly with a pestle 20 until completely broken. Following grinding, the supernatant was removed into a 50 ml conical tube through a 40 μ M filer(Falcon #2340). 10 ml PBS/FBS was added to the mix and the supernatant removed. The supernatant was then centrifuged (1250 rpm) for 5-10 minutes. The supernatant which contains a high concentration of lipid was then decanted and discarded.

25 The cells were then pooled into 25 or 50 ml fresh PBS/FBS, and tiny bone fragments removed by settling. The cells were then counted in crystal violet. Cells were diluted and underlaid with LSM, centrifuged at 2000rpm(1000xg) for 20 minutes. To harvest the buffy coat, the supernatant was removed to within 1 cm of the cells. The next 8-

-19-

10ml of medium and cells were harvested by swirling the media around in the tube to draw cells from all sides of the gradient. The cell volume was then brought up to 50 ml with PBS/FBS and spun at 1400rpm 5-10 minutes.

Lineage Depletion

5 Cells were counted in Crystal Violet and resuspended in fresh PBS/FBS. Lineage-specific antibodies were added as follows:

| | | |
|----|-----------|------------------------------------|
| | TER 119 | 0.1 μ g/ml final concentration |
| | B220 | 15 μ l/10 ⁸ cells |
| | Mac-1 | 15 μ l/10 ⁸ cells |
| 10 | Gr-1 | 15 μ l/10 ⁸ cells |
| | Lyt-2 | 1/20 final dilution |
| | L3T4 | 1/20 final dilution |
| | Yw25.12.7 | 1/100 final dilution |

The cells were incubated on ice for 15 minutes, brought to a volume of 50ml with
15 PBS/FBS and collected at 1400rpm for 5-10 minutes, and washed to remove unbound
antibodies.

During the antibody binding step, Magnetic Beads(Dynabeads M-450) were prepared at a
ratio of 5 beads/cell. The beads were coated with Sheep anti-Rat antibodies that bind to
the lineage-specific antibodies, which are all of rat origin. When the beads are placed in
20 a magnetic field, the Lin⁺ cells are removed. The resulting supernatant contains the Lin⁻
population (granulocytes and lymphocyte populations will be substantially depleted or
absent after this step.)

Hoechst/Rhodamine Staining

Rhodamine 123 was added to a final concentration of 0.1 μ g/ml, then incubated at
25 32°C for 20 minutes in the dark. Without further manipulation or washing, HOECHST
33342 was added to a final concentration of 10 μ M then incubated at 37°C for an
additional hour. The aliquot of crude marrow was brought to 0.5 ml with PBS/FBS and
Hoechst to this cell preparation as well. The volume was brought to 50 ml with
PBS/FBS, centrifuged at 1400rpm for 5-10 minutes, supernatant discarded and cells
30 resuspended to 2x10⁷ cells/ml. The rhodamine only and Hoechst Only/Crude Marrow

-20-

were washed in parallel. These two populations were then resuspended in 0.5ml PBS/FBS for flow cytometry analysis

Total RNA was extracted from approximately 5000 stem cells. Using an oligo-dT primer, double stranded cDNA is synthesized and ligated to an adapter in accordance

5 with the present invention. Using adapter primers, the cDNA is PCR amplified using the protocol of Baskaran and Weissman (1996) *Genome Research* 6(7): 633 and Lie *et al.*, *Methods of Enzymology*, _____. The original cDNA is therefore amplified several fold so that a large quantity of this cDNA is available for use in the display protocol according to the present invention.

10 Synthesis of cDNA for the gene expression profiles was performed as below:

Materials and Reagents

A microPoly(A)Pure mRNA Isolation kit (Ambion Inc.) was used for mRNA isolation. All the reagents for cDNA synthesis were obtained from Life Technologies Inc. Klentaq1 DNA polymerase (25U/ μ l) was from Ab peptides Inc. Native *Pfu* DNA polymerase 15 (2.5U/ μ l) was purchased from Stratagene Inc. Betaine monohydrate was from Fluka BioChemica and dimethylsulfoxide (DMSO) was from Sigma Chemical Company. Deoxynucleoside triphophates (dNTPs, 100mM) and bovine serum albumin (BSA, 10 mg/ml) were purchased from New England Biolabs, Inc. Qiaquick PCR purification kit (Qiagen) was used to purify the amplified PCR products. The oligonucleotides used in the

20 Examples were synthesized and gel purified in the DNA synthesis laboratory (Department of Pathology, Yale University School of Medicine, New Haven, CT).

Table 1. Sequences of oligonucleotides.

| | |
|----------------------------------|-------------------------------------------------------------------------------------------------------|
| T ₇ -SalI-oligo-d(T)V | 5'-ACG TAA TAC GAC TCA CTA TAG GGC GAA TTG GGT CGA C- d (T) ₁₈ V-3' , where V = A, C, G |
| anti-NotI Long | 5'-CTT ACA GCG GCC GCT TGG ACG-3' |

-21-

| | |
|----------------|-----------------------------------------------|
| NotI Short | 5'-AGC GGC CGC TGT AAG-3' |
| NotI/RI primer | 5'-GCG GAA TTC CGT CCA AGC GGC CGC TGT AAG-3' |

Methods

I. Preparation of mRNA

5 MicroPoly(A)Pure mRNA isolation kit was used for the isolation of Poly(A)⁺ RNA following the kit instructions. mRNA from a small number of mouse hematopoietic cells (5,000-10,000 cells) was extracted, eluted from the column, and precipitated by adding 0.1 volume of 5M ammonium acetate and 2.5 volumes of chilled ethanol with 2 μ g glycogen as carrier. The tubes were left at -20°C overnight. The pellets were collected by centrifugation
10 at top speed for 30 minutes, washed with 70% ethanol and air-dried at room temperature. The pellets were resuspended in 10 μ l H₂O/0.1mM EDTA solution. We observed that the dissolved mRNA solution was cloudy due to the leaching of column materials, therefore the samples were centrifuged at 4°C for 5 minutes. The supernatant was collected for further use.

15 II. cDNA synthesis

First strand cDNA synthesis

The cDNA synthesis reaction (final reaction volume is 20 μ l) was carried out as described in the instruction manual (Superscript Choice System) provided by Life Technologies Inc. For the first strand cDNA synthesis, mRNA (10 μ l) isolated from a small
20 number of cells was annealed with 200ng (1 μ l) of T₇-Sall-oligo-d(T)V-primer (see Table-1) in a 0.5-ml micro centrifuge tube (no stick, USA Scientific Plastics) by heating the tubes at 65°C for 5 minutes, followed by quick chilling on ice for 5 minutes. This step was repeated

-22-

once and the contents were collected at the bottom of the tube by a brief centrifugation. The following components were added to the primer annealed mRNA on ice prior to initiating the reaction, 1 μ l of 10mM dNTPs, 4 μ l of 5 x first strand buffer [250mM Tris-HCl (pH 8.3), 375mM KCl, 15mM MgCl₂], 2 μ l of 100mM DTT and 1 μ l of RNase Inhibitor (40U/ μ l). All 5 the contents were mixed gently and the tubes were pre-warmed at 45°C for 2 minutes. The cDNA synthesis was initiated by adding 200 units (1 μ l) of Superscript II Reverse Transcriptase and the incubation continued at 45°C for 1 hour.

Second strand cDNA synthesis

At the end of first strand cDNA synthesis, the tubes were kept on ice. Second 10 strand cDNA synthesis reaction (final volume is 150 μ l) was set up in the same tube on ice by adding 91 μ l of nuclease free water, 30 μ l of 5x second strand buffer [100mM Tris-HCl (pH 6.9), 23mM MgCl₂, 450mM KCl, 0.75mM (β -NAD⁺ and 50mM ammonium sulfate], 3 μ l of 10mM dNTPs, 1 μ l of *E.coli* DNA ligase (10U/ μ l), 4 μ l of *E.coli* DNA polymerase.I (10U/ μ l) and 1 μ l of *E.coli* RNase H (2U/ μ l). The contents were 15 mixed gently and the tubes were incubated at 16°C for 2 hours. Following the incubation, the tubes were kept on ice, 2 μ l of T₄ DNA polymerase (3U/ μ l) was added and the incubation was continued for another 5 minutes at 16°C. The reaction was stopped by the addition of 10 μ l of 0.5M EDTA (pH 8.0) and extracted once with equal volume of phenol: chloroform 1:1 (v/v) and once with chloroform. The aqueous phase was then 20 transferred to a new tube and precipitated by adding 0.5 volumes of 7.5M ammonium acetate (pH 7.6), 2 μ g of glycogen (as carrier) and 2.5 volumes of chilled ethanol. The samples were left at -20°C for overnight and the cDNA pellets were collected by centrifugation at top speed for 20 minutes. The pellets were washed once with 70% ethanol, air-dried and dissolved in 14 μ l of nuclease free water.

25 As the amount of cDNA derived from a small number of cells may be low, it may be necessary to amplify the cDNA for further analysis. To uniformly amplify the cDNA, an adaptor (NotI adaptor) was first ligated to both ends of the cDNA. Following adaptor

-23-

ligation, the cDNAs were amplified with *NotI*/RI primer (see *table 1*), by a modified PCR method using betaine and DMSO.

Ligation of cDNA with *NotI* adaptor

Preparation of NotI adaptor: The *NotI* adaptor was prepared by annealing

- 5 *NotI*-short and anti-*NotI*-long oligonucleotides (see Table 1). The anti-*NotI*-long oligonucleotide was phosphorylated to ensure that both the adaptor oligonucleotides are ligated to the cDNA. 1 μ g of anti-*NotI*-long was mixed with 1 μ l of 10x *T₄* polynucleotide kinase buffer [700mM Tris-HCl (pH 7.6), 100mM MgCl₂ and 50mM DTT], 1 μ l of 10mM adenosine triphosphate (ATP), adjusted the volume to 9 μ l with water and the
- 10 reaction was initiated by adding 1 μ l of *T₄* polynucleotide kinase (10U/ μ l). The tubes were incubated at 37°C for 30 minutes and then the enzyme was inactivated at 65°C for 20 minutes. The annealing was carried out by adding the following components to the above phosphorylated anti-*NotI*-long: 1 μ g of *NotI*-short, 2 μ l of 10x oligo annealing buffer [100mM Tris-HCl (pH 8.0), 10mM EDTA (pH 8.0) and 1M NaCl] and water to adjust
- 15 the final volume to 20 μ l. The sample was heated at 65°C for 10 minutes and allowed to cool down to room temperature. The annealed adaptor was stored at -20°C.

Ligation of cDNA with annealed NotI adaptor: To set up this reaction,

- 14 μ l of cDNA was mixed with 100ng of annealed *NotI* adaptor in a 0.5-ml micro centrifuge tube. To this mixture 2 μ l of 10x *T₄* DNA ligase buffer [500mM Tris-HCl (pH 20 7.8), 100mM MgCl₂, 100mM DDT, 10mM ATP and 250mg/ml BSA] was added and adjusted the volume with water to 18 μ l and mixed gently. The reaction was initiated by adding 2 μ l of *T₄* DNA ligase (400U/ μ l) and incubated at 16°C overnight.

III. cDNA amplification

A modified betaine-DMSO PCR method (Baskaran *et al.* (1996) Genome

- 25 Research 6:633) was used to uniformly amplify the cDNA with different GC content. This method uses the LA system, which combines a highly thermostable form of *Taq* DNA polymerase (Klentaq1, which is devoid of 5'-exonuclease activity) and a proofreading enzyme (*Pfu* DNA polymerase, which has 3'-exonuclease activity). The

-24-

LA16 enzyme consists of 1 part of *Pfu* DNA polymerase and 15 parts of KlenTaq1 DNA Polymerase (v/v). The NotI adaptor-ligated cDNA was diluted 10 fold with water. 2 μ l of this diluted cDNA was used as the template for PCR. The PCR reaction (50 μ l final volume) was set up with the following components: 5 μ l of 10x PCR buffer [200mM

5 Tris-HCl (pH 9.0), 160mM ammonium sulfate and 25mM MgCl₂], 16 μ l of water, 0.8 μ l of BSA (10mg/ml), 1 μ l of NotI/RI PCR primer (100ng/ μ l), 5 μ l of 50% DMSO (v/v), 15 μ l of 5M Betaine and 0.2 μ l of LA16 enzyme. These components were mixed gently on ice and then heated to 95°C for 15 seconds on a PCR machine, and held at 80°C while 5 μ l of 2mM dNTPs were added to start the reaction. The PCR conditions were as follows: *Stage*

10 *1*: 95°C for 15 seconds, 55°C for 1 minute, 68°C for 5 minutes, 5 cycles. *Stage 2*: 95°C for 15 seconds, 60°C for 1 minute, 68°C for 5 minutes, 15 cycles.

After amplification, cDNA was purified with the Qiaquick PCR purification kit (following the instructions provided by the supplier). The purified cDNA was eluted in the desired volume of water.

15 Gene expression profiles were prepared from the purified cDNA as previously described by Prashar *et al.* in WO 97/05286 and in Prashar *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:659-663. Briefly, the adapter oligonucleotide sequences were CTTACAGCGGCCGCTTGGACG, GAATGTCGCCGGCGA or alternatively, A1 (TAGCGTCCGGCGCAGCGACGGCCAG) and

20 A2 (GATCCTGGCCGTCGGCTGTCTGTCGGCGC). When A1/A2 were used, one microgram of oligonucleotide A2 was first phosphorylated at the 5' end using T4 polynucleotide kinase (PNK). After phosphorylation, PNK was heated denatured, and 1 μ g of the oligonucleotide A1 was added along with 10 \times annealing buffer (1 M NaCl/100 mM Tris-HCl, pH8.0/10 mM EDTA, pH8.0) in a final vol of 20 μ l. This

25 mixture was then heated at 65°C for 10 min followed by slow cooling to room temperature for 30 min, resulting in formation of the Y adapter at a final concentration of 100 ng/ μ l. About 20 ng of the cDNA was digested with 4 units of a restriction enzyme such as *Clal*, *Bgl* II, etc. in a final vol of 10 μ l for 30 min at 37°C. Two microliters (\approx 4 ng of digested cDNA) of this reaction mixture was then used for ligation to 100 ng (\approx 50-fold) of the Y-shaped adapter in a final vol of 5 μ l for 16 hr at 15°C. After ligation, the

-25-

reaction mixture was diluted with water to a final vol of 80 μ l (adapter ligated cDNA concentration, \approx 50 pg/ μ l) and heated at 65°C for 10 min to denature T4 DNA ligase, and 2- μ l aliquots (with \approx 100 pg of cDNA) were used for PCR.

The following sets of primers were used for PCR amplification of the adapter

5 ligated 3' -end cDNAs: GCGGAATTCCGTCCAAGCGGCCGCTGTAAG or alternatively, RP 5.0 (CTCTCAAGGATCTTACCGCTT₁₈AT), RP 6.0 (TAATACCGCGCCACATAGCAT₁₈CG), or RP 9.2 (CAGGGTAGACGACGCTACGCT₁₈GA) were used as 3' primer while A1.1 (TAGCGTCCGGCGCAGCGAC) served as the 5' primer. To detect the PCR products

10 on the display gel, 24 pmol of oligonucleotide A1.1 was 5' -end-labeled using 15 μ l of [γ -³²P]ATP (Amersham; 3000 Ci/mmol) and PNK in a final volume of 20 μ l for 30 min at 37°C. After heat denaturing PNK at 65°C for 20 min, the labeled oligonucleotide was diluted to a final concentration of 2 μ M in 80 μ l with unlabeled oligonucleotide A1.1. The PCR mixture (20 μ l) consisted of 2 μ l (\approx 100 pg) of the template, 2 μ l of 10 \times PCR

15 buffer (100 mM Tris-HCl, pH 8.3/500 mM KCl), 2 μ l of 15 mM MgCl₂ to yield 1.5 mM final Mg²⁺ concentration optimum in the reaction mixture, 200 μ M dNTPs, 200 nM each 5' and 3' PCR primers, and 1 unit of AmpliTaq. Primers and dNTPs were added after preheating the reaction mixture containing the rest of the components at 85°C. This "hot start" PCR was done to avoid artefactual amplification arising out of arbitrary annealing

20 of PCR primers at lower temperature during transition from room temperature to 94°C in the first PCR cycle. PCR consisted of 28-30 cycles of 94°C for 30 sec, 50°C for 2 min, and 72°C for 30 sec. A higher number of cycles resulted in smearable gel patterns. PCR products (2.5 μ l) were analyzed on 6% polyacrylamide sequencing gel. For double or multiple digestion following adapter ligation, 13.2 μ l of the ligated cDNA sample was

25 digested with a secondary restriction enzyme(s) in a final vol of 20 μ l. From this solution, 3 μ l was used as template for PCR. This template vol of 3 μ l carried \approx 100 pg of the cDNA and 10 mM MgCl₂ (from the 10 \times enzyme buffer), which diluted to the optimum of 1.5 mM in the final PCR vol of 20 μ l. Since Mg²⁺ comes from the restriction enzyme buffer, it was not included in the reaction mixture when amplifying

30 secondarily cut cDNA. Bands may then be extracted from the display gels as described

-26-

by Liang *et al.* (1995 *Curr. Opin. Immunol.* 7:274-280), reamplified using the 5' and 3' primers, and subcloned into pCR-Script with high efficiency using the PCR-Script cloning kit from Stratagene. Plasmids were sequenced by cycle sequencing on an ABI automated sequencer.

5 Figure 1 presents an autoradiogram of the gene expression profiles generated from cDNAs made with RNA isolated from Lin⁺, LRH, LRH48 and LRBRH cells. All possible 12 anchoring oligo d(T)n1, n2 were used to generate a complete expression profile for the enzyme *Clal*.

Table 2 presents the sequences of numerous differentially expressed bands from
10 expression profiles made from LIN⁺, LRH, LRH48 and LRBRH.

Table 3 presents the expression patterns of the differentially expressed bands set forth in Table 2. The band fragment length (size) in Table 3 is the length before unwanted terminal sequences were removed. Table 3 also presents the results of a GenBank Search and analysis of the sequences of Table 2.

Summary of Known Genes from Vanson HSC Differential Display (I)

| Item No. | Size (bp) | Enzyme | NNN1 (oligo-dT) | Poly(A) Sign | Expression pattern | | | | Gene Bank Search & Analysis | | | |
|-------------|-----------|--------|--------------------|-----------------|--------------------|-------|---------|---------|-----------------------------|-------|--------------------------------------------------|---------|
| | | | | | I m. | I RII | I.RIIA8 | I.RIIII | I m. | I RII | I.RIIA8 | I.RIIII |
| HSC-DD-006 | 213 | Bgl II | AC | fair | 0 | 3+ | / | / | + | + | mouse homeobox protein | |
| HSC-DD-285 | 158 | Xba I | GG | good | + | + | + | + | + | + | human homeobox gene regulator | |
| HSC-DD-007B | 213 | Bgl II | AC | fair | + | 2+ | / | / | + | + | human zinc finger protein 10 | |
| HSC-DD-238 | 363 | Xba I | AG | good | 3+ | 0 | 3+ | 3+ | 3+ | 3+ | mouse cell division control protein 19 | |
| HSC-DD-206 | 123 | Xba I | AC | good | 3+ | 0 | 2+ | 2+ | + | + | human HS1 hematopoietic protein | |
| HSC-DD-214 | 192 | Xba I | AC | fair | + | 2+ | 0 | 0 | 3+ | 3+ | mouse plm-1 proto-oncogene | |
| HSC-DD-035 | 151 | Bgl II | AC | fair | + | 2+ | / | / | + | + | mouse thyroid hormone receptor | |
| HSC-DD-129 | 234 | Cla I | AC | poor | 0 | 3+ | 0 | 0 | 0 | 0 | mouse inositol 1,4,5-triphosphate receptor | |
| HSC-DD-040 | 220 | Bgl II | AC | fair | + | 2+ | / | / | 0 | 0 | mouse G protein beta-3G subunit | |
| HSC-DD-011 | 173 | Bgl II | AC | good | + | + | + | + | 2+ | 2+ | mouse ras-related YPT1 protein | |
| HSC-DD-121 | 186 | Cla I | CT | poor | 0 | 3+ | + | + | + | + | human TBP-associated factor 170 | |
| HSC-DD-015B | 133 | Bgl II | AG | poor | 0 | 3+ | + | + | + | + | mouse HMG1-related DNA binding protein | |
| HSC-DD-039 | 206 | Bgl II | AC | fair | 2+ | 4+ | 1 | 1 | 4+ | 4+ | mouse TAX responsive element binding protein 107 | |
| HSC-DD-042 | 235 | Bgl II | AC | fair | + | 0 | 1 | 1 | + | + | mouse retinoblastoma binding protein isoform III | |
| HSC-DD-256 | 272 | Xba I | AA | poor | 0 | 2+ | + | + | 0 | 0 | Rat androgen-binding protein | |
| HSC-DD-045 | 270 | Bgl II | AC | good | + | 2+ | 1 | 1 | + | + | similar to Rat occ2 | |
| HSC-DD-068 | 164 | Cla I | AC | fair | + | 4+ | 4+ | 4+ | 4+ | 4+ | mouse Jerry mRNA | |
| HSC-DD-143 | 350 | Cla I | AG | fair | + | 2+ | + | + | + | + | similar to human memd | |
| HSC-DD-263 | 292 | Xba I | AT | good | 0 | 2+ | + | + | 0 | 0 | mouse interleukin 5 | |
| HSC-DD-239 | 156 | Xba I | CA | good | + | 3+ | 3+ | 3+ | + | + | human CD9 | |
| HSC-DD-261 | 115 | Xba I | AA | good | 0 | + | 0 | 0 | 0 | 0 | mouse gamma IgM | |
| HSC-DD-028A | 95 | Bgl II | AC | good | + | 4+ | + | + | + | + | mouse chaperon containing TCP1 e subunit | |
| HSC-DD-021 | 143 | Bgl II | AC | bad | + | + | 1 | 1 | 2+ | 2+ | mouse cathepsin | |
| HSC-DD-025 | 326 | Bgl II | AG | good | + | 2+ | 1 | 1 | 2+ | 2+ | mouse melanophenom 1 | |

- 28 -

Summary of Known Genes from Human HSC Differential Display (II)

| Item No. | Size (bp) | Enzyme | NI/N2 (oligo-dT) | Poly(A) Site | Expression pattern | | | | Gene Bank Search & Analysis | |
|-------------|-----------|--------|------------------|--------------|--------------------|------|--------|--------|---------------------------------------------------------|--|
| | | | | | 1 hr. | 1 Hr | 1 R14h | 1 R14H | | |
| HSC-DD-077 | 203 | Cla I | AC | good | + | 2+ | 2+ | 3+ | Rat malin cyclophilin | |
| HSC-DD-200 | 450 | Cla I | AA | fair | + | + | 2+ | + | mouse G-utrophin | |
| HSC-DD-245 | 272 | Xba I | CA | fair | 3+ | 1 | 3+ | 2+ | rat basement membrane-associated chondroitin | |
| HSC-DD-226 | 387 | Xba I | AC | good | 1 | 3+ | 1 | 0 | mouse cytoplasmic g-actin | |
| HSC-DD-182 | 149 | Cla I | GC | poor | 1 | 3+ | 1 | + | mouse A-X actin | |
| HSC-DD-089 | 364 | Cla I | AC | poor | + | 3+ | 2+ | + | mouse TIE receptor tyrosine kinase | |
| HSC-DD-151 | 424 | Cla I | GA | good | 0 | + | 2+ | 1 | rat elk, brain-specific receptor tyrosine kinase | |
| HSC-DD-013 | 248 | Bgl II | AC | fair | 1 | 2+ | 1 | 3+ | mouse hexokinase | |
| HSC-DD-029 | 103 | Bgl II | AC | fair | 0 | + | 1 | 0 | mouse brulin α gammaglobulinemia tyrosine kinase | |
| HSC-DD-034 | 140 | Bgl II | AC | fair | 0 | 2+ | 1 | 2+ | mouse spermine synthase | |
| HSC-DD-082B | 244 | Cla I | AC | fair | + | 4+ | 2+ | 2+ | mouse stearoyl-CoA desaturase (SCD2) | |
| HSC-DD-084 | 261 | Cla I | AC | good | 1 | + | 1 | 2+ | mouse antioxidant enzyme AOE 372 | |
| HSC-DD-128 | 189 | Cla I | AC | fair | 0 | 3+ | 3+ | 1 | mouse casein kinase II beta chain | |
| HSC-DD-140 | 229 | Cla I | AG | good | 1 | 0 | 0 | + | mouse creatine kinase B | |
| HSC-DD-148 | 313 | Cla I | GA | good | + | + | 2+ | 1 | human esterase D | |
| HSC-DD-176 | 470 | Cla I | CG | fair | 1 | 3+ | + | 0 | mouse putative E1-E2 ATPase | |
| HSC-DD-178 | 130 | Cla I | GC | good | 1 | 3+ | 0 | + | mouse aspartate aminotransferase | |
| HSC-DD-180 | 142 | Cla I | GC | good | + | + | 0 | + | mouse tyrosylprotein sulfotransferase-1 | |
| HSC-DD-186 | 252 | Cla I | GC | poor | 1 | + | 2+ | 2+ | mouse ubiquitin-conjugating enzyme E214K | |
| HSC-DD-191 | 136 | Cla I | AA | fair | 0 | 1 | 3+ | 2+ | mouse b-1,4-galactosyltransferase | |
| HSC-DD-158 | 391 | Cla I | GT | fair | + | 3+ | 0 | + | spermophilus tridecemlineatus 26s proteasome | |
| HSC-DD-099 | 265 | Cla I | CC | fair | 1 | 3+ | 0 | 1 | mouse proteasome epsilon chain precursor | |
| HSC-DD-222 | 270 | Xba I | AC | good | 0 | 2+ | 1 | + | Rat 3-hydroxyisobutyrate | |
| HSC-DD-104 | 368 | Cla I | CC | fair | 0 | 1 | + | 1 | human copper chaperone for superoxide dismutase | |
| HSC-DD-172 | 365 | Cla I | CG | fair | 1 | 3+ | 2+ | 0 | mouse Erc-4 DNA repair gene | |
| HSC-DD-169 | 223 | Cla I | CG | fair | 1 | 1 | 2+ | 0 | Cricetulus griseus nucleotide excision repair protein | |
| HSC-DD-003A | 148 | Bgl II | AC | poor | 0 | + | 1 | 1 | human G-rich sequence factor | |

Summary of Known Genes from Mouse HSC Differential Display (III)

| Items No. | Size (bp) | Enzyme | NN N2 (oligo-dT) | Poly(A) Sign | Expression Pattern | | | | | Gene Bank Search & Analysis | |
|-------------|--------------|--------|---------------------|-----------------|--------------------|------|--------|-------|--------|-----------------------------------------------|--|
| | | | | | L.m+ | L.RH | L.RH48 | L.RDH | L.RDH4 | | |
| HSC-DD-092 | 118 | Cla I | CC | fair | + | 3+ | 1 | + | + | mouse elongation factor 1-a | |
| HSC-DD-288 | 480 | Xba I | GC | fair | 1 | + | + | + | + | human elongation factor-1-delta | |
| HSC-DD-114 | 267 | Cla I | CA | poor | 1 | + | 1 | + | + | Rat elongation factor-1-alpha | |
| HSC-DD-213 | 178 | Xba I | AC | fair | 1 | 3+ | + | + | + | human splicing factor (SFRS7) | |
| HSC-DD-155 | 198 | Cla I | GT | fair | 0 | 2+ | + | 0 | 0 | mouse transcription elongation factor S-II-T1 | |
| HSC-DD-212 | 162 | Xba I | AC | poor | 0 | 3+ | 1 | 0 | 0 | mouse translation initiation factor 4E | |
| HSC-DD-090 | 375 | Cla I | AC | fair | 1 | 3+ | 3+ | + | + | mouse protein synthesis elongation factor | |
| HSC-DD-173 | 367 | Cla I | CG | fair | 1 | 3+ | + | 0 | 0 | mouse protein synthesis elongation factor Tu | |
| HSC-DD-249 | 304 | Xba I | CA | poor | 4+ | + | 4+ | 4+ | 4+ | rat histone macroH2A1.2 | |
| HSC-DD-250 | 356 | Xba I | CA | good | + | 2+ | 3+ | 2+ | 2+ | mouse MER9 processed pseudogene | |
| HSC-DD-108 | 281 | Cla I | GG | good | + | 2+ | + | 2+ | 2+ | mouse heat shock protein 70 | |
| HSC-DD-116 | 326 | Cla I | CA | fair | 1 | 2+ | 0 | 0 | 2+ | mouse 84 kD heat shock protein | |
| HSC-DD-166 | 587 | Cla I | AT | good | 1 | 2+ | 3+ | + | + | mouse heat shock protein 70 cognate | |
| HSC-DD-184 | 196 | Cla I | GC | fair | 1 | 2+ | 0 | 1 | 1 | mouse breast heat shock protein 73 | |
| HSC-DD-101 | 331 | Cla I | CC | fair | + | 3+ | 0 | 1 | 1 | mouse MHC locus II region | |
| HSC-DD-017 | 215 | Bgl II | AG | good | 0 | 4+ | 1 | 0 | 0 | mouse MHC class III region | |
| HSC-DD-026 | 505 | Bgl II | AG | fair | 2+ | 4+ | 1 | 4+ | 4+ | mouse ribosomal protein S4 | |
| HSC-DD-064 | 146 | Cla I | AC | good | 2+ | 2+ | 2+ | 3+ | 3+ | mouse ribosomal protein S12 | |
| HSC-DD-066 | 150 | Cla I | AC | good | 2+ | 3+ | 2+ | 2+ | 2+ | mouse ribosomal protein S20 | |
| HSC-DD-041 | 226 | Bgl II | AC | good | + | 3+ | 1 | 3+ | 3+ | mouse ribosomal protein L17 | |
| HSC-DD-111 | 161 | Cla I | CA | poor | 1 | + | 1 | + | + | rat ribosomal protein L23a | |
| HSC-DD-0260 | 100 | Bgl II | AC | poor | 1 | 4+ | 1 | 1 | 1 | mouse LINE-1/M1 element | |
| HSC-DD-142 | 267 | Cla I | AG | poor | 1 | 2+ | 1 | 1 | 1 | mouse 11Md A13 repetitive sequence | |
| HSC-DD-095 | 210 | Cla I | CC | poor | 1 | 2+ | 1 | 1 | 1 | mouse mitochondrial 12S ribosomal RNA | |

-30-

As is apparent to one of ordinary skill in the art, this same procedure can be used to identify stem cells genes whose expression levels are associated with stem cell proliferation, dedicated differentiation and survival.

5 Example 2

Method to identify a therapeutic agent that modulates the expression of at least one stem cell gene associated with the differentiation process of a stem cell population.

The methods set forth in Example 1 offer a powerful approach for identifying therapeutic agents that modulate the expression of at least one stem cell gene associated with the differentiation process of a stem cell population. For instance, gene expression profiles of undifferentiated stem cells and partially differentiated or terminally differentiated stem cells are prepared as set forth in Example 1. A profile is also prepared from an undifferentiated stem cell sample that has been exposed to the agent to be tested. By examining for differences in the intensity of individual bands between the three profiles, agents which up or down regulate genes associated with the differentiation process of a stem cell population are identified.

Example 3

Method to identify a therapeutic agent that modulates the expression of at least one stem cell gene associated with the proliferation of a stem cell population.

The methods set forth in Example 1 offer a powerful approach for identifying therapeutic agents that modulate the expression of at least one stem cell gene associated with the proliferation of a stem cell population. For instance, gene expression profiles of undifferentiated stem cells and actively proliferating stem cells are prepared as set forth in Example 1. A profile is also prepared from an undifferentiated stem cell sample that has been exposed to the agent to be tested. By examining for differences in the intensity of individual bands between the three profiles, agents which up or down regulate genes associated with the proliferation of a stem cell population are identified.

-31-

As is apparent to one of ordinary skill in the art, this same procedure can be used to identify stem cells genes whose expression levels are associated with stem cell dedicated differentiation and survival.

Example 4

5 *Production of solid support compositions comprising groupings of nucleic acids or nucleic acid fragments that correspond to genes whose expression levels are associated with the differentiation, proliferation, dedicated differentiation or survival of stem cells.*

As set forth in Example 1, expression profiles prepared from stem cells at different stages of differentiation, from proliferating stem cells, from stem cells that are 10 dedicated to a differentiation pathway and from stem cells resistant to apoptosis (which may be linked to increased survival) provide a means to identify genes whose expression levels are associated with stem cell differentiation, proliferation, dedicated differentiation and survival, respectively.

Solid supports can be prepared that comprise immobilized representative 15 groupings of nucleic acids or nucleic acid fragments corresponding to the genes from stem cells whose expression levels are modulated during stem cell differentiation, proliferation, dedicated differentiation and survival. For instance, representative nucleic acids can be immobilized to any solid support to which nucleic acids can be immobilized, such as positively charged nitrocellulose or nylon membranes (see Sambrook *et al.* 20 (1989) *Molecular Cloning: a Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory) as well as porous glass wafers such as those disclosed by Beattie (WO 95/11755). Nucleic acids are immobilized to the solid support by well established techniques, including charge interactions as well as attachment of derivatized nucleic acids to silicon dioxide surfaces such as glass which bears a terminal epoxide moiety. At 25 least one species of nucleic acid molecule, or fragment of a nucleic acid molecule corresponding to the genes from stem cells whose expression levels are modulated during stem cell differentiation, proliferation, dedicated differentiation and survival may be immobilized to the solid support. A solid support comprising a representative grouping of nucleic acids can then be used in standard hybridization assays to detect the presence

-32-

or quantity of one or more specific nucleic acid species in a sample (such as a total cellular mRNA sample or cDNA prepared from said mRNA) which hybridize to the nucleic acids attached to the solid support. Any hybridization methods, reactions, conditions and/or detection means can be used, such as those disclosed by Sambrook *et al.* (1989) *Molecular Cloning: a Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Ausbel *et al.* (1987) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience. N.Y. or Beattie in WO 95/11755.

One of ordinary skill in the art may determine the optimal number of genes that must be represented by nucleic acid fragments immobilized on the solid support to effectively differentiate between samples that are at the various stages of stem cell differentiation, including terminal differentiation, proliferating stem cells, stem cells dedicated to a given differentiation pathway and/or stem cells with increased survival rates. Preferably, at least about 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000 or more preferably, substantially all of the detectable mRNA species in a cell sample or population will be present in the gene expression profile or array affixed to a solid support. More preferably, such profiles or arrays will contain a sufficient representative number of mRNA species whose expression levels are modulated under the relevant differentiation process, disease, screening, treatment or other experimental conditions. In most instances, a sufficient representative number of such mRNA species will be about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100 in number and will be represented by the nucleic acid molecules or fragments of nucleic acid molecules immobilized on the solid support. For example, nucleic acids encoding all or a fragment of one or more of the known genes or previously reported ESTs that are identified in Tables 2 and 3 may be so immobilized. Additionally, the skilled artisan may select nucleic acids encoding the protein cell surface markers discussed above at page 8 (i.e., CD 34) in order to help identify the particular stage of differentiation of a given stem cell population and to identify agents that are involved in promoting such differentiation. The skilled artisan will be able to optimize the number and particular nucleic acids for a given purpose, i.e., screening for modulating agents, identifying activated stem cells, etc.

-33-

In general, nucleic acid fragments comprising at least one of the sequences or part of one of the sequences of Table 2 can be used as probes to screen nucleic acid samples from cell populations in hybridization assays. Alternatively, nucleic acid fragments derived from the identified genes in Table 3 which correspond to the sequences of Table 5 2 may be employed as probes. To ensure specificity of a hybridization assay using probe derived from the sequences presented in Table 2 or the genes of Table 3, it is preferable to design probes which hybridize only with target nucleic acid under conditions of high stringency. Only highly complementary nucleic acid hybrids form under conditions of high stringency. Accordingly, the stringency of the assay conditions determines the 10 amount of complementarity which should exist between two nucleic acid strands in order to form a hybrid. Stringency should be chosen to maximize the difference in stability between the probe:target hybrid and potential probe:non-target hybrids.

Probes may be designed from the sequences of Table 2 or the genes of Table 3 through methods known in the art. For instance, the G+C content of the probe and the 15 probe length can affect probe binding to its target sequence. Methods to optimize probe specificity are commonly available in Sambrook *et al.* (*Molecular Cloning: A Laboratory Approach*, Cold Spring Harbor Press, NY, 1989) or Ausubel *et al.* (*Current Protocols in Molecular Biology*, Greene Publishing Co., NY, 1995). Any available format may be used in designing hybridization assays, including immobilizing the probes to a solid 20 support or immobilizing the cellular test sample nucleic acids to a solid support.

It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It therefore should be apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. All documents, 25 patents and references, including provisional patent application 60/056,861, referred to throughout this application are herein incorporated by reference.


What is Claimed Is:

1. A method to identify an agent that modulates the expression of at least one stem cell gene associated with the differentiation process of a stem cell population, comprising the steps of:
 - 5 preparing a first gene expression profile of an undifferentiated stem cell population;
 - preparing a second gene expression profile of a stem cell population at a defined stage of differentiation;
 - treating said undifferentiated stem cell population with the agent;
 - 10 preparing a third gene expression profile of the treated undifferentiated stem cell population;
 - comparing the first, second and third gene expression profiles; and
 - identifying an agent that modulates the expression of a least one gene in undifferentiated stem cells that is associated with stem cell differentiation.
- 15 2. A method to identify an agent that modulates the expression of at least one stem cell gene associated with the proliferation of a stem cell population, comprising the steps of:
 - preparing a first gene expression profile of a non-proliferating stem cell population;
 - 20 preparing a second gene expression profile of a proliferating stem cell population;
 - treating the non-proliferating stem cell population with the agent;
 - preparing a third gene expression profile of the treated stem cell population;
- 25 comparing the first, second and third gene expression profiles; and
- identifying an agent that modulates the expression of a least one gene that is associated with stem cell proliferation.

-35-


3. A composition comprising a grouping of nucleic acid molecules that correspond to at least part of the sequences of Table 2 or genes of Table 3 affixed to a solid support.

1/2

FIG. 1

SUBSTITUTE SHEET (RULE 26)

FIG. 1 (Cont.)



SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

<110> Yale University

<120> A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN STEM CELLS

<130> 44574-5014-WO

<140> PCT/US98/17283

<141> 1998-08-21

<160> 93

<170> PatentIn Ver. 2.0

<210> 1

<211> 178

<212> DNA

<213> murine

<220>

<221> variation

<222> (various)

<223> bases designated as "n" at various positions throughout the sequence may be A, T, C or G

<400> 1

ttaatttagc gctctatata cattgcggaa cttcccccga ctgcagcagt ttgactttgg 60
cacaacatca agttccatTT ctttggaca ttggattctg ttttganagt atgtatgcc 120
caaagcattt tcagtgtcat caggattagt tgggcccatt cacagtaatt cananatc 178

<210> 2

<211> 148

<212> DNA

<213> murine

<400> 2

tagaataacct ggatggcttc tcttgcac ccgatctccc gtgttaccaa tggatgtatgg 60
ctccttctcc cgaaagtgtt cttaatcttt gctttctttg cacaatgtct ttggatgca 120
gtcataagcc tgaggcaaat aaaattcc 148

<210> 3

<211> 203

<212> DNA

<213> murine

<400> 3

gatctggcta gacagttatt ctgaactatg gcttcaagat gaacaagaca agcctaaaag 60
gatggagaga ggcaatggag ataatgtttt ggaggaagta tgtcaactaa gcatgaactc 120
tggttattta gaaatgagat tccatatatg tggtacatgt ggaaagaatc taaaaagtcc 180
tttaattttt ttcattccaa aag 203

<210> 4

<211> 336

<212> DNA

<213> murine

<220>

<221> variation

<222> (various)

<223> bases designated as "n" at various positions throughout the sequence may be A, T, C or G

<400> 4

ctnnannnagc actcttcttg gccagacctc tgtccaaggc tcattagaaa gctggggtn 60
tgtncacgtn acnnacttna tcnaaactnt tgctgtntg gcataagttg tgtntctgga 120
ctgttnntgta ttccccctcta gacaaaggan caacnnaaaa gtnnttgcnn nctttncag 180
aacatnctca aagcctntga tggaggagca caaggaccct gtctgctgag gccccatgn 240
tcctctcagg ggttctncc cacnaggca gtgccttcat tngctagtn gncagttact 300
tgtagnntat ctttnaataa atttnaataa aancta 336

<210> 5

<211> 113

<212> DNA

<213> murine

<220>

<221> variation

<222> (various)

<223> bases designated as "n" at various positions throughout the sequence may be A, T, C or G

<400> 5

ctagattgtg tggtttgcct cattgtgcta tttgcgcact ttccctccct gaagaaatan 60
ctgtgaanct tctttctgtt cagtcctaatttcaaaata nagtgagact atg 113

<210> 6

<211> 164

<212> DNA

<213> murine

<220>

<221> variation

<222> (various)

<223> bases designated as "n" at various positions throughout the sequence may be A, T, C or G

<400> 6

ctcaagnacg ggccaggtaa gggcctttaa cacaactaaa tcaaggtgtg cttncctccg 60
ggttctatgc aagcaaggca tacacactgc actctcncnc tcnctaaact ggaaangtac 120
agtnccaggg ctggtttcag acnacgtgat gcntgttac aaac 164

<210> 7

<211> 141

<212> DNA

<213> murine

<400> 7

tttttattca atatattaaa tatattaatc agaaaagtca catcctataa atccaggaaa 60
atacacaaat ataaatcaga atctgtcaat caccttcttg agtgcacagtt atgtacacat 120
ggaaggagag cggaagagat c 141

<210> 8

<211> 224

<212> DNA

<213> murine

<400> 8

cgatatacac catcggtctg gggccaaacgc taatactact tggtgctgcc aattgaattc 60
tggtttgcgtg tgaatctcta tcaacaagag tatcatttgt gaatgcttta atttatttgag 120
aaagaacaag aagatgatgg atacattgtat acatttgcgc agccttgcag cctgactcaa 180

ttctgctgtt catcagttt aatgtccctt ctgtgtcata cgtg 224

<210> 9
<211> 210
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 9
gatctttttt ccttcactta ttgctgaaac caagngcaca attcccaatta agngaaggat 60
ctctgtctg taaactaaac aaattgtgca tttttctgg ggccattgtt tttggtttat 120
tttggttattt tggtttgtt ttgtttttt ggtttcattt tggtttgggt tggtccaatt 180
ttaaaaggaa atactacaat aaaaatgtta 210

<210> 10
<211> 163
<212> DNA
<213> murine

<400> 10
gatctgattt gctagttctt cctggtagag ttataaaatgg aaagattaca ctatctgatt 60
aatagtttct tcataactctg catataattt gtggctgcag aatattgtaa tttgttgcac 120
actatgtaac aaaactgaag atatgtttaa taaatattgt act 163

<210> 11
<211> 176
<212> DNA
<213> murine

<400> 11
gcgtatgttct tctactcaca actcacgttg gtggcctggg cctgaacttg actggagctg 60
acactgtgggt gtttgtggag catgactgga accctatgcg agatctgcag gccatggacc 120
gggccccatcg tattggcag aaacgtgtgg ttaatgtcta ccgttgata accaga 176

<210> 12
<211> 123
<212> DNA
<213> murine

<400> 12
gatctgaaag ggaatgtcca aagagaagaa ggaggagtg gaccgcaagg ctgaggatgc 60
taggagggag tatgagaaag ccatgaaaga gtatgaagga ggaagagggg actcatctaa 120
aag 123

<210> 13
<211> 196
<212> DNA
<213> murine

<400> 13
gattttcgac acagagaagg agaaatacga gattacagag cagcggaaagg ctgaccagaa 60
agctgtggat ttgcagat ttgcggat taaagctgtt cctcagatcc agggctaccc 120
gcgtctcag tttccctga caaacggat gttatcctcac aaactggct tctaaattgt 180
taacctaattt aaacag 196

<210> 14

<211> 225
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 14
actcaatctc ttcaaactct ttatactggn ctatnatnag ngggatgtg ncaanatnga 60
cnctgggtgt gtatgaaaga aaagntcnat ggacntnggc atnccaagat tgaattcacc 120
tgcttcctac gatgtgtgaa actgctaata gcaaaatatac tctanggtta tgangagttac 180
tgtcggttcg caaatattca cttcanaact annccaccacg ttcaa 225

<210> 15
<211> 244
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 15
ctagataatc ctttactgag tctttcttcn caggtgattc antttagttg acaattannn 60
ctaagaattc aatggactan tgaggtgcct cagcagntaa tagcattgc tgttcttc 120
gaggaccaga gttcagttc tcattccaaag ttgggctgtc cgtnagtgac gtaantcca 180
gcttcagggg cttgaattta tactgaccat gggcacctgt accccaacac anacacatac 240
acat 244

<210> 16
<211> 233
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 16
ctagaaggta atcctgttnaa gcatggtaag aatancattc tcaanatctt gagttaaaa 60
agatcttgg gggngctggn gagatggctc antggtaag ancncgtact gctcttccag 120
aggcctgan ttcaattccc ancaaccaca tggtggnntca caaccanctg taatgataacc 180
tgcgtccatc ntccgtggta tatctgaana canctacagt gacagctaca ncg 233

<210> 17
<211> 260
<212> DNA
<213> murine

<400> 17
ggattttatt ctaggcttgg ccagatacag gttggcatcc taggggagga agataacaat 60
gtcataaggta aatttgttag gagaggcaag acatggaaaa tcattgattt cttcagattt 120
ctttaaagca aattagaaga taaatgtcta aaagagatac acttaaaaaa tggtggaaact 180
ataaccctt aaggagagcc agatgtggca ggagccaggt ctgaaaatgg tagctgaagt 240

aagcagacca gcgtaaagatc 260
 <210> 18
 <211> 154
 <212> DNA
 <213> murine

 <400> 18
 cgatgagtca gagaggaagt ggacagtgcg ttattcatta cagcaaagga tttcggttgc 60
 atcaaaatct aagtttttt tacaagatt gtttttagta ctaagctgcc ttggcagttt 120
 gcattttga gccaaacaaa aatatattat ttcc 154

 <210> 19
 <211> 340
 <212> DNA
 <213> murine

 <400> 19
 cgattcaatt gtataaatga ttataatttc tttcatggaa gcatgatcct tctgattaag 60
 aactgtaccc catatttat gctgggtgtc tgcaagcttgc tgcatgtatg ttatgttcat 120
 gttaatccta tttgtaaaat gaagtgttcc tgacctttagt taaaaaagag agaagtaaat 180
 aacagacatt attcagttat ttgtccttt atcgaaaaac cagattcat tttccttt 240
 tgtttgcgtat ctcatttggaa aataattggc aagttgaggt actttcttcc catgcttgc 300
 acaatataaa ctgttatgcc ttcaagtgcg ttactgtggg 340

 <210> 20
 <211> 277
 <212> DNA
 <213> murine

 <400> 20
 ctagaggtgg gaactggctc cactccacac agcagccagt tagttgtga cggtcagctg 60
 catgcagggg aatgaaggac tcggagagaa cgttctgtgc tatgtgtgtt ccatagagat 120
 taaaaaggag gcctggagcc gagcatggtg gtgcacgcct ttaatcccag cacttggag 180
 gcagagtcag gtggatttct gagttcatttgc ccagcctggc ctacagagtg aattccagga 240
 caggcagggc tacacagaga aaccctgtct caaaaaaaaa 277

 <210> 21
 <211> 66
 <212> DNA
 <213> murine

 <400> 21
 ctagaatttg cagtagcatt aattcaagcc tacgtattca ccctcctagt aagcctataat 60
 ctacat 66

 <210> 22
 <211> 121
 <212> DNA
 <213> murine

 <220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions
 throughout the sequence may be A, T, C or G

 <400> 22
 ctagacataa gatattgtac ataaaganaa ttttttttgc ctttaatag ataaaaagtat 60
 ctatcagata aaaatcangt tgtaagttt attgaagaca atttgataca taataaaaga 120
 t 121

<210> 23
<211> 127
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 23
ggggagnnnn cnagnaanna gantcgtagc taaanagaan nntggtgcnt ttanatagaa 60
aangtactat canataanaa tcaggttgta agttatattg aagacgnttt gatacataat 120
aaaagat 127

<210> 24
<211> 105
<212> DNA
<213> murine

<400> 24
ctagactgac aaagactttt tgtcaacttg tacaatctga agcaatgtct ggcccacaga 60
cagctgagct gtaaacaat gtcacatgga aataaatact ttatc 105

<210> 25
<211> 85
<212> DNA
<213> murine

<400> 25
ctctcttgcc acccagatgg ttaggatgat tctgaagatg atgacatccg taagcctgga 60
gaatctgaag aataaactgt accat 85

<210> 26
<211> 85
<212> DNA
<213> murine

<400> 26
ctctcttgcc acccagatgg ttaggatgat tctgaagatg atgacatccg taagcctgga 60
gaatctgaag aataaactgt accat 85

<210> 27
<211> 316
<212> DNA
<213> murine

<400> 27
gatctcgaa tggaccaac tgctcctgct ccacccggcg 60
cctgcgcctg caagaactgc aagtgcacct cctgcaagaa gagctgctgc 120
ccgtgggctg ctccaaatgt gcccaggct gtgtctgca 180
cgtgcgtgc ctgatgtac gAACAGCCTGCT GCCACCACTGTA 240
ccagcgtctt cctatacagt tccaccctgt ttactaaacc 300
tgaataataa aagcct 316

<210> 28
<211> 136
<212> DNA
<213> murine

<400> 28
attcagacga atgagactcc tccacattgg agacaaggaga tgcagagagc tcagagaatg 60
agggtgtcaa gtggtaaaag atggatcaaa gggataaga gtgagttaaa tgaaataaaa 120
gaaaatcaaa ggagcc 136

<210> 29
<211> 243
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 29
ngcnrrnnnn ccagnaggag gagaagatga ctggccagta tcanaatggg ataagatgag 60
gcgcgcctg gactacacca tctacaacca ggagctcaac gagacgcgcg ctaagctcga 120
cgagcttct gctaancgag aaacnagtgg agagaaatcc ngacaactaa gggatgccc 180
gcaggatgca ngagacaaaaa tggaggatat tgagcgccag gttagagaac tgaaaacaat 240
nat 243

<210> 30
<211> 359
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 30
ctcaaggaaaa agacagcacc ncgtgcctgg catctgntgn nttagntnat ntnnaantnt 60
cnnntngncc tggcaacggt tcctgaacna attaccactc ctttttgccca gtcnaanagg 120
gtggaaaagt ccgagcctt a gacccagtt tca gttctgg tttttccct cctgancacc 180
atcggttgtt agttgcctt a gttggaaac gtttgcatcg acacctgtaa atgtattcat 240
tcttttaattt atgtaagggtt ttntgtnctc aattctttaa gaaatgacaa attttggttt 300
tctactgttc aatgagaaca ttagccccca gcaacacgtc attgtgtaaa naaataaaa 359

<210> 31
<211> 139
<212> DNA
<213> murine

<400> 31
cgatggctcc atcctggcct cactgtccac cttccagcag atcggctcag caagcaggag 60
taggatgagt ctggcccttc catcgatgcac cgcaaattgt tctaggcgga ctgttttaca 120
ccctttctt gacaaaaacc 139

<210> 32
<211> 354
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)

<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 32
cnnatgtac atgctgnagg atgcctaagg ctgccccca ccatcccctg gctctgctgn 60
ccggancaa ttgcttccag atgtgacttt ggaacctcn cacccctnac ccnaccnnnc 120
tcnagaannt cttttattta aaggaggaaa nannacatcc aagaaaangg ggggaggggg 180
gatgaaann cgcacccct ttctagccag ctgtcccaa aaggtaccct tcctctctgc 240
tgctcccaa acncaaanc cactcngan cctccaccta aancatcang caagtcaacnt 300
acaccctgtt tancccccna ctctctgctt ataccnngga acaattnntg ctcg 354

<210> 33
<211> 412
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 33
cgatgggtgg gatcttactg gggaaagagga aggaccatta gcacaccatc atgatgtcag 60
atgacaaaat ggaagccaag acacccctgaa ggtgactttc taggaaggtc ttaagcatgt 120
aatgtccctt tatcagaggg aaggggacaa actcagggca gccctgtcca ggtagaaata 180
ttttgcccc cctgtctgtat gttgatgagg ggtcatacca nccaggggaga ccctctggga 240
ggaagctgcc acacacaang actctggaag tatccagatg tgagcccagc cagggtccta 300
tggttccaaa tctgaanaaa aggttttca cacactcctt gcttctgct aagataanaa 360
aggcgtcact ctgccagagt gtgactttt acagattaaa taaagctgtt at 412

<210> 34
<211> 239
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 34
gatctactcc attccccctgg aaatcatgca gggcacccggg ggtgagctgt ttgatcacat 60
tgtctccctgc atctccgact tcctggacta catggggatc aaaggccccg gatgcctctg 120
ggcttcacct tctcggttcc ctgcaagcag acgagccat attgcggaat cttgatcagc 180
tggacaaaagg gattcaaagc caccgactgt gtgggtcacaatgtanccac tttactgag 239

<210> 35
<211> 93
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 35
gatctgagtt cgaggccagc ctggcttaca gagtgagttc caggnccagcc aggnctacac 60

agagaaaaccc tgtctcgaaa aaacagaaaag aga 93

<210> 36
 <211> 130
 <212> DNA
 <213> murine

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions throughout the sequence may be A, T, C or G

<400> 36
 ctttcattaa aaagaaaacca ggggctggan agatggctca gtggtaaga gcaccaactg 60
 ctcttcccgaa aggtcctaag ttcaaattccc agcaaccaca tggtggtcaa caaccactcg 120
 taatgagatc 130

<210> 37
 <211> 234
 <212> DNA
 <213> murine

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions throughout the sequence may be A, T, C or G

<400> 37
 atgcntggc tctcctgnng cctggcntac gacnnngaaaa ggagtgtcca cggctgctgt 60
 cngggccacg attaattaaa actgaagtac cgaggntncc ccagngncng antgtgggt 120
 cnngccnttc ntgntccaca anccaacttg gcagacgctt actgtntctgt caactntcnn 180
 nngaataccn ccaccncat gctaaaatga tgactgacgt taanccatgc tgg 234

<210> 38
 <211> 251
 <212> DNA
 <213> murine

<400> 38
 cgatgacaaa ggagtccctga ggcagattac tctgaatgac cttcctgtcg gaagatcgt 60
 ggacgagaca ctgcgtttgg ttcaagcctt ccagtacact gacaagcatg gagaagtctg 120
 ccctgctggc tggaaacacccgt gtagtggaaac aataatccca gatccagctg gaaaactgaa 180
 gtatttcgac aagctaaact gaaaagtact tcagttatga tggggacc ttctcaataa 240
 aggtcattgt g 251

<210> 39
 <211> 179
 <212> DNA
 <213> murine

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions throughout the sequence may be A, T, C or G

<400> 39
 cgatgctgaa taagctccctc aaaaagtggg aaatttaacc tttnaaaaaa acaagtttc 60
 tctgtacagc tctggctgtt ttgttctgga atacattctg tagaattgtc tggcctctaa 120

cttggagatc caactccctc tgcttga gtgctggat taatggcatg tgacactgt 179

<210> 40

<211> 219

<212> DNA

<213> murine

<220>

<221> variation

<222> (various)

<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 40

cgatgacctc atgccggccc agaagtgaag cctggccctc gccaccatca ggctgcccgt 60
tcctaactta ttaaccgggc agtgcggcc atgcattctt gangtttgcc gcctggcggc 120
tgagccctta gcctcgctgt agagacttct gtcgccttgg gtagagttta ttttttgat 180
ggntaanctg ttgctgacac tgaaaataan ctagggttt 219

<210> 41

<211> 303

<212> DNA

<213> murine

<220>

<221> variation

<222> (various)

<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 41

cgatcaatga aaagatgacg agtttcttgc aaatggcag ttactccctg ataacttcat 60
agctgcctgc acagagaaga aaatccctgt tgggtttaga ctacaagagg gttatgatca 120
tagtactac ttcattgcaa cttcatcgcc tgaccacatc agacaccatg ctaagtacct 180
gaatgcatga naagcctcag ccaagagaat ctcatcagga ggcggaaagg gaatcaacag 240
gagtgcgtac ttcctcgac aagatcatgc tcctgcagct gaatcgctt tctgaataaa 300
tat 303

<210> 42

<211> 460

<212> DNA

<213> murine

<220>

<221> variation

<222> (various)

<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 42

cgatgtntac ttcattgcca ccctgtcant cctcttggaa gtgtccgtca tcaccttgg 60
cagctgtctc cccctctatg tcctcaagta cctgcggaga cgggtctccc caccctgg 120
ctcgaagctc acttcctaag ctgcagggtc gcctcggca gggcctccgg cctccggcgc 180
tctcccaggaa ggagggtcaag ttccacacgc acgaggccgc tctgtggac ggtgcagtc 240
tggctggcac atgaggcttc gctgaggcga cactgggcac ctaatgggta tggaaacattg 300
gtgaaaccgg agggaggggac ctgagagctg tacctatcag aaccttgggt gctaagctgt 360
gctgagggggg aagacgtggg accggatggc ccgtctgagg ttgtgggt cactgtgcaa 420
gcttccttat gggttgaacc tcttgtcatg tgataaaaagt 460

<210> 43

<211> 120

<212> DNA
<213> murine

<400> 43
cgatttacgt atttgactga aatgaaaagtt ccactaaacg gtatttgctc ttgtgatatg 60
tggcacattg tgatattttc ttagtctgtt ctgtttcatt taaaaaataa aactgctgat 120

<210> 44
<211> 132
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 44
ccgatgtncg ataataatgtaa atacottaat tanttaaata attcattgna ttgtttcaga 60
gacgtttgga aatttactgtt tacatttaca acctaattgac ttttgtatTT tatttttcaa 120
aanaaaaagct ta 132

<210> 45
<211> 240
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 45
cnttngnnnn tccntncatc ncngcngtnt gagtcccnc caannagtcc atccaananc 60
canngcatnn cagtttatac atgacaacaa antggagnaa gaagaagatg agtttcggcc 120
actgttgagg caaatcnntg nnnantcnnta atanacacct ggtccgctca tccttcaacg 180
ttgttnntnta naanttacct cccagtagaa angctagcaa nttnacctg ccacngttn 240

<210> 46
<211> 126
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 46
cgatcagatg tcacgcggga cacancncg ccncagtnaa tggnaatata tttgcattt 60
accccaaatt ancttctntg catngaacat angtangtgt ctttggggac acgtgtgttc 120
tactac 126

<210> 47
<211> 383
<212> DNA
<213> murine

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions
 throughout the sequence may be A, T, C or G

<400> 47
 cgatttacaa atgaacaanc aagattacat atantaaaaa tccacgcagg acctattaca 60
 nagcatggtg aaatagatta tgaagcaatt gtaaagctt cagatggctt taatggagca 120
 tgacctgaca aatgtttgta ctgaagcagg tatgttgca attegtgccg atcatgattt 180
 tgtanttcag gaagacttca tgaaggcagt cangaangtg gctgactcca agaagctgga 240
 gtccaaagctg gactacaaac ctgtgtgatt cactannagg gtttgggtggc tgcacatgacag 300
 acattggttt aatgtanact taacngttan ngaaactaat gtaanntattt gcaatganct 360
 tattanaagt gaatanacat gtg 383

<210> 48
 <211> 255
 <212> DNA
 <213> murine

<400> 48
 cgatgtttt aattaagaag aaattcactt tctcattacc tatgaatctg tgccagggca 60
 ggtgattttt gagtatgaga actttgtcct ctccacagtt gtcacaaaaa tggttcccttc 120
 tcattgaact attgtggcat gctaattaag aagtgagtga ccacttggga ggcagaggca 180
 ggtggatttc tgagttttag gccagcctgg tctacaaagt gagttctaaag acagccaggg 240
 ctatacagag aaacc 255

<210> 49
 <211> 243
 <212> DNA
 <213> murine

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions
 throughout the sequence may be A, T, C or G

<400> 49
 ccaagnaata tggtctaatac aaaggtcgtc tgtctgcttt tgattgtcta catcacagca 60
 atccctggga atttctatcc attttaatg cngccgctt catctgttta gccagcacac 120
 ccaatggttt cactaacttag cccagttgac cttttggaag tttgagccctt gagcaccttc 180
 aacaaaattt agcactctga ttaggatatac cactttgcaa ataaaaaccaa atgttttgtc 240
 aac 243

<210> 50
 <211> 358
 <212> DNA
 <213> murine

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions
 throughout the sequence may be A, T, C or G

<400> 50
 cgatgagggg aagatgacct gggccggggga ggccatccct tateccaagat cacagggaaat 60
 tctgggaaga ggttggcctg tggcatcatt gcacgctctg cccggcctttt ccagaacccc 120
 aagcagatct gctcctgtga tggcctcaact atctgggagg agcgaggccg gcccattgcc 180
 ggtcaaggcc gaaaggactc agcccaaccc ccagctcacc tctaaacaga gcctcatgtc 240

aggttatttg gtcctcgtag ctgaacatct tcttcagag ggagctgcng gcccttgctt 300
gtacaggcct aagtacaggg cagataagtg ctgtagcctg aacaaattaa attgtcac 358

<210> 51
<211> 355
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 51
cgatttagctg ngtctctag ganatactcg tcactatatg agctcaggan gccagctctt 60
agtagctctg aancaggtga agaatcctcc tctgaggaaa cagactggga ggaagaagca 120
gcccattacc agccagctaa ttggtaaaga aaaaagccaa aagcnctgg cgaaagtca 180
cgtactgttc aaccccccgg cagtcgttt caaggtccgc cctatgcgga gcccccggcc 240
tgcgtagtgc gtcagcaatg cgcagagggg caatgcgcag agaggtgcgc agaggggcag 300
tgcgcagaga ggtgcgcaga gaggcagtgc gcagagaggc agtgcgcaga ctcat 355

<210> 52
<211> 213
<212> DNA
<213> murine

<400> 52
cgatttctaa atcagtctcg cctgtgctag gatgaccggt aatgagcctg tttaaaataa 60
gacttaaaag tgcgtgcgt tggccggcg gtaggggcgc atgccttaa tttcataact 120
tggaggtaga gacaggcgga tcttgcgttcaaggtca gcctgggtgtc cagagtgtact 180
tccagaacac ccaggctgt taaacagaga aac 213

<210> 53
<211> 113
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 53
ttgtttgtt nttcagatag ggtcttacat atccatgtt ggtctcaaac tcacattatg 60
catgcgggga aagccattta ctgactgata taccctggc cctaagatag atc 113

<210> 54
<211> 108
<212> DNA
<213> murine

<400> 54
cgatcgctgt tctggtaaga agctggaga tggccccaag ttccgtaaatg ctggccattt 60
aagttaata gtaaaagact gttaatgtt aacaatgcat cgtaaaac 108

<210> 55
<211> 257
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 55
cgatcgctgt tctgagtaan aagctggaan angccccaa gttcctgnng tctggcgatg 60
ctgccattta agtnnannag ananaagact ggctnatgat aacaatgcan cntaaaacct 120
tcaggnaggn aacgaatgtt gtggaccatt tttntngnt gtggcagttt naagttatna 180
agnttcaaa ancantactt nttaanggga acaacttgac ccatcanctg tcacagaatn 240
ttgangacca ttaacac 257

<210> 56
<211> 151
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 56
nctacgatca tctagatcta ctagacctac nacnagacca tggccaaan atggtcgacc 60
tgcaaacttg caaggtttat tttanataca cattatggcg ttttatnttt tgtaattcta 120
agttgtaatt cagctttaa caaatctttt t 151

<210> 57
<211> 152
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 57
ccaagnanat cnagactact agacctacta cnagaccatn ggncaaacat ggtcgaccnn 60
caaacgnata ngtatatttn anatacacan anatagcggt ntatgtctng taattctaa 120
tngtanatca nctattanca aaatctttt tt 152

<210> 58
<211> 188
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 58
cgatggaagt tctgctgagc ccttctgacg taaccctggc natggctaac actgtccttc 60
ctgcaatgtt cntggtgac acancttctc tgganatacc ctgaangtgg cacgcctgt 120
tccagccac ctggtgca cttttgccc tcttacctc attantaaat gtttcntgc 180

| | |
|-----------------------------------------------------------------------|-----|
| tccttaatg | 188 |
| | |
| <210> 59 | |
| <211> 136 | |
| <212> DNA | |
| <213> murine | |
| | |
| <220> | |
| <221> variation | |
| <222> (various) | |
| <223> bases designated as "n" at various positions | |
| throughout the sequence may be A, T, C or G | |
| | |
| <400> 59 | |
| ctnagnaagg anctgtactt cgtattgcaa ggcagtcctct tgggtcttct tagagtgtct | 60 |
| tccccatgca cagcctcagt ttggagcact agtttataat gtttattaca attttaata | 120 |
| aatttgantag gtagta | 136 |
| | |
| <210> 60 | |
| <211> 365 | |
| <212> DNA | |
| <213> murine | |
| | |
| <220> | |
| <221> variation | |
| <222> (various) | |
| <223> bases designated as "n" at various positions | |
| throughout the sequence may be A, T, C or G | |
| | |
| <400> 60 | |
| tcntcncntctt ggttaagaact ggaatatggc cccaaaggccc tgaagtcgtgg cgatgtgcc | 60 |
| attgttgcata tgggtccctgg caancccatg tgggttgcata gcttctctga ctaccctcca | 120 |
| cttggcgct ttgtgttgcg tgacatgagg cagacagttt ctgtgggtgt catcaaaagct | 180 |
| gtggacaaaaa angctgtgg agctggcnaa gtcaccaagt ctgcccnaaa agctcagaag | 240 |
| gctaaatgaa tattaccctt aacanctgcc accncantct taatcagtgg tggaaagaacg | 300 |
| gtctcagaac tggttngtctc aantggccat ttaagttaa tantaaaaga ctggtaatg | 360 |
| ataac | 365 |
| | |
| <210> 61 | |
| <211> 357 | |
| <212> DNA | |
| <213> murine | |
| | |
| <220> | |
| <221> variation | |
| <222> (various) | |
| <223> bases designated as "n" at various positions | |
| throughout the sequence may be A, T, C or G | |
| | |
| <400> 61 | |
| cgatcncgt tctggtaaga nnncnngaaca tggcccaag ttccnngannt ctggcgangc | 60 |
| ngccancgtt gatatggtcc ctggcaagcc catgtgtntt gagagttca cncnacnaccc | 120 |
| tccancgtt cgctttgtcg ttctgtacat gaggcagaca gttgtgtgg gtgtcancaa | 180 |
| anctgtggac aananggtcg ctggagctgg caagntcacc aantctgcc agaaaagctca | 240 |
| gaatgttaaa tnaatattac ccctaannacc tgccacccca gtcntaatca gtgggtggaaat | 300 |
| aacngtctca gaactgttttgc tcncaattgg ccanttangt ttaatnatac aagactg | 357 |
| | |
| <210> 62 | |
| <211> 305 | |
| <212> DNA | |
| <213> murine | |

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions
 throughout the sequence may be A, T, C or G

<400> 62
 gnnnnnnnnn nnchngaaa aagaggtgaa aaatgcttgg ctctagctga tgacagaaaag 60
 ctgaaatcca tcgccttccc atccattggc agcggcagga acgggttccc ggaagcagac 120
 agcggcccccag ctcattctga agtgcacatct ccagctacnt tgctccacg atgtccctcct 180
 ccacataaaac tggacttc atgcttttg acagtggagag ctaggtatc tatgtgcagg 240
 aaatggccaa gctggacgcc aactaggcca gtgatcccta gagccagcac atgcgggtgc 300
 cccca 305

<210> 63
 <211> 327
 <212> DNA
 <213> murine

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions
 throughout the sequence may be A, T, C or G

<400> 63
 ctnangaaaag ctgctggggc nccctgacat cactcatcac tcactatgct accaattctta 60
 tttatttcgg aattacaaga tattcggaaat ctctctgcag gctggactgg caggctgtgg 120
 ggtggccggg acacggctct taacatttnc agagggaaac gcgcanaatgt cccaaagtct 180
 aaataaatgc attcagaggt ttntgggtc catggccaaag tggagttccc ccncagggggg 240
 aggtggggta agtgcctcca ggaaggcagg cagcctgcct tanacttgca ncccggtgt 300
 ggaatgaat cattggagta ataaaact 327

<210> 64
 <211> 271
 <212> DNA
 <213> murine

<400> 64
 cgtatccaaat ggcatcctca atgtttctgc ttagataag agcacaggaa aggagaaaagt 60
 ctgcacccct atcattacca agctgtacca gagtgcagg ggcatgcctg ggggaatgcc 120
 tgggtgccttc ccaggtggag gagtcctccc atctgggtgt gcttcttcag gccccaccat 180
 tgaagaggtg gattaagtc gtcacaagaag aagggtgtac tttgtccac agggacccaa 240
 aacaagtaac atgaaataat aaaactat 271

<210> 65
 <211> 310
 <212> DNA
 <213> murine

<400> 65
 cgatgaagat gaggtcactg cagaggagcc cagtgcgtct gttcctgtatg agatcccccc 60
 tctggaaggc gatgaggatg cctcgccat ggaagagggtg gatataagcc tcctggaaga 120
 agccctgccc tctgtatagt atccccgtgg ctccccccagc agccctgacc cacctggatc 180
 tctgcctatg tctacaagaa tcttctatcc tgcctgtgc cttaaggcag gaagatcccc 240
 tcccacagaa tagcagggtt ggggtttatg tattgtgggtt tttttgtttt 300
 ttctaaaattt 310

<210> 66
 <211> 579

<212> DNA
 <213> murine

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions
 throughout the sequence may be A, T, C or G

<400> 66
 cgatccat ggcatccatc atgtttctgc ttagataag agcacaggaa aggagaacaa 60
 gatcaccatc accaatgaca agggccgtt gagtaaggaa gatattgagc gcatggcca 120
 agaagcttag aagtacaagg ctgaggatga gaagcagaga gataagggtt cttccaaagaa 180
 ctcactggag tcctatgcct tcaacatgaa agcaactgtg gaagatgaga aacttcaagg 240
 caagatcaat gatgaggaca aacagaagat tcttgacaa tgcataatgaaa tcatcagctg 300
 gctggataag aaccagactg cagagaagga agaatttgag catcagcaga aagaactgga 360
 gaaagtctgc aaccctatca ttaccaagct gtaccagatg gcaagggtggca tgcctgggg 420
 aatgccttgtt ggcttcccag gtggaggagc tccccatct ggtgggtctt cttcaggccc 480
 caccattgaa nagggtggntt aagtnatcca nnaagaaagg ntnccctttt ttccaaagg 540
 anccaaaaaaa gtaanatgga taataaaacc tatttaatt 579

<210> 67
 <211> 186
 <212> DNA
 <213> murine

<220>
 <221> variation
 <222> (various)
 <223> bases designated as "n" at various positions
 throughout the sequence may be A, T, C or G

<400> 67
 cgatccat agnanccaa ntntctgcng tngataagac acangaaaag agaacaagat 60
 caccatcacc aatgacaagg gcccgtttag taaggaagat attgagcgc tggtccaaga 120
 tcaatgtga ggacaaacag aagattcttg acaagtgc aaatcattc agctggctgg 180
 ataaga 186

<210> 68
 <211> 321
 <212> DNA
 <213> murine

<400> 68
 cgattagcgg aggtctctag gagatactcg tcactagatg agctcaggaa gccagcttt 60
 agtagctcg aagcaagtga agaatccctcc tctgaggaaa cagactggga ggaagaagca 120
 gcccattacc agccagctaa ttgttcaaga aaaaagccaa aagcggctgg cgaaagtca 180
 cgtactgttc aacctcccg cagtcggttt caaggtccgc cctatgcggaa gccccggccc 240
 tgcgttagtgc gtcagcaatg cgcagaggaa caatgcgcag agaggcagtg cgcagagagg 300
 cagtgcgcag actcattcat t 321

<210> 69
 <211> 321
 <212> DNA
 <213> murine

<400> 69
 cgattagcgg aggtctctag gagatactcg tcactagatg agctcaggaa gccagcttt 60
 agtagctcg aagcaagtga agaatccctcc tctgaggaaa cagactggga ggaagaagca 120
 gcccattacc agccagctaa ttgttcaaga aaaaagccaa aagcggctgg cgaaagtca 180
 cgtactgttc aacctcccg cagtcggttt caaggtccgc cctatgcggaa gccccggccc 240

tgcgtagtgc gtcagcaatg cgcaaggggg caatgcgcag agagggcagtg cgcaagagg 300
cagtgcgcag actcattcat t 321

<210> 70
<211> 495
<212> DNA
<213> murine

<400> 70
gatctttgtatggcacaaaatgaatccgcacctgggtgaccatgtatgcgtgtactattcg 60
gtaccctgtatcccctcatcaaggtaacga caccattcaggattgatttggagacagcaa 120
aataactgatttcatcaagtttgacactgggaacctgtgtatggtgactggaggtgctaa 180
cttggaaatgttgggtaatcaccaacagagagagacatccggctcttttgatgtggt 240
tcatgtgaaaatgtccaaatggcaacagttggactcggctgtccaaaca ttttttttat 300
tggcaagggtaaacaaaccatggatctctctccagagagaaatccgcctcaccat 360
tgctgaagagagagacaagaaggcttgcggccaaacagagcagtgggtgaatggctcc 420
taggagacatgcctggaaatgtttgttcaaccttccatggcaacatacattgttag 480
aattaaacagccat 495

<210> 71
<211> 136
<212> DNA
<213> murine

<400> 71
cgatcgagaggcaaaaccac ggaagggtggttggttgcagt tgctgtgg ttaaggacta 60
tggcaaaagaaatctcaggccaaaggatgtcatcgaggaaatacttcaagtgc aagaaataaa 120
taaattttggctgatt 136

<210> 72
<211> 140
<212> DNA
<213> murine

<400> 72
attccagataggaccacaa gcgactcattgatcacatagtcctctgatattgttaag 60
cagattacttccatcgatgttggccaggatgtcatcgaggaaatacttcaagtgc 120
taagacaactgaataatcg 140

<210> 73
<211> 216
<212> DNA
<213> murine

<400> 73
gatctataca gtcggaaac gcttcaagga agcaataac ttccgtggcccttcaagtt 60
atcttccca cgaggtggatgaaagaaaa gacaactcac ttgttagaaatggagatgc 120
tggcaacaggaaagaccaga taaacaggcttattagacggatgaaactaagtgtcaccc 180
ttgtatccccgtatctggatgttcaataacatgtc 216

<210> 74
<211> 151
<212> DNA
<213> murine

<400> 74
cgatgtggccaaagtcaataccctgataagccccgacgga gagaagaagg cgtatgttcg 60
cttggctcttattatgtatgtccctatggatgttgccaaacaatggatcatctaaactga 120
gtccagatggcttataatctaaatataacttt 151

<210> 75

<211> 90
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 75
gatctggAAC catagatgCG agcatcAGCA acagaataCA agaaatggAA gngngaatct 60
caggtgcAGA agnttccATA gagaacatCG 90

<210> 76
<211> 257
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 76
gcgatgcaaa atccttaata naattcttgc taaccgaatc caagaacaca ttaaagcaat 60
catccatcct gaccaagttag gttttattcc agggatgcng ngatggttt atatatgaaa 120
atccatcaat gtaatccatt ntataaacaa nctcaangac anaaaaccaca tgatcatctc 180
gttagtgca gaaaaagcat ttgacaagat ccaacacaca ttctgtataa nagttttgg 240
aagatcagga attcaag 257

<210> 77
<211> 200
<212> DNA
<213> murine

<220>
<221> variation
<222> (various)
<223> bases designated as "n" at various positions
throughout the sequence may be A, T, C or G

<400> 77
cgatnnnaccc gctctacctc accatctctt gctaattcag cctatatacc gccatcttca 60
gcaaaacccta aatnaggtag taaagtaagc atcnagaatc anccataactc aacgtnacgt 120
caagggtgtac ccaatgnaat gggaaagaaat gggctacatt ttcttatana agaacattnc 180
tatacccttt ntgaaactaa 200

<210> 78
<211> 56
<212> DNA
<213> oligo used in gene expression

<400> 78
acgtaataacg actcaactata gggcgaattt ggtcgacttt tttttttttt tttttv 56

<210> 79
<211> 21
<212> DNA
<213> oligo used in gene expression

<400> 79
cttacagcgg ccgcttggac g 21

<210> 80
<211> 15
<212> DNA
<213> oligo used in gene expression

<400> 80
agcggccgct gtaag 15

<210> 81
<211> 30
<212> DNA
<213> oligo used in gene expression

<400> 81
gcggaattcc gtccaaaggcc ccgctgttaag 30

<210> 82
<211> 21
<212> DNA
<213> adapter oligo

<400> 82
cttacagcgg ccgcttggac g 21

<210> 83
<211> 15
<212> DNA
<213> adapter oligo

<400> 83
aatgtcgcc ggcga 15

<210> 84
<211> 25
<212> DNA
<213> adapter oligo

<400> 84
tagcgtccgg cgcaagcgacg gccag 25

<210> 85
<211> 29
<212> DNA
<213> adapter oligo

<400> 85
gatcctggcc gtcggctgtc tgcggcgc 29

<210> 86
<211> 30
<212> DNA
<213> primer

<400> 86
gcggaattcc gtccaaaggcc ccgctgttaag 30

<210> 87

<211> 40
<212> DNA
<213> primer

<400> 87
ctctcaagga tcttaccgct tttttttttt ttttttttat 40

<210> 88
<211> 40
<212> DNA
<213> primer

<400> 88
taataccgcg ccacatagca tttttttttt ttttttttgc 40

<210> 89
<211> 40
<212> DNA
<213> primer

<400> 89
cagggtagac gacgctacgc tttttttttt ttttttttga 40

<210> 90
<211> 19
<212> DNA
<213> primer

<400> 90
tagcgtccgg cgcagcgc 19

<210> 91
<211> 19
<212> DNA
<213> primer

<400> 91
ctctcaagga tcttaccgct 19

<210> 92
<211> 20
<212> DNA
<213> primer

<400> 92
cagggtagac gacgctacgc 20

<210> 93
<211> 20
<212> DNA
<213> primer

<400> 93
taataccgcg ccacatagca 20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17283

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/68; C12N 15/12

US CL : 435/6; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Medline, WPIDS

search terms: hematopoietic stem cell, differential display

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X | TAGOH et al. Molecular Cloning and Characterization of a Novel Stromal Cell-Derived cDNA Encoding a Protein That Facilitates Gene Activation of Recombination Activating Gene (RAG)-1 in Human Lymphoid Progenitors. Biochem. Biophys Res. Commun. 1996, Vol. 221, pages 744-749, especially page 744. | 1, 2 |
| X | MOREB et al. Human A1, a Bcl-2-related gene, is induced in leukemic cells by cytokines as well as differentiating factors. Leukemia. July 1997, Vol. 11, Number 7, pages 998-1004, especially page 998. | 1, 2 |

Further documents are listed in the continuation of Box C.

See patent family annex.

| | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Special categories of cited documents: | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "B" earlier document published on or after the international filing date | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" | document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | | |
| "P" document published prior to the international filing date but later than the priority date claimed | | |

Date of the actual completion of the international search

30 NOVEMBER 1998

Date of mailing of the international search report

24 DEC 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

JOHN S. BRUSCA

Telephone No. (703) 308-0196



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17283

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **Claims Nos.:**
because they relate to subject matter not required to be searched by this Authority, namely:

2. **Claims Nos.: 3**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

No sequence listing or computer readable form of sequence listing has been supplied, and claim 3 is drawn to specific sequences that therefore cannot be searched.

3. **Claims Nos.:**
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.